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Prostate cancer (PCa) is common 
cancer in males with challenging 
diagnosis. Prostate specific proteases 
KLK3 (PSA) and KLK2 are used 
in monitoring of PCa but they are 
also involved in prostate cancer 
progression. Synthetic peptides, 
which modulate the protease 
activity of KLK2 and KLK3, have 
low bioavailability limiting the 
use of the peptides in therapeutic 
applications. This study focuses on 
the improvements in the activity and 
stability of peptide-based activity 
modulators of KLK2 and KLK3.
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ABSTRACT
Peptides and peptide-based pharmaceuticals have been a subject of growing interest during
the last decades because of their wide influence to the different biological actions.
Numerous  hormones,  neurotransmitters,  growth  factors  and  antigens  are  peptides,  many
of them directly used as therapeutics. However, peptides are considered as poor drug
candidates because they are usually rapidly metabolized by enzymatic degradation and
extracted  from  the  organism  resulting  in  very  poor  bioavailability.  Therefore,  the
administration of peptide drugs is challenging and must be repeated many times per day,
often intravenously or intramuscularly. The developments in peptide synthesis, in the
strategies aimed at reducing metabolism and improving bioavailability and advances in
alternative delivery routes have resulted in a rapid increase in the number of peptide-based
pharmaceuticals on the market. Furthermore, peptides are widely used as lead molecules in
radiopharmaceuticals and imaging agents because their high selectivities and specificities.
The prostate produces several proteases including two highly specific enzymes KLK2
and KLK3 (PSA) which are used as marker for prostate malignancies. The measurement of
the KLK3 concentration in the human serum has been used for detection and monitoring of
prostate cancer for decades although one problem with the serum test is the high false-
positive rate mainly caused by benign prostate hyperplasia. Thus, a more accurate
detection method is needed. KLK2 and KLK3 have been shown to be involved prostate
cancer proliferation. KLK3 has been proposed to participate in the inhibition of the
angiogenesis which is necessary for tumor growth and metastasis. KLK2 participates in the
proteolytic cascades which degrade extracellular matrix and thereby KLK2 may mediate
tumor  growth  and  invasion.  Thus,  if  one  could  discover  agents  which  wouyld  be  able  to
modulate the enzymatic activity of KLK2 and KLK3, it might be possible to modify the
growth rate of prostate cancer and impair its ability to metastase.
In  this  study,  peptide  based  modulators  of  KLK2  and  KLK3  have  been  studied  by  the
means  of  peptide  modifications  and  conformational  analysis  with  NMR  and  structure-
activity relationship studies. The residues essential for the activity stimulation of KLK3
were identified via sequential replacement studies. The stability against degradation in
plasma as well as against degradation by KLK3 could be enhanced in one selected peptide
by the replacement of terminal disulphide bridge by analogous bridges without the loss of
bioactivity. It was also shown that backbone cyclization of KLK2 inhibitory peptides
increased stability without the loss of biological activity. A series of peptide analogs also
provided valuable structure–activity relationships information for peptide mimetic studies.
The improved in vivo stability is essential for in vivo applications, such as diagnostic tumor
imaging and prostate cancer therapy.
National Library of Medicine Classification: QU 68, QU 136, QV 745, WJ 762
Medical Subject Headings: Prostate-Specific Antigen; Kallikreins; Peptide Hydrolases; Prostate Neoplasms;
Peptides; Peptides, Cyclic; Peptides/chemical Synthesis; Molecular Conformation; Amino Acid Substitution;
Serine Proteases; Proteolysis; Protein Stability; Biological Availability; Drug Design; Structure-Activity
Relationship
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TIIVISTELMÄ
Peptidit ja peptidipohjaiset lääkeaineet ovat olleet kasvavan kiinnostuksen kohde
viimeisten vuosikymmenten aikana, koska peptidit osallistuvat moniin biologisiin
prosesseihin. Useat hormonit, välittäjäaineet, kasvutekijät ja vasta-aineet ovat peptidejä ja
useita niistä on käytetty suoraan lääkinnällisiin tarkoituksiin. Peptidejä pidetään kuitenkin
heikosti soveltuvina lääkeaineaihioiksi, koska ne metaboloituvat nopeasti entsyymien
vaikutuksesta ja erittyvät elimistöstä. Tällöin niiden hyötyosuus jää pieneksi ja annostelu
vaikeutuu vaatien useita yleensä suonensisäisiä päiväannoksia. Menetelmäkehitys, joka on
johtanut peptideihin liittyyvän syntetiikan  ja metaboliaa hidastavien menetelmien
paranemiseen ja hyöty-osuuden kasvuun sekä vaihtoehtoisten annostelumenetelmien
kehitys ovat edesauttaneet peptidipohjaisten lääkeaineiden myynnin kasvua. Lisäksi
peptidien kyky sitoutua usein spesifisesti ja selektiivisesti kohteesensa edesauttaa niiden
käyttöä lähtörakenteina radiolääkeaineiden ja kuvantamisaineiden kehityksessä.
Eturauhanen tuottaa useita proteaaseja mukaanlukien hyvin spesifiset KLK2 ja KLK3,
joita voidaan käyttää eturauhasen poikkeuksellisen kasvun määrityksessä ja seurannassa.
KLK3:n seerumipitoisuuden nousua on käytetty eturauhassyövän diagnostiikkaan jo pari
vuosikymmentä. Pitoisuustestin ongelma on suuri virheellisten diagnoosien osuus johtuen
pääosin eturauhasen hyvälaatuisesta liikakasvusta. Testin tarkkuutta on parannettava ja
eräs mahdollisuus on seurata myös KLK2:n seerumipitoisuutta. KLK2:n ja KLK3:n on myös
todettu osallistuvan eturauhassyövän kehitykseen. KLK3:n on esitetty ehkäisevän
syöpäkasvaimen verisuonten kehitystä vaikuttaen myös mahdolliseen etäispäsäkkeiden
syntyyn. KLK2 toimii osana proteolyyttista kaskadia, joka hajoittaa soluväliainetta ja näin
edesauttaa syöpäkudoksen leviämistä. Eturauhassyövän kasvua ja leviämistä voidaan täten
mahdollisesti kontrolloida vaikuttamalla KLK2:n ja KLK3:n entsyymiaktiivisuuksiin.
 Tämän tutkimuksen pohjana ovat peptidit, jotka vaikuttavat KLK2:n ja KLK3:n
entsyymiaktiivisuuteen. Peptidien bioaktiivista rakennetta on pyritty määrittämään ja
muokkaamaan käyttäen NMR-rakenneanalyysiä sekä kohdennettuja modifikaatioita ja
tutkimalla niiden aiheuttamia rakenne-aktiivisuus suhteiden muutoksia. KLK3:n biologisen
aktiivisuuden kannalta tärkeät aminohapot on kartoitettu. Yhden valitun peptidin
vastustuskykyä sekä plasman proteaaseista että KLK3:sta aiheutuvaa entsymaattista
hajoitusta kohti on pystytty kasvattamaan tuottamalla analogi, jossa rikkisilta peptidin
päiden välillä on korvattu epäluonnollisella synteettisellä osalla. Myös KLK2:sta inhiboivan
peptidin stabiilisuutta on kyetty lisäämään syklisaatiolla joka ei tuhoa biologista
aktiivisuutta. Tutkimuksessa on lisäksi saatu arvokasta tietoa peptidin rakenteen ja
rakenteen muutoksen vaikutuksesta biologiseen aktiivisuuteen. Kasvanutta in vivo
stabiilisuutta voidaan hyödyntää uusien terapeuttisten ja diagnostisten aineiden ja niiden
rakenteiden suunnittelussa.
Luokitus: QU 68, QU 136, QV 745, WJ 762
Yleinen suomalainen asiasanasto: prostatapesifinen antigeeni; kallikreiinit; eturauhassyöpä; peptidit; sykliset
peptidit; kemiallinen synteesi; peptidisynteesi; aminohapposubstituutio; proteolyysi; proteiinin stabiilius;
lääkesuunnittelu; rakenne-toimintasuhde
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1 General Introduction
1.1 PEPTIDES IN DRUG DISCOVERY
The word ”peptide” was first introduced by the German chemist Emil Fischer in the
beginning of the 20th century (Suresh Babu 2011, Kimmerlin & Seebach 2005). The name is
based on the term pepsis, meaning the digestion product of proteins. Peptides, like
proteins, consist of amino acids termed as residues when they are incorporated in a
peptide.  The Amino acids  are  connected one to  the  next  via  amide bonds between the  C-
terminal -carboxylic acid group of one amino acid and the N-terminal -amino group of
the following residue and therefore amide bonds are commonly called peptide bonds
(Figure 1). Peptides are commonly depicted in a left to right direction, from the N-terminus
to the C-terminus  (Figure  1). Naturally occurring peptides and proteins consist of 20
genetically encoded amino acids with the L-configuration. The D-configuration is rare,
however, it has been found for example in the bacterial cell walls and in some antimicrobial
peptides (Suresh Babu 2011). Peptides are shorter than proteins, they can range from two
(dipeptide) up to 50-100 (polypeptide) residues depending on the source material (Lien &
Lowman 2003, Watt 2006). In fact the limit where a peptide turns into a protein is not
defined. For example, the sweetener aspartame is a dipeptide (H-Asp-Phe-OMet, Figure 1)
with molecular weight (Mw) below 300 Da and the hormone insulin containing 51 residues
with Mw almost 5800 Da is also classified as a peptide.
Figure 1. Structures of peptide backbone (left) and dipeptidic sweetener aspartame (right).
Peptides exert a wide range of biological actions since numerous hormones, antigens,
neurotransmitters, growth factors and cytokines are peptides. Therefore, peptides have
gained growing interest in pharmaceutical research. Many natural peptides such as certain
hormones, insulin for treatment of diabetes, calcitonin for osteoporosis and oxytocin for
labor  (Table 1) have been used directly as drugs for many years. However, peptides have
been considered as poor drug candidates mainly because they are usually rapidly
metabolized and their oral bioavailability is poor, even non-exixtent. The developments in
the  field  of  synthetic  chemistry,  new  strategies  for  reducing  metabolism  and  improving
productivity and advances in alternative delivery routes for example pulmonary, nasal and
oral administration have led to a rapid increase in the number of peptide-based
pharmaceuticals on the market (Vlieghe et al. 2010, Kimmerlin & Seebach 2005). Further,
peptides are widely used as lead molecules in radiopharmaceuticals and as imaging agents
(Okarvi 2004).
21.1.1 Synthetic therapeutic peptides on the market
The market for synthetic therapeutic peptides was €8 billion in 2005 and it has been
estimated that it will rise to €11.5 billion in 2013 (Pichereau & Allary 2005, Vlieghe et al.
2010). Among the different therapeutic peptides in use in 2003, the largest class was the
gonadotropin/luteinizing hormone releasing hormone (GnRH/LHRH) agonists (Table  1)
used in the treatment of prostate and breast cancers, having 45% market share. Other large
selling classes of peptide related drug were somatostatin and somatostatin analogs like
ocreotide for the treatment of acute variceal bleeding and acromegaly (15%),
immunopeptides such as glatiramer used in the therapy of relapsing multiple sclerosis
(12%) and calcitonins for the treatment of osteoporosis (10%)( Table 1) (Pichereau & Allary
2005). The list of Pichereau and Allary excluded insulin and insulin-based products
apparently because insulin is produced by several methods, not exclusively via synthesis. It
has been calculated that the market of insulin products alone was around US $4.5 billion in
2002 and the need for insulin products was estimated to 4,600 kg in year 2000 in the
industrial world alone (Walsh 2005). The occurrence of diabetes mellitus and the growth in
the numbers of subjects with disorders requiring insulin, have made this peptide one of the
most significant biopharmaceutical product categories, both in terms of medical impact and
market value. Furthermore, insulin-based therapy of diabetes has been an exemplary
research object not only for production of peptide-based pharmaceuticals but also for
development of non-parenteral delivery systems, as well as organ-/cell-based and gene
therapy-based approaches to controlling the disease (Walsh 2005).
Peptides and peptide-based pharmaceuticals have been used also as therapeutic agents
for example for the treatment of oncologic (leuprolerin), gastroenterologic (GLP-2, glucagon
like peptide-2, teduglutide), cardiovascular (bivalirudin, eptifibatide), immunotherapy
(cyclosporine),  enuresis (vasopressin analogs like desmopressin), antiviral (enfuvirtide for
human immunodeficiency virus, HIV) and antimicrobial (defensin) indications (Stevenson
2009, Vlieghe et al. 2010). Examples of synthetic therapeutic peptides and peptide
derivatives which have reached the market in the developed countries are listed in the Table
1 with the sources, their indications, sequences and routes for dosing.
In the past, many of the peptide therapeutics were derived by extraction from organs, for
instance insulin from porcine and bovine pancreatic glands (Johnson 1983). Nowadays
therapeutic peptides are most commonly manufactured via a synthetic route due to the
rapid development of synthetic chemistry and most of the compounds listed in Table 1 are
also  synthetic.  Some unmodified peptides  with  long sequences  such as  insulin,  glucagons
and calcitonins can still be manufactured using viral particles or plasmids via recombinant
DNA technology (Verlander 2007, Walsh 2005). Nonetheless, the large scale synthesis of
relatively short and highly structured peptides still remains a challenge. One practical
example is cyclosporine which is highly hydrophobic and contains many N-methylated
residues (Table 1). The first complete synthesis of cyclosporine was published by Wenger in
1984 (Wenger 1984) and since then numerous reports using differing synthetic method have
been published. However, cyclosporine is still usually manufactured via microbial
fermentation (Verlander 2007).
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1.1.2 Disadvantages and advantages of using peptides as therapeutic agents
Since bioactive peptides are often derived from natural sources, they are commonly well-
tolerated. However, living organisms also have mechanisms to rapidly degrade and excrete
peptides out of circulation and these are considered as their main disadvantages when
peptides are used as therapeutic agents. These problems and several other disadvantages
and advantages are discussed in the subsequent sections and they are also listed in Table 2.
Bioavailability and biodistribution of a drug molecule depend on its absorption,
transport and distribution through biological membranes and cellular barriers and then
how it is eliminated. The most important properties affecting bioavailability are aqueous
solubility, lipophilicity, H-bond formation and both chemical and metabolic stability (Witt
et al. 2001, Vlieghe et al. 2010). Peptides are relatively hydrophilic, hence they cannot pass
passively through physiological barriers such as hydrophobic membranes. This also means
that their access is extremely limited to the central nervous system (CNS) through the blood
brain barrier (BBB) (Witt et al. 2001, Vlieghe et al. 2010, Lindgren et al. 2000). Since they are
bulky molecules with molecular weights usually over 1000 Da, they need active
transportation if they are to penetrate through the physiological barriers. There is a certain
class of peptides, called cell-penetrating peptides (CPPs) which can pass through biological
membranes and they can also act as transporters for macromolecules (Lindgren et al. 2000).
In addition, the membrane penetrating ability of calcitonins (Table 1) and the possibility to
use them as carriers of macromolecules has been studied (Rennert et al. 2008). Recently, the
use of various biodegradable nanoparticles in cytosolic delivery of therapeutics has
attracted attention and these materials may also be used as carriers to help the peptide pass
through cell membranes (Vasir & Labhasetwar 2007).
The main disadvantage of peptides is their sensitivity toward metabolic degradation by
the proteolytic enzymes in the blood and gastrointestinal tract. Short peptides are rapidly
cleared from the circulation by the liver and kidneys, usually within minutes. Proteases,
which are responsible for the degradation of peptides, can be divided into two categories:
endopeptidases which cleave peptide bonds in the middle of their peptide sequence and
exopeptidases which cleave from either N- or C-terminal side and are thus called
aminopeptidases or carboxypeptidases, respectively. These peptidases/proteases are mainly
located in blood, pancreas, liver and kidneys (Turk 2006, Werle & Bernkop-Schnurch 2006).
Endopeptidases often exhibit narrow cleavage specificity requiring the presence of one
certain amino acid on the N-terminal side of cleavage point which is recognized by the
peptidase. The most important endopeptidases are serine, cysteine and aspartic acid
proteases and metalloproteases which have a wide variety of cleavage sites because they
can recognize the next residue after the cleavage site. The most significant exopeptidases
include dipeptidyl- of tripeptidylpeptidases cleaving N-terminal di- and tripeptides
respectively and peptidyl-dipeptidases cleaving C-terminal residues. In addition, there are
various amino- and carboxypeptidases cleaving specific amino acids from the N- and C-
terminal end of the peptide (Vlieghe et al. 2010, Werle & Bernkop-Schnurch 2006).
 It has been estimated that the oral bioavailability of peptides is a mere 1-2% due to their
enzymatic degradation and low mucosal permeability (Pauletti et al. 1996). Due to the low
oral bioavailability of peptide pharmaceuticals, they need to be delivered via parenteral
administration e.g. intravenous infusion which can result in low patient compliance (Table
1). Direct injection can overcome some of the problems due to the low bioavailability and
poor stability in the bloodstream. Due to their short half-life in the bloodstream, repeated
6dosing  is  usually  required  causing  a  fluctuating  concentration  of  the  drug  in  the  blood,
painful injection or infusion and expensive therapy (Antosova et al. 2009). The production
costs of the peptide pharmaceuticals are high, especially longer peptides or modified
analogs. Finally, linear short peptides are highly flexible and this can result in a lack of
selectivity due to unspecific binding to other receptors and thus evoking side effects and
also the risk of generating an immunogenic response (Sato et al. 2006, Vlieghe et al. 2010).
The advantages of peptides as therapeutics must be compared to both small molecules
and large proteins such as antibodies. Monoclonal antibodies (mAb) have been used as
tumor targeting agents and in the therapy of various cancers but the large size of mAbs (160
kDa), the nonspecific uptake of antibody molecules into the reticuloendothelial system such
as the liver,  spleen and bone marrow have limited their use as carriers of cytotoxic drugs,
toxins and radionuclides to the tumor site (Aina et al. 2007). In comparison to antibodies,
the smaller size of peptides increases their potential to penetrate into the target tissues
which are most commonly tumors (Reubi 2003, Sato et al. 2006, Ladner et al. 2004).
Therapeutic peptides are also usually less immunogenic than antibodies mostly due to their
smaller  size,  rapid  degradation  and  elimination.  Furthermore,  the  production  costs  are
lower, storage at room temperature is possible and chemical diversity is higher when
compared to antibodies and proteins (Sato et al. 2006, Vlieghe et al. 2010).
Since  they  often  contain  the  reduced  functional  part  of  a  protein,  usually  composed  of
10-50 amino acids, peptides usually have higher efficacy and selectivity compared to small
molecular weight drucgs (Sato et al. 2006, Ladner et al. 2004). The high specificity based on
a broad interaction site is an advantage when there is a need for a specific, efficacious and
extended peptide-target interaction in order to block or interfere with the biological
protein-protein interaction. Thus, they can act as an antagonist, for example this is usually
their mode of action in cancer therapy. Many of the peptide therapeutics are agonists or
antagonists  and  despite  the  high  production  costs,  only  small  amounts  of  peptide
therapeutic are usually needed to achieve a therapeutic response if the specificity is
sufficiently high (Ladner et al. 2004).
There are several well-studied technigues to routinely produce peptides of different sizes
and sequences including chemical synthesis, recombinant DNA technology, transgenic
plants and animals and enzymatic synthesis. In particular, synthetic production methods
for peptides give the possibility to add an enormous variety of different building block into
the peptides and peptide derivatives (Bray 2003, Vlieghe et al. 2010). Another advantage of
synthetic peptide chemistry is that the purity of the product is usually high when the drugs
are manufactured under good manufacturing practice (GMP). Synthetic chemistry makes it
possible to restrict the enzymatic degradation of labile bonds, to mask recognizable side
chains from proteases and to add variable bridge structures to enhance the structural
rigidity of the peptides. It is also relatively easy to link chelators or radiolabeled ligands
into the peptides via synthetic methods (Reubi 2003). The methods and achievements of
peptide and peptide derivative synthesis will be reviewed in section 1.2.
Finally, the degradation products of peptide therapeutics are usually amino acids
minimizing  the  risk  of  toxic  metabolites  compared  to  small  molecule  drugs.  The
accumulation of peptides or their metabolites to the tissues is low due to the short half-life
in living organisms (Sato et al. 2006, Vlieghe et al. 2010).
Recent developments in methods for discovering peptide lead structures, the better
understanding of biological and chemical nature of peptides and the improved synthetic
7methods  have  expanded  the  use  of  peptides  as  pharmaceutical  agents.  Although
intravenous administration is the main administration route for peptide pharmaceuticals,
alternative delivery routes have been extensively investigated particularly for the widely
used peptide hormones. Innovative examples of alternative administration routes include
pulmonary (e.g. insulin), nasal (e.g. calcitonin, desmopressin), oral (e.g. insulin) and buccal
(e.g. insulin) delivery (Antosova et al. 2009).
Table 2. The main advantages and disadvantages of peptides in therapeutics.
Advantages Disadvantages
High activity Low oral bioavailability, intravenous
administration required
High affinity and high specificity for receptors Usually low stability
Low unspecific binding to molecular structures
other than desired target
Difficult delivery, challenge in transporting
across membranes
Low accumulation in tissues and rapid
clearance from blood and non-target tissues
Costly synthesis
Usually low toxicity Low water solubility
Often very potent The risk of immunogenic effects
Biological and chemical diversity Rapid clearance from the body
Usually low immunogenicity Structural flexibility which can cause non-
specific binding
Relatively small size compared to antibodies
1.1.3 Lead peptide sources
Therapeutic peptides have been derived mainly from three sources: nature, genetic or
recombinant libraries and chemical libraries. The main natural sources, from which
naturally occurring peptides, peptide hormones or fragments of larger proteins have been
isolated and characterized, include plants, animals or humans (Sato et al. 2006, Vlieghe et
al. 2010, Lewis & Garcia 2003). Since peptides from natural sources have undergone natural
selection and therefore they usually have enhanced in vivo stability, most of the peptide
therapeutics used today are derived from natural sources (Sato et al. 2006, Watt 2006).
Salmon calcitonin, somatostatin and corticotropin-releasing factor are good examples of
highly structured peptides from natural sources which also are synthesized using common
peptide synthesis methods. The first commercial peptide drug based on the fragment of a
protein and to be manufactured via a synthetic route was the anti-HIV drug enfuvirtide
(Table 1, see page 3) (Watt 2006). Several peptides from natural sources act as potent
agonists and antagonists targeting receptors involved in the progression of many diseases.
Thus, the development of more sophisticated and powerful methods for the isolation,
identification and characterization of natural peptides has led to the production of a huge
number of potential new lead structures for peptide therapeutics.
Recently, developments in the field of recombinant display technologies such as phage
display, and chemical library methods, together with the advanced synthetic combinatorial
chemistry, and computational methods have dramatically increased the number of
potential lead peptides with therapeutic applications (Marasco et al. 2008, Falciani et al.
2005).  While the use of genetic and recombinant libraries is limited to only the naturally
8occurring L-amino  acids,  both L- and D-amino acids and an enormous number of other
synthetic building blocks can be incorporated via synthetic combinatorial chemistry.
Furthermore, one can only create complicated bi- or multicyclic structures or branched
structures by using combinatorial synthetic chemistry.
Chemical combinatorial peptide libraries are also able to yield from thousands to
millions of sequences at one time. The peptides can be screened against biological targets
either as cleaved free compounds or they can be assayed when still attached to their solid
support (Marasco et al. 2008, Lam et al. 1991, Houghten et al. 1991). Synthetic combinatorial
peptide libraries have been used successfully to identify new drugs, for example
antimicrobial peptides (Blondelle et al. 1996) and an opioid receptor antagonist (Dooley et
al. 1998).
However, there are some considerable drawbacks in the use of random peptide libraries.
Firstly, it is possible that randomly encoded peptide libraries do not yield any sequence
that will bind to target because random sequences may not fold to the structure in a stable
enough way to permit a strong interaction between the target and the ligand. This may lead
to poor hit rates despite the fact that a valid sequence may have been created (Watt 2006).
However, although a peptide does not fold spontaneously in solution, it may be capable of
adopting an induced fold within the target. Secondly, if unspecific binding does occur and
there are several hits, the characterization of the sequences may be difficult. It has been
noted that similar biological effects can be achieved with divergent sequences, because
biological molecules usually recognize shape and charge rather than the exact primary
structure (Yang & Honig 2000).
Complex peptide libraries are relatively complicated to synthesize and the individual
peptide products are difficult to identify. Genetically encoded combinatorial libraries,
phages, plasmids or ribosomes, offer the potential to overcome these problems. Genetically
encoded libraries produce peptides with the desired binding activities. In order to optimize
the  specificity  and  affinity  of  the  peptide,  the  clones  can  be  readily  amplified  and  re-
screened (Landon et al. 2004). The phage display method was first introduced by Smith in
1985. It is based on an in vitro selection procedure in which the peptide is displayed on the
surface of the viral particle after the peptide gene is genetically fused onto a bacteriophage
coat protein (Smith 1985). In addition to linear peptides, predetermined cysteine positions
in the sequence can allow for the expression of cyclic peptides. Phage display is a powerful
technology to generate peptides from random peptide libraries and since its discovery, it
has been used in a variety of biological and biotechnological applications (Landon et al.
2004, Laakkonen & Vuorinen 2010, Smith & Petrenko 1997). These include the search and
development of enzyme inhibitors (Hyde-DeRuyscher et al. 2000), angiogenesis inhibitors
(Hetian et al. 2002) protease stimulators (Wu et al. 2000) or inhibitors (Hekim et al. 2006).
Phage display can also be used for specific substrate determination (Cloutier et al. 2002) or
for the selection of target homing peptides such as peptides targeting cancer cells (Shadidi
& Sioud 2003) and peptides which bind specifically to lymphatic vessels (Laakkonen et al.
2002).
Computer-aided drug design is a powerful tool for small molecules but in peptide
research  it  encounters  some  limitations.  The  structure  of  a  peptide  is  usually  flexible  and
there may exist a large population of different conformations. Several factors such as
solvent, pH and the surrounding temperature have major influences on the conformation.
Construction of  a  computational  model  of  a  single  peptide  without  any information of  its
9binding site on the target is pointless. For example, in enzyme research, the peptide lead
structures are usually derived from substrates but some peptides also bind in close vicinity
to the active site, and thus can regulate the activity of the target protein. When the lead
structure has been identified, computational methods can be used to assist in the design of
modifications. For example, novel protein kinase B inhibitors with enhanced
pharmaceutical  properties  were  designed  by  using  structure-activity  relationship  (SAR)
studies  with  synthetic  libraries  of  cyclic  peptides  and  superimposing  the  most  active
nuclear magnetic resonance (NMR) based structures computationally onto the target
protein, (Tal-Gan et al. 2011a).
The computational screening methods for searching for protein binding structures
usually require a knowledge of the three dimensional (3D) structure of the target molecule.
The 3D structure is usually studied using NMR, using mass spectrometry (MS) for the
search of sequential data and modification sites, or by solving the crystal structures of a
protein using X-ray crystallography (DeLucas et al. 2005). In the case of NMR, the size of
the protein is the main limitation. X-ray crystallography is the method routinely used to
resolve structures of macromolecules with molecular weights over 20 kDa. Some proteins
do not form crystals, for example if the surface properties of a protein do not favor the
formation of crystal contact, then structural information may have to be obtained from
homologous proteins from other species (Dale et al. 2003; DeLucas et al. 2003, DeLucas et al.
2005). Human kallikrein-related peptidase 3 (KLK3), is a widely studied serine protease
which crystal structure has not been resolved. The crystal structures of KLK3 in various
complexes have been defined (Menez et al. 2008, Stura et al. 2011). A homologue model of
KLK3, based on the crystal structures of porcine kallikrein and human tissue kallikrein
(HK1), was used in substrate specificity studies of KLK3 and for inhibitor design via
docking experiments (Singh et al. 2009). Recently, a comparative model of KLK3 was
constructed by using KLK1 as a reference structure (Härkonen et al. 2011). Using this model
together with peptides, which are able to stimulate the enzymatic activity of KLK3, the
small molecule stimulators of KLK3 activity were discovered (Härkonen et al. 2011).
1.1.4 Peptides in cancer research
Today cancer therapy is one of the leading areas of peptide research because there is
growing evidence that several peptide receptors, such as growth factor receptors, are
involved in various cancers (Landon et al. 2004). Many of these receptors are overexpressed
in  the  cancer  or  become  expressed  in  other  tissues  in  a  response  to  cancer  growth.  Thus,
peptides with specific binding may be used for example as receptor antagonist for long-
term use in therapy. They can also function as peptide derivatives for example with an
adduct containing cytotoxic or imaging agent (Okarvi 2004, Zaccaro et al. 2009, Reubi 2003).
In the following sections, some commonly known bioactive peptides will be discussed.
Somatostatins are 14 (SST-14, Figure 2) or 28 (SST-28) residues containing cyclopeptide
hormones  possessing  a  variety  of  biological  effects  in  different  cells  and  organs.  Both
somatostatins have an inhibitory effect not only on the secretion of growth hormone, but
also on thyroid stimulating hormone, prolactin, insulin, glucagon and cholecystokinin
(Patel 1999). Somatostatins can also act as neurotransmitters and may function as
modulators of motor and cognitive functions (Reissmann & Imhof 2004). Somatostatins
have been also shown to inhibit both normal and tumor cell proliferation (Weckbecker et al.
2003). Therefore somatostatins are good candidates for anticancer agents and for the
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treatment of neuroendocrine disorders but their specificity for certain receptors is low and
their half lives in organs are very short (<3 min) (Pyronnet et al. 2008). Somatostatin has
been the subject of a vast number of studies involving synthetic derivatives and in 1982
Bauer et al. published synthesis of ocreotide (Bauer et al. 1982, Harris 1994, Weckbecker et
al. 2003). Ocreotide is cyclic octapeptide containing disulphide bridge and D-amino acids
(Figure  2). This compound showed increased resistance against enzymatic degradation
while maintaining the biological activity of the original somatostatin. In fact, its half-life of
degradation was long enough to permit long-term therapy (Bauer et al. 1982, Reubi 2003).
Ocreotide became the first synthetic peptide analog for the treatment of agromegaly and
neuroendocrine tumors (NETs) (table 1, see page 3) (Zaccaro et al. 2009). Somatostatin and
its analogs, especially ocreotide, have been used successfully in the diagnosis of NETs and
for the radionuclide therapy of these tumors for years (Zaccaro et al. 2009, Reubi 2003).
Figure 2. Somatostatin 14 (SST-14, left) and its synthetic analog ocreotide (right) with the non-
naturally encoded residues indicated.
Integrin receptor binding ligands contain the tripeptide sequence RGD (Arg-Gly-Asp)
and this tripeptide has been used as a lead structure in the development of various
diagnostic and imaging agents. Integrins are heterodimeric transmembrane glycoproteins
consisting of two subunits,  and , and to date 18 - and 8 -subunits have been identified
(Zaccaro et al. 2009). A group of integrins are closely connected to angiogenesis since they
can promote the development of new blood vessels and they also contribute to the survival
of the newly formed vasculature (Ruoslahti & Pierschbacher 1987, Ivaska & Heino 2000).
The RGD-sequence is present in several extracellular matrix proteins such as fibronectin,
fibrinogen, lamin, collagen and thrombin (Ruoslahti & Pierschbacher 1987). One of the
integrins, V3,  has  been  found  to  be  overexpressed  in  several  tumor  forms,  including
melanomas, breast cancer, ovarian and lung carcinomas, neoblastomas and glioblastomas
and therefore integrin V3 is interesting target for the early diagnosis and detection of
metastases (Zaccaro et al. 2009). Based on the RGD-sequence, a series of studies with linear
and cyclic analogs with the RGD sequence have been described including also radiolabeled
derivatives (van Hagen et al. 2000, Haubner et al. 1996, Zaccaro et al. 2009, Okarvi 2004).
Neurotensin (NT, Figure 3) is a linear 13 amino acid long peptide which functions as both
a neurotransmitter and a hormone (Vincent 1995). NT exerts its biological effects via a
specific interaction with cell-surface receptors and these NT-receptors are known to be
overexpressed in various human tumors including Ewing sarcoma, meningioma,
astrocytoma and, medulloblastoma. This NT-receptor overexpression in these tumors has
been targeted with NT analogs (Okarvi 2004). Residues 8-13 of NT are the important amino
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acids  determining the  binding and biological  activity,  and the  NT 8-13  residues  (Figure 3)
have been examined in various studies as a lead structure. In an attempt to enhance the
stability of NT against degradation in blood several methods including the introduction of
a pseudopeptide bond into the natural cleavage site between residues 8 and 9 (NT-IV) and
amino acid replacements (NT-VIII) have been investigated (Okarvi 2004, Garcia-Garayoa et
al. 2002). The NT analogs displayed increased stability in vivo and they were further used in
imaging studies (Garcia-Garayoa et al. 2002, de Visser et al. 2003).
Figure 3. Neurotensin (NT), NT 8-13, NT-IV and NT-VII.
1.1.5 Proteases as therapeutic target
Proteolytic enzymes, usually known as proteases, are enzymes that catalyze the breakdown
of proteins by hydrolyzing their peptide bonds. Proteases are extremely important
molecules  in  the  signaling  pathways  and  they  regulate  many  physiological  processes  like
cell proliferation, cell death, DNA replication, wound healing, immune response and blood
coagulation. Proteases are overexpressed in several diseases and tissue abnormalities and
increased proteolytic activities are associated with tumor invasion and metastasis (Turk
2006, Koblinski et al. 2000, Overall & Kleifeld 2006). These enzymes have a broad functional
diversity and also tumor suppressive effects have been proposed (Lopez-Otin & Matrisian
2007). At present, several proteases are widely used as biomarkers for many cancers such as
human breast, lung, head and neck carcinomas, melanoma, colorectal carcinoma and
prostate cancer (Kos & Lah 1998, Stamey et al. 1987). Cysteine proteases, serine proteases
and matrix metalloproteases (MMP) have also been evaluated as targets for tumor imaging
(Sloane et al. 2006, Fonovic & Bogyo 2007). Due to the potential of proteases in the
diagnosis of diseases and in therapeutics, it would be important to find ligands which bind
selectively and with high specificity to their target protease. Phage display and different
combinatorial methods have been used to define substrate specificities of proteases
(Thornberry et al. 1997, Harris et al. 2000, Matthews & Wells 1993). Specific substrates can
be considered as potential lead structures for therapeutic and imagining agents.
The inhibition of proteases has been the main goal of protease targeting studies because
protease inhibition, blocks the activity of downstream proteases (Turk 2006). Antibodies are
well-known specific protease inhibitors, but their large size limits their specificity and
uptake and therefore their use as therapeutic agents. Small molecule inhibitors often lack
the requisite specificity. Thus peptides and peptide derivatives may serve as prototypes for
protease activity modulators. Some natural peptidic inhibitors such as tick anticoagulant
peptide (TAP), selective inhibitor of serine protease Factor Xa, and antistasin, an inhibitor
of coagulation but also metastasis, have been investigated in inhibitor design tests
(Dunwiddie et al. 1992, Tuszynski et al. 1987).
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The stimulation of protease activity has not been a widely studied area but some
activating molecules already exist. Stimulation of protease activity can be achieved using
agents  which  block  the  inhibitory  activities  of  protease  inhibitors  such  as  inhibitors  of
apoptosis (IAP) protein family in cancer cells (Schimmer et al. 2004). In the study of
Schimmer and co-workers, small molecular-weight inhibitors for IAPs were developed and
the stimulation of apoptosis was observed in several types of tumor cell lines in culture. It
is  not  common to  find agents  that  directly  stimulate  the  protease  activity  but  for  example
peptide-based stimulators of KLK3 protease activity have been described (Wu et al. 2000).
1.2 PEPTIDE SYNTHESIS
Peptides  can  be  produced  by  various  technologies,  mainly  depending  on  the  source  of
peptide  and  the  molecular  size  of  the  product.  The  naturally  existing  peptides  can  be
extracted directly from the living organism. However, the most popular approaches in
peptide production for pharmaceutical purposes are chemical synthesis, recombinant
DNA-technology (rDNA) or enzymatic synthesis (Guzman et al. 2007, Gill et al. 1996).
Chemical peptide synthesis is a flexible technology for the synthesis of small and medium
size peptides, particularly due to the high purity of products, and the possibility to
incorporate a wide variety of non-natural building blocks. Other technigues, i.e. rDNA and
enzymatic synthesis, offer some advantages over chemical synthesis e.g. use of inexpensive
and non-hazardous chemicals and mild reaction conditions. In addition, there will be no
racemization present in the products. However, rDNA-methods are used mainly in the
production of large peptides and proteins such as insulin and other hormones and also
antibodies.  Enzymatic  synthesis  is  used  for  the  production  of  very  short  (up  to  10  amino
acids) peptides including certain food additives like aspartame (Figure 1, see page 1)
(Guzman et al. 2007, Gill et al. 1996, Kumar & Bhalla 2005, Walsh 2005). Today, the different
methodologies to produce peptides and peptide derivatives are not only competitive but
they can also be used in combination. For example the combination of chemical and
enzymatic synthesis has been used in the large scale and low cost production of the RGD-
tripeptide.  Chemical  synthesis  of  RGD  (Arg-Gly-Asp)  is  challenging  because  of  the
hydrophilic residues and thus the low solubility in organic solvents and this lead to
increases in the total costs of synthesis and purification. This problem can be bypassed
when chemically synthesized Gly-Asp was coupled enzymatically with Arg (Hou et al.
2005).
Chemical peptide synthesis has advanced during the last few decades now having
routine methods for the synthesis, purification and characterization of peptides. There are
still problems that limit the efficacy of peptide synthesis e.g. racemization during peptide
bond formation, the costs and the availability of special chemicals and commonly used
protected amino acids and activators, low yield of sterically hindered couplings and the
toxic nature of solvents and coupling reagents when applied to pharmaceuticals or food
grade end products. Furthermore, recycling of the chemicals and solvents used in synthetic
peptide chemistry is not a common practice (Guzman et al. 2007, Kumar & Bhalla 2005).
However,  chemical  peptide  synthesis  is  the  most  convenient  method  for  small  scale
production  of  short  and  medium  sized  peptides  (up  to  50  residues)  and  it  is  the  only
method which can produce peptides with non-natural structures and modifications.
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1.2.1 Development of peptide chemistry
Fischer  and  his  group  described  the  synthesis  of  first  peptide,  glycylglycine  (Gly-Gly)  in
19011 and a few years later they published the synthesis of 18 residues peptide (see Suresh
Babu 2011, Kimmerlin & Seebach 2005). The problems with the suitable protection and
deprotection of terminal amino and carboxylic groups and with racemization i.e. the
conversion of the L-configuration to D-configuration (and vice versa) of the residues
hindered progress in peptide chemistry for a long time. Further, there were few suitable
purification and identification methods for the products. The introduction of the
benzyloxycarbonyl (Z, also Cbz) –protection group (Figure  4) for temporary N-terminal
amino protection in 1931 was a huge step forward, not only for protecting of the
compounds but also preventing the racemization (Kimmerlin & Seebach 2005). It took more
than 50 years from the first peptide synthesis when the first peptide hormone, oxytocin,
could be synthesized and purified by du Vigneaud and his collaborators (du Vigneaud et
al. 1953). This initiated the era of peptide pharmaceuticals. The next groundbreaking
breakthrough was the introduction of a new, acid-labile protecting group, tert-
butyloxycarbonyl (Boc) (Figure  4),  which  was  stable  toward  hydrogenation  and  strong
alkali and therefore orthogonal to the Cbz (Carpino 1957, McKay & Albertson 1957). The
combination  of  Boc-  and  Cbz-protecting  groups  was  used  for  the  synthesis  of  several
peptides  including  the  synthesis  of  a  39-residue  -corticotropin,  also  known  as
adrenocorticotrophic hormone (ACTH) in 1963 (Schwyzer & Sieber 1963). In 1970, Carpino
was once again involved in a major breakthrough in the synthetic peptide chemistry field
when his group discovered the acid-labile -amino-protecting group, 9-
flourenylmethoxycarbonyl (Fmoc, Figure 4) (Carpino & Han 1970). This enabled the use of
acid-labile protection for side-chains and selective deprotecting of the -amino group after
amide bond formation. Today, a large number of protecting groups are in common use
with selective and specific coupling and deprotecting methods and these allow very
specific modifications to the peptides (Isidro-Llobet et al. 2009).
Figure 4. Selective -N-protecting groups.
In  addition  to  the  amino  acid  protecting  method  development,  new  coupling  methods
were intensively studied. The first important innovation was the introduction of
carbodiimides in 1955 which allowed the activation of carboxylic group (Sheehan & Hess
1955). However, the activation of the carboxylic group via carbodiimides such as N,N’-
diisopropylcarbodiimide (DIC) and N,N’-dicyclohexylcarbodiimide (DCC) (Figure  5)
caused the racemization of activated residue through the highly reactive intermediate of the
O-acyl-isourea (Figure  6).  The  activation  of  the  carboxylic  group  often  causes  some
racemization, but the introduction of less-reactive benzotriazole based activators such as 1-
1 Original publication: Fischer, E. & Fourneau, E. 1901, ”Ueber einige Derivate des Glykocolls”, Berichte der deutschen
chemischen Gesellschaft, vol. 34, no. 2, pp. 2868–2879.
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hydroxybenzotriazole (HOBt, Figure 5) and 1-hydroxy-7-azabenzotriazole (HOAt, Figure 5)
has been shown to minimize racemization (König & Geiger 1970, Kimmerlin & Seebach
2005, Carpino 1993) Subsequently, a large number of coupling reagents and methods has
been described based on carbodiimides and benzotriazoles and their combinations such as
uronium salt derivative of HOBt, 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU, Figure 5) ( Albericio & Carpino 1997, Albericio 2004).
Figure 5. Commonly used activators based on carbodiimides and benzotriazoles.
Figure 6. Activation of C-terminal carboxylic group by carbodiimides during coupling (above)
and the mechanism for racemization via 5-(4H-)oxalozone intermediates (below).
The synthesis method used for the peptide production until 1960 was called solution- or
liquid-phase peptide synthesis (LPPS, sometimes called also SPS). This consists of
consecutive cycles of the synthesis, isolation, purification and characterization of
intermediate products. Peptide chemistry progressed slowly until Bruce Merrifield
published the revolutionary solid-phase peptide synthesis method (SPPS) in 1963
(Merrifield 1963). The main concept of SPPS method is the linking of the growing peptide
to an insoluble support and after each reaction step, the byproducts are simply removed by
filtration and washing. Since the peptide synthesis is a continuous cycle of washings,
couplings of new residues, washings and deprotections, it can be performed in a single
reaction vessel. This led to the rapid development of the first automated peptide
synthesizer (Merrifield & Stewart 1965, Merrifield et al. 1966). With LPPS, it took weeks or
months to produce even a short peptide, whereas with the Merrifield method syntheses
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could be completed within days. The developments of SPPS together with new
chromatographic purification techniques, especially high performance liquid
chromatography (HPLC), and powerful product characterization via MS turned SPPS into a
routine and highly automated method. There are several manufacturers of automatic
peptide synthesizers e.g. AAPPtec, Biotage AB, Protein Technologies Inc and CEM
Corporation. Some manufacturers sell a synthesizer which can use microwave assisted
heating during synthesis.
The coupling reactions of peptide synthesis have been performed traditionally at room
temperature  (RT)  without  the  need  of  external  heating  or  with  gentle  heating.  In  organic
chemistry, microwave (MW) assisted heating has been used widely since the middle of
1980’s with the first time it was used in peptide synthesis being in 1992 (Yu et al. 1992).
There was still some delay in the development of MW-assisted peptide synthesis because of
the  requirements  of  the  technology  including  reactors  which  could  work  at  specific
pressures with temperature control and also chemicals stable enough to work at elevated
temperatures and pressures. The MW-assisted heating also raises the number of unwanted
side reactions such as the racemization of certain amino acids and possible aspartimide
formation. Recently in many studies, MW-assisted peptide synthesis has been shown to
have advantages in terms of speed, yields and purity. The coupling times can be even
reduced to 30s instead of the commonly used ½ - 2h. More complete coupling reactions can
increase the yields in terms of purity and also the synthesis of some difficult sequences can
be enhanced (Sabatino & Papini 2008).
1.2.2 Solid-phase and solution-phase peptide synthesis
The  main  advantages  of  LPPS  are  the  control  of  synthesis  via  the  purification  and
characterization of intermediate products and the limited sterical hindrance in the coupling
sites. However, when the peptide chain elongation is continued, then the purification
becomes  more  difficult.  This  problem  could  be  resolved  by  the  condensation  of  short
protected peptide fragments and coupling them to larger molecules (Guzman et al. 2007,
Bray 2003). Several peptide-based pharmaceuticals have been manufactured via LPPS
including atosiban, eptifibatide, ocreotide and, bivaluridin (Table 1, see page 3) (Guzman et
al. 2007, Verlander 2007). LPPS could be used also in the condensation of peptide fragments
produced by SPPS. This hybrid type of synthesis has been used successfully in the
production of enfuvirtide, a 36 amino acid containing drug for treatment of HIV (Table 1).
The annual production of enfuvirtide was believed to be 4000 kg in 2007 (Guzman et al.
2007)  and  it  has  been  one  of  the  driving  forces  in  the  development  of  new  synthetic
strategies. The yield of enfuvirtide via conventional SPPS was initially only 6-8% from the
loaded  resin  but  after  several  improvements,  the  efficiency  of  the  hybrid  synthesis  via
solution phase condensations of three SPPS-produced fractions reached over 30% (Bray
2003).
The main advantage of  SPPS is  that  when the  growing peptide  is  attached to  the  solid
resin, the excess amino acids, coupling reagents, impurities and deprotecting products can
be removed easily via simple washings. When the sequence is ready, the peptide is cleaved
and  isolated  via  conventional  purification  methods.  There  are  a  high  number  of  different
solid supports with a wide variety of cleaving protocols enabling the cleavage of peptide
with side chains protected or deprotected and with an unmodified or modified carboxy-
terminal. There are also resins which can be preloaded with a wide variety of available
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chemical groups. The prepared peptides are usually cleaved from the resin using strong or
mild acids. In addition, base labile resins and further photolabile resins have been
developed (Guzman et al. 2007). Today almost all of the synthetic steps can be automated
and the protocols have become well-established. The peptides which are manufactured by
SPPS  include  leuprolide,  calcitonins,  desmopressin,  somatostatin  and  glugacon  derived
peptides (Guzman et al. 2007, Verlander 2007).
The  disadvantages  of  SPPS  are  more  or  less  based  on  the  limited  space  inside  and
around the porous resins. Protected residues in the growing sequence and the incoming
bulky protected amino acid just cannot react in the limited space. The growing peptide
chain can fold over onto itself or aggregate with a neighboring peptide chain. These can
cause the truncation of the peptide chain and result in a high amount of incomplete
sequences and impurities which are difficult to separate. The introduction of analytical and
preparative HPLC-methods in the late 1960’s by Horvath and coworkers and developments
in the HPLC techniques have improved the purification of peptide products (Horvath &
Lipsky 1969). The success of peptide synthesis is highly sequence dependent. It has been
noted that peptides including <15 amino acids are generally efficiently synthesized and
purified but if the number of residues increases, then the purification becomes more
challenging. It is rare that peptides containing 40 or more amino acids can be successfully
synthesized with the correct sequence and with clear peak when analyzed by HPLC (Bray
2003).
Long peptides can be prepared by combining fully protected peptide fragments cleaved
from  very  weak  acid  labile  resins.  The  coupling  of  peptide  fragments  in  solution  to  the
other fragments is usually the only possible method with which to produce the correct full
length peptide. This usually means conducting many studies via trial and error to find the
best combination as seen in the case of enfuvirtide a peptide with 36 residues (Bray 2003).
The  hybrid  synthesis  of  green  fluorescent  protein  with  its  238  residues  was  performed
using 26 fully protected fractions in solution phase coupling (Nishiuchi et al. 1998). Another
approach for producing long peptide sequences is the method called native chemical
ligation (NCL). This is based on the prior thiol capture strategy for the coupling of two
peptide fragments and it was introduced by Kemp and collaborators (Kemp et al. 1981,
Kemp & Kerkman 1981). The original NCL method was based on the acyl shift between one
peptide connected to template molecule via C-terminal ester bond and another peptide
connected to the same template via a disulphide bridge between side chain of the N-
terminal cysteine and the template molecule. After the acyl shift has occurred forming an
amide bond between peptides, the disulphide bond is cleaved yielding long peptide. One
problem may be that there can be steric hindrance due to the amino acid attached to the
template and this limits the efficiency of the synthesis (Kimmerlin & Seebach 2005).
Improved NCL methodology was introduced in the middle of 1990’s. This technique allows
the selective ligation of the two purified unprotected peptide sequences (Dawson & Muir
1994, Tam et al. 1995). The ligation occurs between C-terminal thioester and N-terminal
cysteine via transesterification and rapid intramolecular S to N acyl shift, forming the
amide bond at the ligation site (Figure 7). The chemical ligation overcomes problems that
usually limit the synthesis of large peptides and proteins such as poor solubility and
difficulties in the purification of large protected fragments (Kimmerlin & Seebach 2005).
Several specific chemical ligation methods have been developed also for the on-resin to
minimize the losses during repeated purification and lyophilization steps especially in the
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protein synthesis (Canne et al. 1999, Brik et al. 2000, Kimmerlin & Seebach 2005).
Furthermore, it has been shown that the epimerization of the residue next to the ligation
site does not occur during the ligation reaction (Lu et al. 1996).
Figure 7. Native chemical ligation via N-terminal cysteine.
One major limitation of NCL method is that many peptides or proteins do not contain
cysteine. The ligation reaction can also be performed via using for example histidine or
homocysteine, which can be methylated to methionine, as the N-terminal residue
(Kimmerlin & Seebach 2005). Chemical ligations have been utilized mainly in the synthesis
of proteins but they also provide an interesting possibility to permit the synthesis of
complex peptides.
1.2.3 Strategies in peptide synthesis
The basic principle of peptide synthesis contains repetitive steps of the couplings of
protected amino acids and the deprotection of the backbone protection. This is usually
performed by attaching the first residue to the solid phase via the C-terminal carboxylic
group followed by the deprotection of N-terminal  amino  group.  The  next  step  is  the
attachment of the second residue via the carboxylic group, usually activated for better
coupling  efficiency.  This  synthetic  direction  is  called  the  CN direction and the basic
principles are represented in Figure 8. N-terminal deprotection is usually removed under
mild conditions and the reactive groups of side chains are masked with permanent
protection groups which are stable towards the reaction conditions during peptide
elongation. The permanent side chain protection groups can be deprotected during the
cleavage of the peptide from the solid support or afterwards.
The reaction conditions such as coupling, deprotection and cleavage times, solvents and
mixing method are case-dependent. The literature is full of references for peptide synthesis
protocol using LPPS or both manual and automated SPPS. The main factors to be
considered when a new peptide synthesis is being planned, are: 1) the choice of the
synthetic strategy between Fmoc- and Boc-strategy, 2) the choice of side chain protection
groups, 3) the choice of coupling reagents, 4) the solvent to be used and the concentration
of reagents, 5) ratio of substrates, 6) reaction times, 7) temperature, 8) mixing method
(shaking, stirring, bubbling with inert gas such as N2 or Ar) and when SPPS is used, 9)
the choice of the solid phase, the resin (Li & Roller 2002, Amblard et al. 2006, Albericio
2004, Sabatino & Papini 2008). Several associations such as the Association of Biomolecular
Resource Facilities (ABRF), reagent suppliers such as Bachem, GL Biochem Ltd, Sigma-
Aldrich corporation, ChemPep Inc and Merck and also manufacturers of peptide
synthesizers (earlier mentioned) have published their own protocols for basic peptide
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synthesis usually covering all of the above mentioned factors. The next sections will
describe the main factors to be considered.
Figure 8. Basic peptide synthesis protocol.
Fmoc versus Boc. There are currently two main strategies being used with SPPS for
peptide  synthesis:  Boc  (Boc/Bn)  -strategy  with  Boc-protected  -amino  group  and  Fmoc
(Fmoc/But) -strategy with Fmoc-protected -amino group. The protection of the -amino
group is the most important issue in peptide chemistry in order to control the
polymerization. The -amino group should be removed rapidly and specifically without
any side reactions. -N-Protected amino acids have to be soluble in most common solvents
and they should be crystalline solids with good stability to allow easy handling and
storage. They also should prevent or minimize racemization during the coupling (Isidro-
Llobet et al. 2009). In SPPS, Fmoc and Boc are the most widely used protecting groups. In
the LPPS, also Z (Figure 4, see page 13) can be used for -amino protection.
The Boc-strategy is based on the use of mild acid labile Boc-group (Figure  4) for the
protection of -N-group and benzyl-based protection (Bn) of the side chains of amino acids.
This method has been in use since the development of SPPS by Merrifield (Merrifield 1963,
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Amblard et al. 2006). The N-terminal Boc is usually removed by using 25-50%
trifluoroacetic acid (TFA) in dichloromethane (DCM). This combination is an excellent
solvent for the protected peptide chain since it reduces the amount of aggregation and
usually achieves the quantitative deprotection of the N-teminal amine. The use of acidic
conditions in the deprotection step results in the protonation of the amino group and this
might affect the next coupling if the neutralization remains insufficient (Sabatino & Papini
2008). This can be avoided by, for example, using in situ neutralization during the coupling
step by adding a slight excess of a weak base such as diisopropylethylamine (DIEA)
(Schnölzer et al. 1992). The rapid deprotection of the N-amino group means that the Boc-
strategy suitable for the synthesis of difficult and/or high molecular weight sequences
(Guzman et al. 2007). Furthermore, the advantage of the Boc-strategy is the relatively low
costs of Boc-protected amino acids and the other building blocks. The major disadvantage
for Boc-chemistry is the need for the highly toxic chemical, hydrogen fluoride (HF), during
the final cleavage step in the release of the complete sequence from resin. This means that
one must utilize polytetraflouroethylene-lined equipment and this limits the use of Boc-
chemistry in many research laboratories (Amblard et al. 2006). However, as an alternative
for  HF,  trifluoromethanesulphonic  acid  (TFMSA)  can  be  used  and  this  agent  can  be  used
with normal laboratory glassware (Yajima et al. 1974). The use of the very strong acid can
lead to the production of many acid catalyzed side reactions such as alkylations of aromatic
moieties and deletions in sequences containing fragile bonds and residues (Kimmerlin &
Seebach 2005). The extent of some of these side reactions can be reduced by the use of
diluted  HF  in  H2S (Tam et al. 1983). However, the repeated Boc-deprotections in acidic
conditions may cause the undesirable cleavage of the side chain protecting groups
(Verlander 2007, Amblard et al. 2006, Sabatino & Papini 2008).
The Fmoc –strategy is based on the use of the base-labile Fmoc-group (Figure 4, see page
13) for the protection of N-teminal amino group and tert-butyl-based protection for the side
chains (Carpino & Han 1970). The use of base-labile -N-protection enables the use of acid-
labile side chain protection and linkers in the resin. There is a wide variety of possibilities
for  the  temporary  or  permanent  orthogonal  protection.  Peptide  synthesis  based  on  the
Fmoc-strategy  can  be  performed  without  any  special  laboratory  equipment  and  this
decreases the costs of synthesis. Fmoc-based SPPS is today the method of choice for routine
peptide synthesis (Amblard et al. 2006). There are however some considerable
disadvantages associated in the Fmoc-strategy. Fmoc is a bulky protecting group and its
presence may decrease both coupling and deprotection efficiency. Steric hindrance can be
critical, especially when the Fmoc--N-protected amino acid does contain bulky and
protected side chain such as Trp or Tyr. The deprotection reaction with Fmoc is slower than
with Boc and may produce a significant amount of incomplete side products if quantitative
deprotection is not achieved (Schnölzer et al. 2007). The most widely used deprotection
cocktail for use with Fmoc is 20% piperidine in N,N-dimethyl formamide (DMF) (Atherton
et al. 1978) but also many other methods has been reported including the use of 50%
morpholine in DMF (Isidro-Llobet et al. 2009). The major problem in piperidine-based
deprotection is aspartimide formation from aspartic acid. This may cause the conversion of
-peptide to -peptide and also the formation of a piperidine adduct to the side chain of
aspartic acid (Figure 9). The most widely used side chain carboxylic acid protecting group is
tert-butyl (But, Table 3). This minimizes the aspartimide formation via sterical reasons but it
does not prevent the reaction completely (Isidro-Llobet et al. 2009, Mergler et al. 2003). In
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addition to But, various other side chain protection groups for Asp have been described
such  as  more  bulky  3-methylpent-3-yl  (Mpe)  and  9-fluorenylmethyl  (Fn)  (Isidro-Llobet  et
al. 2009). The addition of a small amount of HOBt into the deprotection step further reduces
the aspartimide formation (Mergler & Dick 2005, Isidro-Llobet et al. 2009). Compared to the
Boc strategy, the price of Fmoc-protected amino acids is relatively high and the solubility of
some Fmoc derivatives in the commonly used solvent, DCM, can be very low (Isidro-Llobet
et al. 2009).
Figure 9. Aspartimide formation and piperidine adduct attachment during Fmoc synthesis.
Protection of functional groups.  The  protection  of  side  chain  functionalities  against
unwanted reactions is highly dependent on the -N-protection method chosen. When the
Boc-strategy is selected, then the side chain protection has to be stable against relatively
strong acidic conditions whereas in the Fmoc-strategy, side chain protection has to be able
to withstand mild bases. The focus in this section is on protection of naturally encoded
amino acids but it will also cover a wide range of functionalities in common use in organic
chemistry. The side chain functional groups, which should be protected are primary amino
(Lys),  guanidino  (Arg),  secondary  amino  groups  (His,  Trp),  amide  groups  (Asn,  Gln),
carboxylic  acids  (Asp,  Glu),  primary  alcohols  (Ser,  Thr),  phenol  (Tyr),  thiol  (Cys)  and
thioether (Met). Gly and aliphatic or aromatic hydrocarbon side chains containing amino
acids (Ala, Val, Leu, Ile, Phe, Pro) do not need side chain protection. The optimal protecting
group must possess a few desirable properties: a straightforfard introduction to the
functional group, stability towards a broad range of reaction conditions and specific
removal when needed. The most commonly used protection groups for Fmoc-based
peptide synthesis will be briefly discussed below and the protecting groups with removal
conditions are shown in Table 3.
The primary amino group can be related to the -N-group of backbone and it can be
protected in the same manner. A Free side chain amine group leads to branched peptides
during Fmoc-based peptide synthesis and commonly it has to be specifically protected. The
side chains of Lys and its shorter analogs such as Orn can be used as a linker in cyclization
reactions  but  also  for  the  conjunction  of  additional  molecules  such  as  chelating  agents.  If
permanent or specifically removable protection is needed, allyloxycarbonyl (Alloc) or 4-
methyltrityl (Mtt) can be used in the Fmoc-strategy (Isidro-Llobet et al. 2009).
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Table 3. Protection groups and removal conditions commonly used in Fmoc-peptide synthesis.
Protected
functionality
name structure removal
conditions
stabile to the
removal of
backbone amino Fmoc 20% piperidine in
DMF,
Boc, Pbf, Mtt,
Trt, All, tBu,
Dmab, Acm
Lys, Orn (sc amino) Boc 25-50% TFA in
DCM,
Fmoc, All, Trt
Mtt 1% TFA in DCM, Fmoc, All, Boc,
Dmab, Acm
Arg (sc guanidino) Pbf 90% TFA (H2O, TIS
as scavengers)
Fmoc, Trt,
Alloc
His (sc imidazole)
Asn, Gln (sc amide)
Cys (sc thiol)
Trt 1% TFA-DCM, Fmoc, Alloc,
Acm
Trp (sc indole) Boc 95% TFA  and
scavengers
Fmoc, Trt, All
backbone carboxylic
acid, (sc carb. acid)
All Pd(PPh3)4 (0,1eq),
PhSiH3
Fmoc, Boc, Trt,
tBu,
Asp, Glu (sc carb.
acid)
But 90% TFA in DCM, Fmoc, Trt, All
Dmab 2% hydrazine in
H2O-DMF (1:1)
Fmoc, Boc, Trt,
All, tBu
Ser, Thr, Tyr (sc
hyxroxy)
But 90% TFA in DCM, Fmoc, Trt, All
Cys (sc thiol) Acm I2,
Hg (II)
Fmoc, All, Trt
Abbreviation used: sc, side chain; carb. acid, carboxylic acid
The  guanidino  group  of  Arg  can  undergo  deguanidination  under  basic  conditions,
especially during Fmoc deprotection, converting Arg to Orn (Rink et al. 1984). The side
chain of Arg has to be protected with strongly electron withdrawing and bulky groups such
as pentamethyl-2,3-dihydrobenzofuran-6-sulfonyl (Pbf) in the Fmoc strategy.
The imidazole ring of His may be involved in racemization via N of His residue during
the activation step for the next amino acid coupling (Isidro-Llobet et al. 2009). The
imidazole ring can also be acylated when endcapping with acetic anhydride is performed
after coupling, leading to the termination of synthesis via N to -N-migration (Ishiguro &
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Eguchi 1989). Thus, N is usually protected with a bulky or an electron withdrawing group
such  as  trityl  (Trt)  in  the  Fmoc-strategy  to  prevent  acylation  and  to  reduce  basicity  of  N
(Isidro-Llobet et al. 2009).
The nitrogen in the indole group of Trp can undergo alkylation by carbocations from
deprotection or  degradation products  from the  resin  (Giraud et  al.  1999).  Trp can be  used
without protection but usually it is Boc-protected in the Fmoc strategy (Isidro-Llobet et al.
2009).
Asn and Gln can be used without deprotection but the solubility of unprotected Asn and
Gln is  low and there  is  the  risk  of  side  reactions:  Asn can undergo the  dehydration of  its
side chain yielding nitrile instead of the amide in side chain (Figure 10), especially when the
Fmoc-strategy is being used (Mojsov et al. 1980, Gausepohl et al. 1989). The use of HF in the
Boc-strategy usually reverts the dehydration (Mojsov et al. 1980). Gln can undergo the same
side reaction as Asn but its most significant side reaction is the formation of cyclic
pyroglutamyl leading to a truncated sequence (Figure 10)(Dimarchi et al. 1982). This
reaction is weak acid catalyzed and is more important in the Boc-strategy. The most widely
used protecting group for Asn and Gln is Trt in the Fmoc- strategy.
Figure 10. Dehydratation of Asn during the coupling (left) and pyroglutamyl formation (right).
In addition to the amino function, the carboxylic acid function is the most extensively
used function for modification site in peptide synthesis. The C-terminal carboxylic acid is
usually protected via resin attachment because most commonly peptide synthesis in SPPS
is  performed in  the  CN direction.  In  LPPS or  in  the  reversed peptide  synthesis  strategy
(NC direction), specific C-terminal protection will be necessary (Jensen et al. 1998,
Thieriet et al. 2000, Isidro-Llobet et al. 2009). The side chains of Asp and Glu are usually
protected in  order  to  prevent  their  unwanted cyclization or  branching of  peptide.  During
NC synthesis, the duplication of residues is prevented via the backbone -carboxylic acid
protection.  The most  important  side  reaction to  be  considered for  Asp and Glu side  chain
protection is the prevention of the above mentioned aspartimide formation (Figure 9, see
page 20) and pyroglutamic formation, respectively. However, the cyclization of Glu
yielding pyroglutamic acid is much less problematic. The most commonly used side chain
protection groups are But in the Fmoc-strategy despite the fact that it is only capable of
minimizing aspartimide formation (Isidro-Llobet et al. 2009, Mergler et al. 2003). Allyl (All),
which can be selectively removed with a Pd-catalyst, is a very useful carboxylic acid
protection group when C-terminal modifications are needed. All has been used in the NC
synthesis  strategy  and  for  the  production  of C-terminally modified peptides using
backbone amide linker (BAL) (Jensen et al. 1998, Thieriet et al. 2000) or in head-to-tail, side
chain to tail and side chain to side chain cyclizations (Alcaro et al. 2004, Li & Roller 2002).
When it is used in a synthesis where the target is to combine the Fmoc-protected amino
group and the All-protected carboxylic acid, the latter’s protection should be first removed
to prevent allylation of the amino function (Kates et al. 1993). Another selectively
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deprotected carboxylic function protection group which can be used in cyclization
chemistry  is  4-(N-[1-{4,4-dimethyl-2,6-dioxocyclohexylidene}-3-methylbutyl]amino)benzyl
(Dmab) which is labile toward dilute hydrazine solution but nonetheless stable toward
piperidine (Isidro-Llobet et al. 2009).
The amino acids which contain a hydroxyl group in the side chain include Ser, Thr and
the aromatic Tyr. These molecules can undergo O-acylation followed by O-N migration
after N-deprotection when excess acylating agents are used. Ser and Thr are also prone to
dehydration but this is not common in the usual peptide synthetic methods. The hydroxyl
group is commonly protected as an ether and But is  used  in  the  Fmoc-strategy  (Isidro-
Llobet et al. 2009).
Cys plays a major role in natural rigid structures and in disulphide bridges between two
Cys  residues  are  very  commonly  present  as  the  stabilizing  agents  in  3-D  structures  of
proteins. The nucleophilic thiol undergoes spontaneous oxidation to the disulphides in air
if it is not protected. Cys can also undergo several side reactions even with protection.
These include oxidation, base catalyzed -elimination of sulphur resulting dehydroalanine,
S-alkylation and racemization (Isidro-Llobet et al. 2009, Angell et al. 2002, Han et al. 1997).
The racemization occurs during treatments with bases in the coupling steps and the
racemization rate can be reduced either by using no base or some alternative base such as
N-methylmorpholine (NMM) or 2,4,6-trimethylpyridine (TMP, collidine) in place or the
commonly used DIEA in the Fmoc-strategy (Han et al. 1997). Racemization can also be
controlled by the choice of activators, by protecting groups and resins (Kaiser et al. 1996,
Angell et al. 2002). The choice of protecting group depends on the desired product. If a free
thiol is wanted, then Trt in the Fmoc strategy is a feasible choice whereas acetamidomethyl
(Acm) is the recommended protecting group if the disulphide bridge is needed (Isidro-
Llobet et al. 2009). However, it should be noted that some Acm adducts may well be
detected for example from Tyr after Acm removal (Engebretsen et al. 1997). The variety of
different types of protection of cysteine is very important when the desired product
contains more than one disulphide bridge. The disulphide bridge assembly can be
controlled using different pairs of protection groups (Table 3).
Methionine is a challenging residue in peptide chemistry because it is prone towards
oxidation of its thioether to sulfoxide and in some cases it can become S-alkylated. Met is
still commonly left unprotected in the Fmoc strategy (Isidro-Llobet et al. 2009).
Backbone NH-protection is not commonly used but it can be helpful for preventing the
aggregation of the growing peptide chain, especially in the Fmoc strategy. The aggregation
of the protected sequence reduces coupling and deprotection yields and can result in
incomplete sequences. The incorporation of dimethyloxazolidine dipeptides (Figure 11)
which  can  be  derived  from  Ser  or  Thr  in  combination  with  the  next  residue  in  the N-
terminal side has been shown to enhance the synthesis of challenging sequences (White et
al. 2004, Abedini & Raleigh 2005).  Backbone protection can be also used for preventing
aspartimide formation which is a severe problem especially when the sequence contains
Asp-Gly. The rate of aspartimide formation can be affected by the choice of resin, the
deprotection reagents, coupling additives and resin cleavage cocktails but the use of
backbone N-protection such as 2-hydroxy-4-methoxybenzyl (Hmb) has been shown to
prevent efficiently aspartimide formation (Packman 1995, 284 Cebrian et al. 2003).
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Figure 11. Fmoc-protected oxazolidine dipeptide building block (a) and Acid-catalyzed ring
opening of  oxazolidine to regenerate Ser or  Thr (b).  R = H, Ser; R = CH3,  Thr; R1,  R2 = any
amino acid side chain.
Another harmful side reaction, which can result in sequence shortening by two residues,
is diketopiperazine formation (DKP, Figure 12) between two adjacent residues. The DKP
formation has been detected mainly between the first couple of residues connected to the
resin during the -N-deprotection  of  the  second  and  the  coupling  of  the  third  residue
(Albericio & Carpino 1997). The DKP formation can be prevented by using bulky and mild
acid labile trityl for -N-protection and via the choice of a resin with the use of a sterically
hindered Barlos-resin (e.g. 2-Cl-trityl) (later in Table 4) being recommended (Albericio 2004,
Amblard et al. 2006, Albericio & Carpino 1997). The prevention of DKP formation is crucial
when the reverse SPPS method (NC) or backbone amide linker (BAL) method is used for
the production of C-terminally modified peptides. During reverse synthesis, the choices of
the resin and the coupling conditions have to be considered (Thieriet et al. 2000). The use of
acid labile protection group for -N-group leaves the amino function protonated after
cleavage, and this prevents DKP-formation (Jensen et al. 1998). DKP formation is
commonly detected during the synthesis of backbone N-methyl rich peptides or when both
D- and L-amino acids are used (Teixido et al. 2005). The DKP formation can occur also
during chain elongation (Thieriet et al. 2000, Tulla-Puche et al. 2007, Isidro-Llobet et al.
2009).
Figure 12. The diketopiperazine formation between two C-terminal residues.
Activation of coupling steps. The growing need for the efficient and low cost synthesis
of peptides, especially peptide pharmaceuticals, has resulted in a wide variety of activation
reagents which can be used in amino acid couplings. These have been widely discussed in
the literature and only the most commonly used in basic peptide synthesis protocols will be
discussed in this section (Albericio 2004, Amblard et al. 2006, Albericio & Carpino 1997, Li
& Roller 2002). Carbodiimides (Figure 5, see page 14) are known to be effective coupling
reagents but the racemization of the activated residue via oxazolone intermediate (Figure 6,
see page 14) limits their use and therefore the less active uronium and phosphonium salts
of HOBt are currently extensively used in peptide chemistry. However, carbodiimides are
cheap, especially DIC, and they are thermally stable which makes them suitable for MW-
assisted peptide synthesis (Hachmann & Lebl 2006). DIC is the recommended choice of
carbodiimides for Fmoc-based SPPS, because the diisopropylurea formed after activation is
more soluble in commonly used DMF than the dicyclohexylurea (DCU) formed after DCC
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activation (Albericio & Carpino 1997). In the Boc strategy, DCC can be used because HF
used for the -N-deprotection is a good solvent for DCU. HOBt can be used as an additive
with carbodiimides to form active HOBt-ester which is not so prone to racemization. The
DIC/HOBt activation is still the recommended choice in some instances, for example in
MW-assisted peptide synthesis (Bacsa et al. 2008). The most commonly used activators in
conventional peptide synthesis are uronium salts of HOBt despite the fact that they can
irreversibly block the N-terminus by forming tetramethylguanidium derivatives (Amblard
et al. 2006). However, this can be avoided by creating the carboxylate of amino acid before
adding uronium-based activators and also by using reduced equivalency for the activator
compared to the amino acid (Albericio et al. 1998, Amblard et al. 2006).  The most widely
used uronium derivatives are HBTU, HATU and HCTU (Figure 5, see page 14) because of
their rapid and efficient coupling and reduced racemization associated with their use.
HOAt derived HATU is said to possess superior acylation kinetics and to have a better
ability to prevent racemization but its use is usually limited to the challenging coupling
steps such as N-methylated amino acids and cyclizations because it is expensive (Carpino
1993, Miranda & Alewood 1999). The development of Cl-HOBt derived HCTU about 10
years ago represented a relatively cheap alternative to HBTU and HATU and recently it has
been shown to be very efficient in the rapid synthesis of seven biologically active peptides
including oxytocin and -amyloid 1-42 requiring only 5 min coupling times (Sabatino et al.
2002, Hood et al. 2008). The phosphonium salts of benzotriazoles such as PyBOB and
PyAOP (Figure 5) can be used as an alternative to the uronium salts but their efficiency is
not as high as the uronium-based activators (Hachmann & Lebl 2006, Sabatino & Papini
2008). However, by using the phosphonium salts of benzotriazoles, the guanidylation side
reaction can be prevented (Sabatino & Papini 2008, Albericio 2004). In addition, the mixing
of different types of coupling reagents can also be an option (Hachmann & Lebl 2006). Mild
tertiary bases are used in conjunction with activators to convert the amino acid into an
active benzotriazole-ester (OBt) with DIEA being most commonly used for this purpose
although racemization can occur when Fmoc-Cys(Trt)-OH or Fmoc-Ser(But)-OH is used (Di
Fenza et al. 1998, Han et al. 1997). TMP can serve as an alternative for DIEA to reduce
epimerization (Carpino et al. 1996). -Branched amino acids including Ile, Val and Thr may
result in incomplete acylation due to steric hindrance. The recoupling (double couple) of
the  residues  is  recommended  if  incomplete  coupling  is  suspected  (Albericio  &  Carpino
1997). Sometimes, if there is a suspicion of incomplete coupling, a method called end-
capping can be used to terminate incomplete sequences in order to prevent deletions from
the sequences. -N-functionality is terminated readily using acetic anhydride and the same
method has been applied to terminate free amino groups from the resin before proceeding
with the synthesis (Garcia-Martin et al. 2006, Bacsa et al. 2006, Albericio & Carpino 1997).
Solvents for peptide synthesis. The choice of the solvents is dependent on the method
being used for the synthesis. In solution phase synthesis, it is important that there are good
reaction rates with all reagents i.e. protected amino acids and activators are completely
dissolved together with growing peptide chain. During SPPS, the complete solubility of
reagents is virtually essential because insoluble particles can precipitate in an insoluble
carrier and then the risk of contamination becomes significant. The most widely used
solvents in peptide syntheses are DMF, DCM, and 1-methyl-2-pyrrolidinone (NMP) but
also dimethyl sulfoxide (DMSO) and tetrahydrofuran (THF) can be used (Albericio &
Carpino 1997). DMF is commonly used in SPPS because it is aprotic and polar and thus it
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offers good solubility for the different kinds of reagents and protected amino acids
(Amblard et al. 2006). The disadvantage of DMF is its tendency to form dimethylamine
during long storage periods and the amine moieties can cause unwanted Fmoc-
deprotection during the synthesis procedure. DMF is usually distilled after a long time
storage. NMP is a feasible alternative and in fact it is usually preferred in MW assisted
syntheses because of its better thermal stability (Bacsa et al. 2008). The relatively nonpolar
DCM is a widely used solvent in the Boc-strategy. Another highly important factor for
determining  which  solvent  to  use  in  SPPS  is  the  ability  to  swell  the  resin  beads  because
most of the coupling sites lie inside of the beads. The swelling ability of the solvent will be
dependent  on  the  resin  chosen  and  this  can  affect  significantly  the  aggregation  of  the
growing peptide chain leading to incomplete coupling via steric hindrances. For example
when a hydrophobic polystyrene-based resin is used, dichloromethane (DCM) is used for
swelling. However, the solubility of the activators and protected amino acids is often
limited  in  DCM  and  the  synthesis  may  be  performed  in  a  mixture  of  DCM  and  DMF  at
variable concentrations. The more hydrophilic polyethylene glycol (PEG) containing resins
can  be  swelled  also  in  more  polar  solvents  such  as  DMF  or  DMSO  and  PEG-resins  are
therefore useful with a variety of solvents and mixtures (Garcia-Martin et al. 2006, Kates et
al. 1998).
Amount of reactants. The basic principle is that the concentration of reactants should be
kept  high and thus  concentrations  between 0.5  and 1.0  M should be  utilized (Albericio  &
Carpino 1997). Reagent and peptide synthesizer manufacturers usually recommend
suitable concentrations and methods. Usually moderate or a clear excess of amino acids and
activators is used in peptide synthesis, ensuring the maximal coupling efficiency. Typically
concentrations 2-10 times in excess compared to the peptide or resin load equivalency are
used (Albericio & Carpino 1997, Amblard et al. 2006). If one is utilizing uronium
derivatives of activators, then a slight excess of amino acid compared to the uronium
derivatives is recommented to avoid guanidium adduct formation. The formation of the
OBt-ester of amino acid can be achieved in the presence of a tertiary base, commonly DIEA,
and an equivalent or slight excess (1.5-2 eq.) of base is commonly used (Albericio & Carpino
1997, Amblard et al. 2006).
Reaction times. There is basically no upper limit for the reaction times and usually
reaction times are approximated. However, in the pharmaceutical industry, the time
consumed during synthesis is very costly and a rapid synthesis is desirable. The coupling
efficiency is heavily sequence dependent and thus the optimal coupling times for each step
should be evaluated, if the highest yield is demanded. Difficult couplings can be predicted
in certain reactions e.g. for sterically hindered amino acids with bulky side-chain protection
groups (e.g. Pbf, Trt, Dmab), when N-methylated amino acids are used, for cyclization
steps such as head-to-tail cyclization and when the length of the peptide sequence exceeds
10 residues. In these situations longer coupling times will be needed (Amblard et al. 2006).
For example, the cyclization yield of the marine sponge cycloheptapeptide, Phakellistatin 5,
never exceeded 15% although coupling times of up to 2 weeks were tested (Pettit et al.
2000). However, if the coupling time is long, the possibility for side reactions is also
elevated. One possible side reaction is guanidinylation of amino functionalities when
uronium-based activators are used (Hachmann & Lebl 2006, Albericio & Carpino 1997). The
development of automated and MW-assisted peptide synthesis protocols have resulted in
the publication ofsome studies investigating coupling efficiency with the lower limits being
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defined.  The  optimal  coupling  efficiency  was  monitored  in  the  study  of  Hachmann  and
Lebl  and they found that  with  a  coupling time of  2  min using HBTU as  an activator,  one
obtained a reasonable yield for the well-known test sequence of the acyl carrier protein
(ACP 65-74) (Hachmann & Lebl 2006). The use of DIC as an activator yielded no correct
product and demanded 8 min for coupling times to achieve yields equivalent to those
obtained with HBTU. When finally 30 min was used as coupling time, DIC gave the best
yields. In most cases, the coupling times will vary from 15 to 60 minutes, and for example
almost all coupling reaction examples described in the article of Albericio and Carpino used
a time of 30 minutes (Albericio & Carpino 1997). In many cases the use of external heating
affects both the coupling rates and efficiency. However, when MW-heating is used, the
coupling times are usually still counted in minutes, for example in the study of Brandt et al
the  sufficient  coupling  efficiency  was  achieved  for  the  model  peptides  using  3-4  min
coupling times  (Brandt et al. 2006).
Reaction conditions. As stated earlier, peptide synthesis is routinely performed at
ambient temperature and atmosphere. However, difficult couplings can be performed at
elevated temperatures up to 60-80°C and today these steps are more usually performed
under MW because it enables rapid heating and short reaction times while still providing
pure products (Brandt et al. 2006, Sabatino & Papini 2008). However, the higher the
temperature rises, the more side reactions will occur and the degradation of reactants and
products will be more likely. Most of the automated peptide synthesizers, with or without
MW-heating, utilize the basic Fmoc-reaction procedures. Some reaction steps however
require abnormal conditions. For example, All-deprotection has to be performed under an
inert gas because of the Pd-catalyst. Oxygen poisons the Pd-catalyst and usually argon-
atmosphere is preferred over N2 (Dessolin et al. 1995, Grieco et al. 2001).
Resin for SPPS. The choice  of  the  solid  carrier  for  SPPS is  very case  dependent  on the
peptide or peptide derivative product needed. During the next section, the term resin refers
to both a solid matrix and the linker between the matrix and the attachment site (grey dots
in Figure 8, see page 18 and Table 4)  and  only  attachment  sites  will  be  discussed  in  more
detail. Resins for SPPS can be purchased for both Fmoc- and Boc-strategies and they have a
wide variety of attachment sites for different functionalities, not only for the C-terminal
acid formation after cleavage. The peptide chain can be attached to the resin also via the N-
terminus, via side chains of amino acids (e.g.  Asp, Glu, Lys, Ser,  Thr) or via the backbone
amide. By using different resins the cleavage sites can be released as free unmodified
peptide acids or as ready modified moieties e.g. amides, alcohols or thioesters (Kimmerlin
& Seebach 2005). Furthermore, peptides can be cleaved as unprotected product or either
partially or totally side chain protected. The resin can be purchased with or without
protection on the attachment site or preloaded with some residue or even with multiple
residues. Loading of the first amino acid is dependent on the resin in use and therefore not
discussed here. The selection of the commonly used resins with different functionalities and
cleavage conditions are presented in Table 4.
When  Merrifield  invented  the  groundbreaking  SPPS  method,  he  ended  up  to  utilize  a
polystyrene (PS) -based polymer matrix with chloromethylated attachment sites (Merrifield
1963). He already noted that the porous gel structure of resin allowed good penetration for
reactants, especially in the presence of a swelling solvent. PS resins are relatively
hydrophobic resulting in sequence depended coupling difficulties. The search for better
swelling properties with an extended range of solvents led to the development of
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polyethyleneglycol derived PS-resins (PEG-PS) (Zalipsky et al. 1994). PEG contains both
hydrophobic (ethylene) and hydrophilic moieties (oxygen). At the end of 20th century, PEG-
PS resins became available in a wide variety of structures, for use with many kinds of
synthetical strategies and with variable loading capacities (Kates et al. 1998). Loading
capacity (load) refers to the theoretical amount of the molecules which can be produced on
the resin beads and it is calculated as moles per mass unit of resin (mmol/g). Short peptides
can usually be produced with higher load (0.5-1.0 mmol/g) whereas for long or difficult
sequences a resin with a lower load (0.1-0.3 mmol/g) can be chosen. Recently, a highly
versatile and totally PEG-based resin called chemmatrix was described (Garcia-Martin et al.
2006). It contains only the PEG-mesh with free amino groups conferring high physical
stabily with excellent swelling properties and easy handling when dried. The model
peptides, polyarginine containing peptide and the often aggregation prone -amyloid (1-
42) peptide were synthetized at commendable yields compared to PS- and PEG-PS resins
(Garcia-Martin et al. 2006).
Peptides with an unmodified C-terminus can be synthetized using the Wang-resin
(Wang 1973) in Fmoc-strategy or Merrifield-resin (Merrifield 1963) in the Boc-strategy
(Table  4). In the Fmoc-strategy, the peptide is cleaved from the resin using 95%
trifluoroacetic acid (TFA) which also cleaves the side chain protection exept for those with
Fmoc, All, Dmab and Acm enabling possible post-cleavage modifications to the released
functionalities.  In  the  Boc-strategy,  Merrifield-resin  cleavage  is  performed  using  HF  or
trifluoromethanesulfonic  acid  (TFMSA)  resulting  in  peptide  acid.  Trityl-based  resins  such
as 2-Cl-trityl (Barlos et al. 1989, Barlos et al. 1991) can be used for the production of
protected peptide fragments in the Fmoc strategy. The side-chain protected peptide
fragment can be cleaved from the 2-Cl-trityl-resin using very mild acidic conditions, i.e. 1%
TFA,  with  a  wide  variety  of  side  chain  protecting  groups  remaining  attached.  Further
advantages of the trityl-resins are the loading of the first residue without activators in the
Fmoc strategy creating epimerization free conditions and the bulkiness of resin attachment
site prevents DKP-formation as discussed earlier (Albericio & Carpino 1997, Amblard et al.
2006). The 2-Cl-trityl-resin can be used also for the synthesis in the reverse NC direction
(Thieriet et al. 2000). Peptides with a directly modified carboxylic group can be synthesized
in different ways, for example via Rink amide resin in the Fmoc strategy (Rink 1987) or via
MBHA-resin (p-methylbenzhydrylamine) (Matsueda & Stewart 1981) in the Boc-strategy.
Both Rink amide and MBHA resin can be used for the backbone peptide amide synthesis. It
is also possible to produce head-to-tail cyclic peptides via anchoring of Asp or Glu via the
side chain to the resin producing either Asn or Gln, respectively, after cleavage. The
peptide can also be attached to the resin via the backbone amide bond allowing the
synthesis in both CN and NC directions  and therefore  also  for  the  synthesis  of  cyclic
peptides or C-terminally modified peptides (Jensen et al 1998, Bourne et al 2001).
The final cleavage step of the peptide from the resin and the cleavage procedure are
highly dependent on peptide sequence, C-terminal amino acids and the resin being used
(Jubilut et al. 2007). Thus, different cleavage methods will not be discussed in detail here.
Commonly, care must be taken when the sequence includes one or several amino acids
which contain electron rich side-chains. These kinds of amino acids are Cys, Met, Set, Thr,
Tyr and especially Trp and they are prone to side-chain alkylation via the relatively stable
deprotected carbocations such as tert-butyl or trityl cations (Amblard et al. 2006, King et al.
1990). In the Fmoc-strategy, peptides are usually cleaved with 90-95% TFA with the
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remaining 5-10% consisting of scavengers. A small fraction of H2O is  used to  quench tert-
butyl cations (King et al. 1990). Furthermore, for example ethanedithiol (EDT) for the
prevention of tBu-triflouroacetate formation and tBu-alkylation can be used (Lundt et al.
1978). EDT and the malodorous and less poisonous triisopropylsilane (TIS) also prevent the
realkylations of Cys by trityl cations (Pearson et al. 1989, King et al. 1990). The presence of
EDT and H2O can however result in the cleavage of Acm-protection of Cys and care should
be taken when there is the possibility of the production of unwanted disulphide bridges
(Singh et al. 1996). Overall the cleavage conditions can affect the yields of the synthesis and
the optimization of cleavage step is very important as is the optimization of the coupling
steps during peptide synthesis (Sole & Barany 1992, Albericio et al. 1990).
Table 4. Selected resins for solid phase peptide synthesis.
Name structure attached
group
leaving
group
cleavage notes
Wang RCOOH RCOOH 95% TFA,
Fmoc-strategy
Merrifield RCOOH RCOOH HF, TFMSA,
Boc-strategy
Barlos,
CTC, 2-
Cl-trityl
RCOOH RCOOH 1% TFA in DCM,
protected
peptide
fragments, in
Fmoc-strategy
Rink
amide
RCOOH RCONH2 95% TFA,
Fmoc-strategy
MBHA RCOOH RCONH2 HF, TFMSA,
Boc-strategy
BAL back-bone
amide
back-
bone
amide
95% TFA, both
CN  and  NC
direction
synthesis
Monitoring of coupling and deprotection. Although SPPS is today well-documented
and commonly considered as a standardized method, incomplete couplings and
deprotections still occur. The growing peptide chain is prone to aggregation via hydrogen
bonding  as  well  as  via  hydrophobic  interactions  and  the  aggregation  will  result  in  the
incomplete solvation of the peptide resin and the inaccessibility of reagents to the reaction
site (Amblard et al. 2006). Incomplete reactions can result in the deletion of one or several
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residues and the truncation of peptide chain. The reactivity of differently protected amino
acids varies and if the washing steps are insufficient between the coupling and the
deprotecting steps, also the dimerization of some residues may occur. During SPPS, it is not
reasonable to monitor and characterize the reaction completions via the cleavage of
intermediate product because it is very time and substance consuming. In the Fmoc-
strategy, the deprotection of the N-terminal Fmoc group results in the formation of
dibenzofulvene and its piperidine adduct. Both of these compounds can be monitored by
UV-spectroscopy and this can be conducted automatically during automated SPPS
(Amblard et al. 2006). It is also possible to monitor couplings via infrared spectroscopy (IR)
between the coupling steps (Henkel & Bayer 1998). However, there is not always
equipment and time to conduct such complicated monitoring and therefore a range of
colorimetric tests are commonly used. Usually it is feasible to monitor the presence of free
or blocked N-terminal -N-group and this can be performed via color tests which produce
differing visible color changes depending on the free or blocked amino group. These tests
are only qualitative, not quantitative and they do not rule out incomplete reactions.
Furthermore, when the length of the peptide chain increases or aggregation occurs, the
results of the color test become more difficult to interpret (Amblard et al. 2006, Albericio &
Carpino 1997). The presence of the free N-terminal -N-group has been monitored via a
simple ninhydrin test, usually called the Kaiser-test since it was developed by Kaiser and
his collaborators (Kaiser et al. 1970). Ninhydrin test results can also be monitored
photometrically (Sarin et al. 1981). This test is suitable for free primary amines which give
an intensive blue color but there can be problems encountered with some amino acids as N-
terminal residues e.g. Ser, Asn and Asp. Since proline is a secondary amine, it does not give
the correct positive result instead producing red/brown color (Kaiser et al. 1970). The
chloranilin-test can be used for secondary amines and challenging residues (Christensen
1979, Vojkovsky 1995). Recently, an improved, rapid and sensitive method for monitoring
resin-bound primary and secondary alkyl and aryl amines has been described (Blackburn
2005). The coupling end point can be monitored via the use of a test based on the acid-base
indicator chromophenol blue but this test emits a positive result in the presence of any
resin-bound base (Krchnak et al. 1988). Other functional groups can also be monitored
during peptide synthesis and one commonly used test is the Ellman test for free sulfhydryl
groups (Ellman 1959). The Ellman test can be used to follow the progress of the oxidation
reactions of cysteines.
Difficult sequences. Although unsuccessful syntheses are not usually published, there
are many report describing “difficult sequences” during peptide synthesis. Well-known
examples are oligoalanine when it contains more than five residues and -amyloid
peptides, which are apparently difficult to synthesize with high yields using standard
coupling and deprotection protocols (Abdel Rahman et al. 2007, Hachmann & Lebl 2006).
The difficulties are attributable to intra- and/or intermolecular aggregation, secondary
structure  formation  and  steric  hindrance  of  bulky  residues  and  protecting  groups.  The
tendency towards aggregation and folding will depend upon the nature of the peptide
chain  e.g.  peptides  with  a  high  proportion  of  Asn,  Gln,  Ala,  Val  or  Ile  residues  are
associated with aggregation (Bacsa et al. 2008, Bedford et al. 1992). Hydrogen bonds,
usually between the backbone amide hydrogen and the carbonyl oxygen, as well as
hydrophobic interactions of hydrophobic residues are the main reason for secondary
structures undergoing aggregation. Intrachain interactions result in reverse turns and
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interchain interactions commonly lead to the formation of -helixes or -sheets (Bacsa et al.
2008, Albericio & Carpino 1997). The interchain interactions can become evident already
when  the  fifth  residue  is  coupled.  Thus,  coupling  difficulties  can  exist  even  when  a  short
peptide (5-15 residues) is being synthesized (Bacsa et al. 2008, Albericio & Carpino 1997).
Incomplete acylation of the -amino group during the coupling steps are commonly
associated with -branched amino acids such as Ile, Val and Thr (Milton et al. 1990,
Albericio & Carpino 1997). The simplest way to overcome coupling difficulties is to test
different coupling cocktails, variable coupling times and temperatures or to use double
coupling for a specific residue but if the problems are associated with aggregation, then the
disruption of hydrogen bonds may be a reasonable option. Firstly, the low-load resin (0.1-
0.2 mmol/g) can be tested (Pugh et al. 1992, Tam & Lu 1995). Secondly, elevated
temperatures can be used although there will be an increased probability of racemization
and undesired side reactions such as asparimide formation (Bacsa et al. 2008, Albericio &
Carpino 1997, Souza et al. 2004). An elevated temperature can be achieved rapidly via MW-
assisted heating and for example the commonly known difficult sequence containing
multiple alanines has been efficiently synthesized using MW-heating (Abdel Rahman et al.
2007). Thirdly, the coupling efficiency can be enhanced using polar solvent such as DMF,
NMP,  DMSO  and  2,2,2-trifluoroethanol  (TFE)  or  mixture  of  these  solvents  (Miranda  &
Alewood 1999, Albericio & Carpino 1997). Aggregation can also occur via hydrophobic
interactions when the resin is polystyrene-based or the sequence contains the regions of
apolar  protection  groups  or  residues.  In  that  case,  the  addition  of  some  nonpolar  solvent
such as DCM in polar solvents can be used (Albericio & Carpino 1997). Furthermore, the so
called magic mixture consisting of ethylene carbonate and non-ionic detergent Triton X100
in combination with DMF and NMP can be used for breaking secondary structures
(McNamara et al. 20002). Fourthly, aggregation can be prevented using denaturing agents or
chaotropic salts  such  as  LiCl,  LiBr,  KSCN  and  NaClO4 (Amblard et al 2006, Albericio &
Carpino 1997). These agents can increase resin swelling and disrupt the -sheet formation.
Fifthly, the use of the previously mentioned backbone amide protection groups such as
Hmb (Packman 1995) or the introduction of cleavage cocktail labile derivatives of amino
acids such as dimethyloxazolidine dipeptides (Figure 11, see page 24) when sequence the
contains  Ser  or  Thr  (White  et  al.  2004)  can be  used during chain elongation to  help in  the
prevention of aggregation.
It has to be noted that every coupling and deprotection and also every cleavage step
rarely  results  in  equivalent  yields.  Therefore,  the  crude  product  will  contain  a  mixture  of
incomplete sequences. Thus when SPPS is used, the purification and characterization steps
are  as  important  as  the  synthesis  itself.  To conclude,  it  can be  stated that  a  new synthetic
peptide/peptide derivative can be a very unique project. A molecule seems to be usually
synthesized  by  the  methods  currently  in  use  in  the  particular  laboratory.  Thus,  the
optimization of methods and the maximization of yields seem not to be the first steps
undertaken when conducting peptide research and chemistry.
2 Original  publication:  Zhang,  L.,  Goldammer,  C.,  Henkel,  B.,  Zühl,  F.,  Panhaus,  G.,  Jungs,  G.  & Bayer,  E.  1994,  "‘Magic
mixture’, a powerful solvent system for solid-phase synthesis of ‘difficult sequences’", In Epton, R. (ed.), Innovation and
Perspectives in Solid Phase Synthesis, Mayflower, Birmingham, pp. 711–716.
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1.2.4 Chemical optimization of peptide sequence
The chemical optimization of peptides for therapeutic agents is often intented to improve
their bioavailability, reduce their biodegradation and elimination and increase their
selectivity and affinity toward target (see section 1.1.2.). The chemical optimization strategy
for therapeutic peptide is based on structure-activity relationship (SAR) studies between
peptides or their modified analogs and the biological activity achieved. Most commonly,
the chemical optimization of the peptide lead is based on experimental techniques such as
residue replacement and progressive deletions. The definition of the peptide active 3D-
structure, if it can be possibly determined, is additive information and may enable further
the use of supplemental computational modeling (Falciani et al. 2005). Lead peptides can be
investigated via biophysical studies including multidimensional NMR, X-ray
crystallography, quantitative structure-activity relationship (QSAR) and molecular
dynamic simulations. However, the structural information obtained may be somewhat
limited because of the flexibility of peptides, especially short and linear compounds or
because of inadequate information about the structure of peptide ligand target. It is very
questionable whether the structure of ligand, target or target-ligand complex determined
via  NMR  or  X-ray  crystallography  will  all  be  identical  to  those  occurring  in  solution  or
involved in biological interactions (Hruby 2002, Grauer & König 2009). The flexibility of the
peptide bond structure is somewhat restricted via amide-imidic acid tautomeria, but in
addition every amino acid has two degrees of conformational freedom, N–C ()  and C–
CO  ()  bonds.  In  the  early  and  pioneering  work  of  Ramachandran  and  his  colleagues,  it
was found that the conformational freedom of amino acids cover about one-third of total
structural space available (Ramakrishnan & Ramachandran 1965). As a consequence, it can
be observed that short polypeptides consisting of 20 naturally encoded amino acids rarely
exist in stable conformations.
In addition to SAR-studies, naturally occurring bioactive peptides can be used as a guide
for peptide modification. For example, the toxins of several venomous animals are peptides
or peptide derivatives and in order to function as lethal peptide vemoms, they must be able
to resist enzymatic degradation. The modifications present in peptide venoms include
disulphide bonds formation for the stabilizing structure, amidation (C-terminal), sulphation
(Tyr), bromination (Trp), glycosylation (Thr), -carboxylation (Glu), hydroxylation (Pro),
pyroglutamation, head-to-tail cyclization and isomerization to D-amino  acids  (Lewis  &
Garcia 2003) .
The process in which the peptide is converted into a drug or drug-like molecule can be
crudely divided into three groups (Adessi & Soto 2002, Grauer & König 2009). At first, the
focus is to modify the peptide without altering the peptide bonds. This can be done via
peptide length optimization, amino acid sequence optimization, via chirality changes (L to
D), via non-genetically encoded amino acids, via N- and C-terminal end modification and
via backbone N-amide alkylations (Figure 13). Cyclization can also be used to stabilize
peptide conformational flexibility without dramatically altering the peptide
pharmacophore. Cyclization will be discussed in its own section subsequently. The second
step is to alter the peptide bonds by replacing chemical groups and produce amide bond
surrogates, peptoids and azapeptides (Figure 13). The last step is to produce peptide
mimetics, organic compounds whose essential elements (pharmacophore) mimic a natural
peptide or protein in 3D space. The Peptide mimetic has to retain the ability to interact with
the biological target and to produce the same biological effect as the parent peptide (Vagner
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et al. 2008). Since the peptide mimetic may be a totally non-peptide molecule, peptide
mimetics  will  be  only  briefly  discussed in  this  thesis  referring only  to  the  short  structural
motifs of peptides.
The first step after the lead peptide structure has been obtained is to determine the key
amino-acid(s) responsible for biological activity. Usually the biologically active peptide
sequence covers a relatively large binding site on the surface of the target such as the
protein or a membrane component and traditionally the length of the sequence responsible
for  the  biological  effect  can  be  derived  via  truncation  or  deletion  of  its  lead  sequence
(Hruby 2002, Vlieghe et al. 2010). During truncation, the peptide is shortened from the N-
or C-terminus at one residue at a time to determine the shortest biologically active
sequence. One or more consecutive residues can also be omitted from the middle of the
sequence. One common example of successful truncation and key residue determination
was work done with somatostatin (SST-14, Figure 2, see page 10) a peptide hormone
containing 14 residues. Veber and his collaborators discovered that residues 7-10 were
mainly responsible for the biological activity of SST:s. They developed cyclic hexapeptide
analogs with one non-naturally encoded amino acid, -aminoheptanoic acid (Aha), to
stabilize the cyclic conformation and to decrease the in vivo reduction of the disulphide
bridge (Veber et al. 1979, Veber et al. 1981). Finally, the most widely used analog of SST,
ocreotide, was developed by replacing Aha with D-Phe in the N-terminus and Thr-
derivative L-treoninol in the C-terminus resulting in analog with a total of 8 residues (Bauer
et al. 1982, Harris 1994). Ocreotide was 3-times more potent in inhibiting the secretion of the
growth hormone than the parent hormone SST-14 and its elimination half-life was elevated
from 3 minutes up to 90 minutes (Harris 1994).
Figure 13. Schematic presentation of some commonly used peptide modifications, which are
reported to increase proteolytic stability.
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The importance of the side chains can be investigated via the so-called scanning
procedure meaning the replacement studies of certain/all residues in the sequence by some
other amino acids. The most used replacements are L-alanine scan which has been used for
both peptides and protein and D-amino acid scan (Hruby 2002, Vlieghe et al. 2010, Falciani
et al. 2005, Morrison & Weiss 2001). During an alanine scan, each amino acid in the
sequence is replaced by an alanine, one at a time to examine the importance of the side
chain for binding affinity and biological activity. The binding affinity and biological activity
of Ala-replaced mutations can be determined using in vitro, even in vivo assays  and  the
results can be related to the known or presumed function of the parent peptide.
Substitution with alanine removes all side chain atoms beyond -carbon but still maintains
structural  rigidity  with  the  usual  dihedral  angles  in  the  backbone.  However,  it  should  be
noted that the conformational space covered by the methyl side chain of alanine is not the
same as the space of bulky side chains present in groups such as Trp, Tyr and Phe. Thus,
the conformational restrictions are much more limited compared to the bulky residues.
Furthermore, the charge of the side chain of alanine is neutral and it will not form strong
hydrophobic or hydrophilic interactions with other residues. However, during alanine
scans, it is usually assumed that the overall conformation of peptide is not significantly
changed (Hruby 2002). The most problematic amino acids during Ala-scans are Gly (no
side  chains,  flexible),  Pro  (cyclic,  restricted  dihedral  angles)  and  Cys  (usually  forms  a
disulphide bridge with another Cys). The Ala-scan technique was used successfully when
the important residues of neurotensin were being monitored (Figure 3 see page 11) and as a
result Leu13 was found to be the most important amino acid (Henry et al. 1993). In the
same study, also truncation was used to determine the shortest active sequence. In
particular, the Ala-scan of somatostatin-14 (SST-14, Figure 2, see page 10) revealed the
importance of residue Trp8 for biological activity and Trp has been incorporated into
almost all somatostatin analogs during few decades when there has been intensive studies
of this interesting peptide (Vale et al. 1975, Reissmann & Imhof 2004).
The positional or combinatorial D-amino acid scan has been used to eliminate the
potential cleavage sites of peptidases, most notably endopeptidases. D-amino acids have
also  been found to  be  less  immunogenic  than L-amino acids  (Adessi  & Soto  2002)  and D-
amino acids have been shown to be able to stabilize certain reverse turns and destabilize -
helices (Hruby 2002). For example, substitution of Phe7 by D-Phe in -melanocyte
stimulating hormone (MSH) led to the synthesis of a potent analog with prolonged
activity since it avoided enzymatic degradation by serum enzymes perhaps also the -turn
stabilized the molecule (Sawyer et al. 1980, Sawyer et al 1982). D-Amino acid replacement
studies have revealed the potential of the D-Trp substitution for Trp8 in somatostatin. This
led to the synthesis of an analog with around 8 times higher activity (Rivier et al. 1975,
Voyles et al. 1979). It was later concluded that Trp8 is essential for generating activity.
Therefore, the D-Trp8-modification can be found in most of the SST-analogs including
ocreotide (Figure 2, Table 1, see page 10 and 3, respectively) which is the much studied
octapeptide analog of somatostatin (Bauer et al. 1982, Reissmann & Imhof 2004). D-amino
acid  substitutions  can  also  be  found  in  several  other  pharmaceutical  peptides  including
desmopressin, atosiban and leuprorelin and even in cyclosporin A which is derived directly
from  a  natural  source  (Table 1). One major drawback during D-amino acids replacement
work is the possible loss of activity because of conformational changes. Therefore often
only the residue near to the cleavage site is replaced. In some studies, resistance against
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enzymatic  degradation  has  been  shown  to  be  reduced  when D-amino acids have been
incorporated into the peptide. For example, the D-amino acid replacement in the scissile
bond of Dermorphin, an opioid heptapeptide, was not as resistant against in vitro
enzymatic degradation as the native peptide (Darlak et al. 1988). Chirality changes have
been used also in the design of so called retro-inverso peptides (Adessi & Soto 2002, Chorev
& Goodman 1995). The parent peptide sequence is synthesized in an inversed direction
using D-amino acids. Structurally, the retro-inverso peptide maintains the side chain
topology compared to the original sequence, only the peptide ends contain opposite
charges and the peptide bonds are reversed. However, only a limited number of retro-
inverso derivatives have displayed comparable activity to their native sequences, evidence
of the clear importance of the backbone for the structure and binding properties of peptides
(Grauer  &  König  2009).  The  retro-inverso  synthesis  can  be  used  simply  to  partially  cover
the enzymatically unstable region of the sequence. The partial retro-inverso analog of
dermorphin has been shown to maintain the biological opioid activity of the original
peptide (Salvadori et al. 1985).
The importance of side chain groups for biological activity can also be examined by
modifying the steric, acid-base and both hydrophilic and hydrophobic properties of certain
key residues (Hruby 2002). Current knowledge in synthetical chemistry enables the design
and synthesis of a wide variety of derivatives of genetically encoded amino acids and
organic molecules containing amino and carboxylic functions. The structural knowledge of
the ligand and binding site is extremely helpful when the modifications and replacements
are  being  engineered  but  modifications  can  also  be  based  on  SAR-studies.  It  should  be
noted that the binding pocket can modify the ligand structure, at least the orientation of the
side-chain can be altered (Hruby 2002). In brief, the selected residues in the enzyme
recognition site can be modified or replaced by the structures which are close to the original
amino acids. The simplest substitutions might be Ile for Leu, Tyr for Phe, Asn for Asp, Lys
for Arg, norleucine (Nle) for Met or naphthylalanine for Phe and vice versa (Adessi & Soto
2002, Hruby 2002). However, the results of SAR-studies must be assessed carefully, when
substitutions are considered, because sometimes one or two substitutions can result in very
different  biological  activity.  For  example,  the  peptide  hormone  oxytocin,  which  causes
uterine contraction and vasopressin, which is an antidiuretic hormone are identical in all
but two residues i.e. their biological responses are very different (Suresh Babu 2011).
Oxytocin: H-cyclo[Cys-Tyr-Ile-Gln-Asn-Cys]-Pro-Leu-Gly-NH2
Vasopressin: H-cyclo[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Arg-Gly-NH2
The functional groups containing side-chains can be modified relatively easily and it is
not possible to cover all of the reactions here, just a few examples will be provided.
Aromatic side chains can be modified via methylation or halogenations (Adessi & Soto
2002). For example, the chlorination of Phe resulting para-Cl-Phe in the N-terminus of
enkephalin analogs has enhanced their analgesic effects, evidence that these analogs
possess better penetration properties through the blood-brain barrier (BBB) (Weber et al.
1991, Weber et al 1993). The methylation of the Tyr (2,6-dimethyl-tyrosine, DMT) on the
synthetic Met-enkephalin analog enhanced significantly the analgesic effect due to better
BBB penetration and thus increased the bioavailability (Hansen et al. 1992). Hydroxyl
groups  of  Thr,  Ser  and  Tyr  can  be  blocked  reversibly  via  esterification  or  irreversibly  via
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methylation (Witt et al. 2001). Alkylation, including methylation of a hydroxyl group also
reduces possibilities for hydrogen bonding and increases lipophilicity (Witt et al. 2001). The
alkylation of side chain hydroxyl group can be found in the Tyr2 of the oxytocin antagonist
atosiban (Table 1, see page 3).
Conformationally constrained derivatives of amino acids can be used to increase
backbone  rigidity.  Proline  is  known  to  play  a  special  role  in  the  structural  and
conformational properties of peptides and proteins because of its cyclic and
conformationally restricted structure (Figure 14). Proline plays a very important role in -
hairpin structures such as -turns and it can be used along with its analogs to disrupt
helical conformations and to form turned structures (Hayashi et al. 1997, Cowell et al. 2004).
Modifications of Pro can be used to improve the stability and the activity of a peptide drug.
Pseudoprolines, such as serine and threonine-derived oxazolidines, are also a helpful tool
in the synthesis of difficult sequences as discussed before (Cowell et al. 2004, Adessi & Soto
2002). Another commonly used conformationally restricted, although non-naturally
encoded residue is -aminoisobutyric acid (Aib, also known as 2-methylalanine, Figure 14)
(Cowell et al. 2004, Adessi & Soto 2002). Compared to alanine, the -hydrogen is replaced
by a methyl group resulting in an achiral analog with more steric hindrance creating a
derivative which is known to promote the helix formation (Cowell et al. 2004). -Hydrogen
substitution with other bulkier substituents than methyl can be used to further increase
steric restrictions (Cowell et al. 2004, Adessi & Soto 2002). Conformational constraints can
also be included in -carbon. A couple of examples of -carbon modified residues are tert-
Leu (Tle) in the neurotensin analog NT-VIII (Figure 3, see page 11) as well as penicillamine
(Pen, thiol-D-valine, Figure 14) in the cyclic opioid peptide enkephalin analog c[D-Pen2, D-
Pen5]-enkephalin (DPDPE) (Mosberg et al. 1983).
Figure 14. Proline and selected conformationally constrained non-natural amino acids.
Most L-amino acid peptides with free N- and C-terminus are degraded rapidly within
minutes by exopeptidases (Adessi & Soto 2002). Since it is desirable to slow down or to
block biodegradation via exopeptidases, the N-and C-termini can be modified using
covalently bound groups such as an acetyl in the N-terminus or an amide in the C-terminus
(Figure 13 see page 33) or for example via head-to-tail cyclization. These peptide end
modifications will affect the lipophilicity of peptides, for example N-terminal acetylation
increases the lipophilicity of the resulting peptide (Witt et al. 2001, Adessi & Soto 2002).
Many natural peptides hormones and neuropeptides such as the previously mentioned
oxytocin and vasopressin are naturally protected using amino-acetylation or carboxy-
amidation. Both protections are also found in -melanocyte-stimulating hormone (MSH).
Therefore, MSH is degraded practically by endopeptidases, not exopeptidases (Adessi &
Soto 2002). Peptide end modifications are also common in peptide pharmaceuticals, for
example a C-terminal amide can be found in liraglutide, desmopressin, oxytosin,
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enfuvirtide and calcitonin (Table 1, see page 3). An example of N-terminal acetylation can
be found in enfuvirtide (Table 1). The intra residual cyclization of N-terminal Glu resulting
in pyroglutamic acid (Pyr, Figure 14) can also be used for N-terminal protection against
exopeptidases, for example this can be found in the natural peptide hormone neurotensin
(Figure 3, see page 11) and the peptide drug leuprolerin (Table 1). Both N-terminal acetyl
and additional N-terminal pyroglutamyl has been shown to completely resist the N-
terminal degradation of glucagon like peptide 1 (GLP-1) by dipeptidyl peptidase. In
addition N-terminal modifications can improve plasma half-life significantly (Green et al.
2004). Peptide end modifications are commonly used as standard procedures in the
synthetic chemistry of peptides, for example a wide variety of C-terminal end modifications
can be directly added via the choice of the resin and the cleavage method (Alsina &
Albericio 2003). However, it has to be noted that end modifications rarely prevent
enzymatic degradation completely, it is only the activity of exopeptidases that is impaired
or prevented, not the endopeptidases. In fact, the modifications intended to stabilize
peptide or protein drugs towards endopeptidases are commonly more challenging than
protecting the N- or C-terminal sites from exopeptidase cleavage (Werle & Bernkop-
Schnürch 2006).
The alkylation of the amide nitrogen has been discussed before in the consideration of its
use in peptide synthesis, but it is also one of the most commonly used methods to stabilize
the peptide bond against enzymatic degradation by endopeptidases. The N-alkylation also
produces a conformational constraint on the peptide bond, promoting the cis-conformation
and eliminating the ability of the hydrogen bond to undergo amide hydrogen (Cowell et al.
2004, Adessi & Soto 2002, Teixido et al. 2005). Systematic N-alkylation  can  be  used  to
improve biostability and it represents a powerful tool in SAR-studies (Vagner et al. 2008,
Hruby 2002, Grauer & König 2009). N-Methyl scanning has been conducted on
somatostatin octapeptide agonists and antagonists and different N-methylations have been
shown to affect receptor subtype selectivity (Rajeswaran et al. 2001a, Rajeswaran et al.
2001b). Mother nature, especially many marine species, produces several N-methylated
peptides which have been the topics of various conformational studies. These molecules
have also been subjected to synthetic studies because of the much reduced reactivity of N-
methylated residues (Adessi & Soto 2002, Teixido et al. 2005). One of the most widely
studied peptide, which contains N-methylated residues, seems to be cyclosporin A (Table 1,
see page 3). This cyclic undecapeptide contains seven N-methylated residues and although
it is a short peptide, it is exceptionally conformationally rigid. Proline can be considered
also as an N-alkylated amino acid. Thus proline analogs with differing ring substituens as
well as other cyclic amino acid derivatives with differing ring sizes are commonly used to
achieve conformational restrictions (Cowell et al. 2004).
In addition to the above mentioned modifications, several other additional chemical
groups can be attached to the N- or C-terminus, to side chains, to the backbone amide
nitrogen or to -carbons. Glycosylation (glucose, xylose, hexose etc.) can be used to increase
plasma  stability  as  a  peptide  end  modification.  Glycosylation  can  also  be  used  for
enhancing hydrophilicity or improving biodistribution to the brain via BBB nutrient
carriers (Vlieghe et al. 2010, Witt et al. 2001, Egleton et al. 2000). Polymer conjugation, most
commonly the addition of a variable PEG chain, can be used to increase stability against
enzymatic degradation, to decrease elimination by increasing peptide size making the
molecule too large for renal clearance, to decrease toxicity and to decrease protein binding.
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PEGylation can also be used in the desing of potential control-release drugs (Veronese &
Pasut 2005, Witt et al. 2001). Lipidization, i.e. conjugation with a hydrophobic lipid
molecule, is another way to increase the membrane permeability of peptide. Lipidization
can also result in increased plasma protein binding of the hydrophobic conjugates (Witt et
al. 2001). This can be used if one wishes a controlled administration rate as in the case of the
peptide-based drug liraglutide (Table 1). The addition of the C16 fatty acid moiety to Lys20
resulted in binding of the drug to serum albumin, which extended its biological lifetime to
permit once daily injection (Stevenson 2009).
Peptide backbone modifications via the alterations or replacements of some atoms in the
peptide backbone result in the formation of a molecule which is not peptide but an analog
called a pseudopeptide or a peptidemimetic, depending on the source material. According
to one definition, pseudopeptide is any peptide analog which has a peptide backbone
modification such as amide bond surrogates or isosteres, peptoids or azapeptides (Figure
13, see page 33) (Adessi & Soto 2002). Nevertheless, the introduction of the peptide
backbone modification is targeted against enzymatic degradation but can be also used to
control structural flexibility/rigidity and therefore for example in the selectivity of peptide-
based pharmaceutical. Furthermore, there may be different types of backbone
modifications e.g. those intended to modify hydrophobicity, hydrogen bonding ability and
the length of the backbone (Vagner et al. 2008, Adessi & Soto 2002). The peptide bond (-CO-
NH-) replacements can refer to the alterations of carbonyl- or amino-moieties or both of
them  (Figure 13). N-alkylations have been already discussed above and they are not
discussed here. The carbonyl group can be reduced (-CH2-NH-); this change can be found
for example in the neurotensin analog NT-IV (Figure 3, see  page  11).  Furthermore,  the
carbonyl group can be modified to endothiopeptide (-CS-NH-) or phosphoamide [-PO(-
OH)-NH-]. The amide-NH can be replaced by O (-CO-O-, depsipeptide), by S (-CO-S-,
thioester) or by –CH2- (-CO-CH2-, ketomethylene). The whole peptide bond can also be
modified to make it a retro-inverso peptide (-NH-CO- bonds) or some of the amide bonds
can  be  replaced  by  thiomethylene  bonds  (-CH2-S-), dicarba bonds (-CH2-CH2-) or
hydroxyethylene bonds (-CHOH-CH2-) (Vlieghe et al. 2010, Adessi & Soto 2002). Recently,
the incorporation of ester and urea bonds and the ester-urea motif instead of peptide bonds
has been shown to reduce the aggregation ability of peptide sequences due to the loss of the
backbone’s hydrogen bonding ability (Hartwig et al. 2010).
 Peptides with the -carbon replaced by nitrogen are called azapeptides (Figure 13). The
azapeptide bond lacks the -hydrogen resulting in the loss of chirality and a reduction of
flexibility; those alterations to the specific secondary structure will tend to influence the
recognition and cleavage of the modified bond by proteases (Zega 2005). Therefore
azapeptides have been used extensively as protease inhibitors, for example targeting
cysteine and serine proteases (Magrath & Abeles 1992). Recently, a method for conducting
an azapeptide scan using MW-assisted heating has been published (Freeman et al. 2011). A
selective linear heptapeptide inhibitor for activated protein kinase B (PKB/Act), an enzyme
which is associated with many human cancers, was aza-scanned and its stability against
proteases trypsin and chymotrypsin was examined (Tal-Gan et al. 2011b). The inhibition
potency declined while the stability increased and the authors emphasized that this
synthetical method enabled a rapid azapeptide scan in SAR-studies.
Another type of modification, which yields the loss of chirality in the -carbon is the use
of  peptoids  (Figure 13, see page 33). The side chain of amino acid is “switched” by one
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position to the amide nitrogen yielding N-substituted glycines. This results in the creation
of a more flexible structure and the loss of recognition by proteases (Adessi & Soto 2002,
Patch & Barron 2002). Peptoids are based on the proteinlike backbone with both the
hydrophobicity and charge being readily modified. Furthermore, these molecules can
adopt helical structures (Patch & Barron 2002). A peptoid has been used in the synthesis of
the antibacterial magainin mimetics (Patch & Barron 2003) and in the development of
potent and selective somatostatin analogs (Tran et al. 1998).
The last possibility for converting a bioactive peptide into a drug is to create a
peptidomimetic. One definition for a peptidomimetic is that it is a molecule which no
longer contains peptide bonds (Adessi & Soto 2002). However, a peptide, which contains
non-natural structures mimicking the local topography of peptide such as peptide bond
isosteres and retro-inverso peptides, can also be considered to be a kind of peptidomimetic.
These mimetics often match the peptide backbone length atom-for-atom and retain
functionality (pharmacophore) allowing them to make important contacts with binding
sites. According to Ripka and Rich, this type of peptidomimetics can be classified as Type-I
peptidomimetics (Ripka & Rich 1998). A peptide mimetic can also be a small non-peptide
molecule that binds to the peptide receptor, being as a functional mimetic and these
molecules can be classified as Type-II peptidomimetics (Ripka & Rich 1998). Functional
mimetics do not necessarily resemble the structure of the parent peptide. Morphine was
one of the first structures identified as a peptide mimetic because it is functional mimetic to
Leu5-  and  Met5-enkephalins  cabable  of  binding  to  the  morphine  receptor  (Adessi  &  Soto
2002). Type-III mimetics have novel templates which contain the necessary groups
positioned on a novel non-peptide scaffold to serve as topographical mimetics. These
molecules can appear to be unrelated to the original peptide and thus represent the ideal in
peptide mimetics (Ripka & Rich 1998). Peptide mimetics can be rationally designed or can
be identified from randomly obtained structures. However, the rational design of the
peptide mimetic requires knowledge of the electronic, conformational and topochemical
properties of the native peptide in its target (Grauer & König 2009). Traditionally, random
screening  has  been  the  most  successful  method  for  producing  peptide  mimetics  but
developments in synthetic and combinatorial chemistry combined with computational
improvements in conformational analysis (NMR, X-ray), molecular modelling and virtual
screening-based methods are today making an important contribution to peptide mimetic
research.
The flexibility of peptides and the dependence of their structure on their environment is
still  a  major  problem  in  the  peptide  mimetic  research.  Therefore,  the  most  widely  used
peptide mimetics are unnatural amino acids and dipeptide surrogates for short structurally
constrained regions such as -turn mimetics (Vagner et al. 2008). -Turns are the reversed
turns commonly present in protein structures and they are stabilized via hydrogen bonding
between the adjacent residues in the turns. The -turns consist of four adjacent (i – i+3)
residues and typically the residues in the corner of turns (i+2, i+3) are replaced by non-
natural dipeptide mimetics (Kieber-Emmons et al. 1997) with a variety of typically bicyclic
structures being utilized (Cowell et al. 2004, Vagner et al. 2008). Another group of
commonly used molecules in peptide mimetic research are -amino acids. The backbone of
-amino acid between the amino and carboxylic group includes an additional carbon atom
compared to the -amino acids. The structurally simplest -amino acid is called -alanine
i.e. 3-amino propanoic acid. The advantages of -peptides include their ability to form
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predictable helical structures and their increased stability against peptidases (Gademann et
al. 2001). -Amino acids have been used in many experiments, for example in the synthesis
of a -tetrapeptide derivative which mimics somatostatin in its binding properties
(Gademann et al. 2001). -Amino acids and -peptides have also been used in the design
and synthesis of peptide mimetics e.g. antimicrobial peptides such as magainin (Patch &
Barron 2002, Patch & Barron 2003). The helical conformation can be affected by the
substituents in the - and -carbon and a knowledge of the structural behavior enabled the
de novo design of synthetic mimetics of antimicrobial peptides (Patch & Barron 2002, Scott
et  al.  2008).  -Helical  structures  can  be  mimicked  also  by  using  both  -helix  inducing
linkers such as side chain to side chain bridges or by using totally non-peptidic molecules.
In addition to -turn mimetics and helical mimetics, also various -sheet mimetics have
been developed and studied.  -Sheets  are  common structural  motifs  in  proteins.  Peptides
can be stabilized into artificial -sheets resembling the conformation using non-natural
building blocks (Grauern & König 2009).
The peptide hormones somatostatin and bradykinin are two molecules which are served
as model compounds to examine and explore what can be done when the lead peptide is
transformed and/or modified to a peptide-based pharmaceutical (Stewart 2007, Janecka et
al. 2001, Harris 1994, Reissmann & Imhof 2004). Somatostatin (Figure  2 see page 10) is
almost  ubiquitous  in  the  brain  and  the  gastrointestinal  tract  possessing  a  wide  variety  of
properties including the modulation of motor and cognitive functions, acting as
neurotransmitter and the causing the inhibition of nutrient absorption (Janecka et al. 2001,
Harris 1994, Reissmann & Imhof 2004). Bradykinin also possesses many physiological and
pathological roles e.g. its involvement in the inflammatory response (Stewart 2007,
Reissmann & Imhof 2004).
1.2.5 Peptide cyclization
The cyclization of peptide is a major tool for the introduction of global conformational
restriction into the peptide sequence. The cyclization reduces conformational flexibility and
may thus enhance potency, selectivity and specificity for a particular receptor. Cyclization
may also reduce hydrogen bonding and increase lipophilicity and in that way improve
membrane barrier permeability and bioavailability (Li & Roller 2002, Adessi & Soto 2002,
Witt et al. 2001). In particular, head-to-tail cyclization is a very powerful tool against
exopeptidases because the peptide no longer contains ionizable N- and C-terminal residues.
The proportion of cis-amide bonds is also higher in cyclic peptides than their linear
counterparts preventing enzymatic degradation (Li et al. 2002). The more constrained
geometry can be utilized in conformational studies, SAR-studies and molecular modeling
because  of  the  more  predictable  structure,  especially  when  the  ring  size  is  small  (Li  et  al.
2002, Landon et al. 2004). Many naturally occurring bioactive peptides are cyclic.
Cyclosporin  A  (Table 1, see page 3) is head-to-tail cyclic peptide whereas oxytocin,
vasopressin and somastostatins all contain a disulphide bridge (Figure 2). Several peptide-
based pharmaceuticals also contain the cyclic structural motif (Table 1, see page 3).
Methods for cyclization are traditionally divided into two classes, the backbone to
backbone cyclization and the cyclization between side chains (Li & Roller 2002, Davies
2003). Head-to-tail backbone cyclization and disulphide bridge formation between side
chains are the most notable examples although the development of sophisticated chemical,
biophysical  and  computational  methods  has  resulted  in  an  enormous  number  of
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possibilities  with  which  to  derive  cyclic  structures.  However,  in  most  cases  one  has  to  be
start from the basics, especially when structural data is limited, and some aspects of heat-
to-tail macrolactamization and disulphide bridge formation and the properties of
disulphide bridge mimetics will be discussed in the next sections.
The cyclization of a peptide can be performed homodetically (all amide bonds) via the
amide bond between N- and C-terminus resulting in the production of a head-to-tail cyclic
peptide. The amide bond can be also formed between the side chain amino group and the
C-terminal  carboxyl  group,  between  the  side  chain  carboxyl  group  and  the N-terminal
amine  or  between  the  side  chain  amine  and  the  side  chain  carboxyl  group  (Figure 15)
(Adessi & Soto 2002). Cyclization via the amide bond is also called lactam bridge formation.
A cyclic peptide is called heterodetic if the bridge is formed in some way other than amide
bonding. The most common heterodetic cyclization is attained via the disulphide bridge
between two cysteine residues (Figure 15). A disulphide bridge can be found universally as
a protein 3D-structure stabilizing component. Peptides can be cyclized heterodetically also
via the ester bond (lactone), ether, thioether (lanthionine) or hydrocarbon bridges (Adessi &
Soto 2002). Cyclization can be performed also using different specific linkers or spacers
with variable lengths or chemical structures. The use of the parent peptide side chains for
cyclization can achieve to the prevention of the interaction between the peptide and its
receptor. The possible involvement of the side chains of peptide in the interactions with
receptors can be circumvented in some cases by backbone cyclization (Reissmann & Imhof
2004). In backbone cyclization, two N and/or  C can be substituted and linked to each
other to a yield cyclic molecule. Backbone cyclization chemistry can be more challenging
than the cyclization chemistry via side chains or between N- and C- terminis mainly due to
sterical reasons (Reissmann & Imhof 2004).
The cyclization site and procedure including the length of the bridge, structural motif
and chemistry being used etc. are highly dependent on the available structural data because
the biological activity of the parent peptide can be lost when conformational restrictions are
used in the wrong position or/and with the wrong composition. Without any or with only
limited knowledge of 3D-conformation, the systematic cyclization between different
positions and SAR-studies based on this cyclic scan products might be the only way to
discover the cyclic bioactive peptide (Reissmann & Imhof 2004). A knowledge about
particular conformational regions including the -helix and -turn is usually beneficial and
the cyclization can be targeted to stabilize those local conformations. Cyclization can be
performed using residues already present in the parent sequence. Residues to be utilized in
cyclization can be also added via replacing residues which are not important for biological
activity (Hruby. 2002). This type of cyclization scan has been used in the systematic
positional-cyclization of glucacon to clarify the structural motifs of glucagon (Ahn et al.
2001). In the study of Ahn and his collaborators, the selected residues, which were not
essential for binding affinity, were replaced by cysteines for disulphide bridge formation or
by lysine and glutamine for lactam bridge formation. Cyclization via disulfide bridges
between Cysi and Cysi+5 was used to induce and stabilize turn conformations, while
cyclization via the lactam bridges between Lysi and Glui+4 was intended to induce the helical
conformation. As a result, the helical structures were achieved in the N- and C-terminal
regions of glucagon, a peptide containing 29 residues (Ahn et al. 2001). Recently, backbone
cyclic peptide libraries with varying ring sizes, bridge chemistry and modes of cyclization
were synthesized to enhance the pharmacological properties of a linear heptapeptide
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inhibitor of activated protein kinase B (PKB/Act), an enzyme associated with many types of
human cancers (Tal-Gan et al. 2011a). The synthesis and SAR-studies were performed by
creating over 60 linear and cyclic analogs and these molecules were then evaluated for in
vitro PKB/Akt inhibition. As a result, more potent analogs of selective PKB/Akt inhibitors
were identified and the importance of addressing all conformational parameters such as
ring position, ring size, ring chemistry and the mode of cyclization were clarified (Tal-Gan
et al. 2011a).
Figure 15. Some representative cyclic peptide structures, a,b  1.
During head-to-tail synthesis macrolactamization is the rate-limiting step. Thus it was
formerly performed in solution using a highly diluted concentration of partially protected
peptide in order to avoid the dimerization or polymerization of peptide (Davies 2003). The
slow cyclization step resulted in tetramethylguanidium mediated end capped amino group
when uronium-based activators were used for cyclization step and the racemization of C-
terminal residues commonly occurred (Davies 2003). From the beginning of 1990,
cyclization on-resin gained popularity and the growing peptide chain was anchored to the
resin via the side chain of C-terminal residue or C-terminal carboxylic acid (Li & Roller
2002, Davies 2003). One of the most useful methods is the use of allyl-protection for -
carboxylic group of Asp or Glu which, depending on the resin being used, yield head-to-
tail cyclic peptide containing Asp or Asn and Glu or Gln at the resin cleavage site (Kates et
al. 1993). The peptide can also be cyclized via the so-called cleavage-by-cyclization method
(Li & Roller 2002, Davies 2003). In this method, the peptide is anchored to the resin via a
specific eletrophilic linker which is prone to nucleophilic attack by a free basic amino group
and the cleavage occurs during this attack (Davies 2003). For example, a cyclic human
calcitonin fragment analog has been synthesized using the cleavage-by-cyclization method
(Kapurniotu & Taylor 1993). The third method for backbone cyclization is the use of
backbone amide linker (BAL) which permits standard peptide chemistry and cleavage steps
(Davies 2003, Jensen et al. 1998, Li et al. 2002). For example, a cyclic peptide library based
on the somatostatin sequence has been synthesized using the backbone amide linker and
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the usefulness of the BAL-method for the synthesis of library was highlighted (Bourne et al.
2001).
 The history of peptide backbone cyclization contains numerous publications with
techniques reported using a wide variety of chemistries but still the cyclization step and
sequence dependence on the cyclization potency are the major yield-limiting factors (Li &
Roller 2002, Davies 2003). The most important factor is the length of sequence to be cyclized
and the influence of residues to be included in the sequence. Cyclodipeptides, in other
words diketopiperazines (Figure 12, see page 24), are usually not wanted as earlier
mentioned, but if desired, they can usually be easily prepared (Fischer 2003).
Cyclotripeptides are almost impossible to construct with all-L amino acids because all of the
residues should adopt cis-conformation. If one uses N-alkylated residues or -amino acids,
then cyclotripeptides can be produced (Davies 2003). Cyclotetrapeptides also are
unfavourable if one tries only to incorporate L-amino acids because the ring should contain
a trans-amide bond in all residues (Davies 2003). The universal cell-recognition sequence
RGD, found in ligands binding to integrins, has attracted considerable attention for
example in cancer research. The RGD sequence has also been intensively studied in the
peptide chemistry field, for example in a study of the cyclization of tetrapeptides including
the RGD-sequence (Alcaro et al. 2004). The cyclization of penta- and hexapeptides is a
challenging  task  if  the  sequence  does  not  contain  any  turn-inducing  residue  such  as  a D-
residue or Gly/Pro (Davies 2003). Certain factors such as the choice of the terminal residues,
the  turn  inducing  properties  and  activators  for  cyclization  have  been  studied  to  see  how
they influence the cyclization of pentapeptides (Tang et al. 2002). The same factors have
been evaluated in heptapetides. When the number of residues in the cyclic peptide is seven
or more, the ring system becomes more and more flexible and there is no universal method
available for cyclization (Davies 2003). There are a couple of backbone cyclic peptides
worth considering from the synthetic point of view, the cyclodecapeptide gramicidin S with
Gram-positive activity and the previously mentioned cycloundecapeptide cyclosporine A,
which are subjects of tens of thousands of publications including numerous synthetical
studies (Davies 2003).
The  high  frequency  of  disulphide  bridges  between  two  Cys-residues  in  the  natural
peptides and protein fueled the research and developments in the structural characteristics
and synthetic chemistry of disulphide bridges. For example, disulphide bridges can be
found in many natural hormones somatostatin, oxytocin, calcitonin and insulin (Table 1,
see page 3). The intramolecular disulphide bonds play a fundamental role in the
stabilization of bioactive conformations such as loops and turns in peptides and proteins,
and these are usually crucial for biological activity. The disulphide bridges are important in
protein folding and if the protein is denatured, the disulphide formation is responsible for
destabilizing the denatured state (Li et al. 2002).
During the past few decades, the chemistry concerning disulphide bridge formation has
been intensively studied (Annis et al. 1997, Li & Roller 2002, Davies 2003), and the practical
procedures are not discussed here in detail. The chemistry around disulphide bridge
formation is focusing on the maximum amount of correct and the desired product and also
targets the avoidance of unwanted bridge formation (mispairing) including dimerization
and further polymerization in the presence of multiple cysteines. Unwanted disulphide
bridges can be reduced back to free thiols but this recycling is time and reagent consuming.
A disulphide bridge between two sulphur atoms can be formed in solution using high
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dilution to avoid unwanted polymerization. Both free thiols and S-protected precursors can
be used (Annis et al. 1997). A disulphide bridge can be created by spontaneous oxidation
under air by using slightly alkaline reaction conditions. In that case, Trt as thiol-protecting
group (Table 3, see page 21) is commonly used in the Fmoc-strategy, because Trt is already
cleaved during the final cleavage of the peptide from resin. Often a disulphide bridge is
formed by using some oxidative reagents, such as iodine or thallium trifluoroacetate. Both
of these reagents also remove Acm-protecting group enabling the selective deprotection for
cysteines (Annis et al 1997). Disulphide can also be formed on solid phase and the
cyclization yields can be enhanced via using low-load resin (Albericio et al. 1991). On-resin
cyclization is enhanced via so called pseudo-dilution phenomena, a kinetic phenomenon
which favors intramolecular prosecces (Albericio et al. 1991). The Acm is a usable
protection group for thiol also during on-resin cyclization process (Annis et al. 1997).
The main advantages of the chemistry of cysteines and disulphide bonds are the
regioselective removal of protective groups permitting the formation of multiple specific
disulfide bridges within the same peptide (Figure 16), the construction of oligomeric
peptides in multi Cys-containing precursors and the nucleophilic conjugation of thiol group
with variable agents such as labeling agents (Li & Roller 2002). Furthermore, if the lead
peptide is derived from a phage display library, directly disulphide bridge constrained
peptides can be screened (Landon et al. 2004). However, the disulphide bridge is known to
be metabolically labile under reductive conditions as well as in the presence of nucleophilic
and basic agents (Williams & Liu 1998) and thus it should be replaced in peptide based
pharmaceutical by other structural units or by mimetics.
Figure 16. Regioselective formation of two specific disulphide bridge by using spontaneous air
oxidation and iodine oxidation.
The structural importance of the disulphide bridge in somatostatin is commonly known
and the disulphide bridge exists usually in most SST-analogs such as ocreotide. It has been
demonstrated that the shortest active sequence is the cyclic hexapeptide including the
active sequence and the disulphide bridge as a stabilizer for an active conformation
(Reissmann  &  Imhof  2004).  Another  one  well-known  successful  example  of  disulphide
bridge incorporation is the development of the -opioid receptor ligand [D-Pen2, D-Pen5]-
enkephalin (DPDPE, Figure 17), an analog of the opioid pentapeptide Met5-enkephalin
(Mosberg et al. 1983). The replacement of Gly2 and Met5 by two Pen-residues and  the
oxidation of thiols to the disulphide bridge resulted in the creation of a highly potent and
selective -opioid receptor ligand (Mosberg et al. 1983, Cowell et al. 2004). The disulphide
bridge was proposed to constrain the biologically active conformation. Another example is
the cyclic analog of the previously mentioned -melanocyte stimulating hormone (MSH)
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which was found to be superpotent due to its stabilized -turn structure via disulphide
bridge although it did not exhibit as prolonged biological activity as the analog with the D-
amino acid in the possible cleavage site for endopeptidases (Sawyer et al. 1982).
Figure 17. The structures of Met5-enkephalin and its analog DPDPE.
Disulphide bonds are known to be very important in proteins and one very interesting
group is small, around 30 residues containing head-to-tail cyclic, and three disulphide
bridges containing miniproteins, called cyclotides. Cyclotides are present in some plant
materials and their main property is to defend the host. They also possess a diverse range
of biological activities including anti-microbial, cytotoxic and anti-HIV activities (Cemazar
& Craik 2006). Cyclotides have been shown to possess exceptional stability against
enzymatic, thermal and chemical degradation mostly due to the cyclic backbone, the
cystine knot formed by disulphide bridges and their extensive hydrogen bonding network.
Several biological activities will be lost if disulphide bridges are removed and the cyclotides
become linearized (Cemazar & Craik 2006).
The importance of the disulphide bridge in biological structures has fueled the research
into disulphide bridge mimetics. The challenges of creating structures mimicking
disulphide bridge is that the atomic radius of sulphur differs from other atoms present in
peptides  (e.g.  C,  O,  N).  The dihedral  angle  between S-C and S-S  is  almost  90°  and thus  it
differs  from  the  bond  angles  in  peptide  bonds  or  all-hydrocarbon  linker  bonds.
Furthermore, cystine contains a total seven rotable bonds whereas all-peptide bridge
contains only four rotable bonds in the area covering approximately the same size (Figure
18) (Stymiest et al. 2005, Cowell et al. 2004). By using all-hydrocarbon linkers it is possible
to maintain the number of rotable bonds compared to the disulphide bridge, between
residues which are connected to a bridge structure (Figure 18).
Figure 18. The structure and rotating bonds in the disulphide bridge (on the left), all-peptide
bridge (in the middle) and olefin linker (on the right).
Bacterial microorganisms produce antimicrobial peptides such as nisin and epidermin
derivatives, which are called lantibiotics because they contain a building block called
lanthionine (Li & Roller 2002). Lanthionine consists of two alanines joined together via a
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thioether bond between the -carbons, in other words lanthionines are monosulfide analogs
of cystine. The main advantage of thioether-cyclized analogs compared to the disulfide
bridge containing peptide is its stability against redox conditions. Lanthionines have been
successfully used in the formation of ocreotide analogs. When the disulphide bridge of the
ocreotide (Figure 2 see page 10) was replaced with a lanthionine bridge, the serum stability
of lanthionine-ocreotide was increased by 2.4 fold (Osapay et al. 1997). In addition, highly
potent and selective lanthionine analogs of above mentioned enkephalin derivative DPDPE
has been developed (Rew et al. 2002).
Another widely used disulphide bridge mimetic procedure is the use of dicarba analogs
to  form  olefin-linked  cyclic  structures.  An  olefin-bridge  can  be  formed  via  ring  closing
metathesis (RMC) i.e. olefin metathesis and this has been shown to increase the metabolic
stability and helicity of certain peptides. The olefin bridge can be used also for the
stabilization of the peptide’s secondary structures like -turns and -sheet (Miller et al.
1996, Grubbs 2004, Li & Roller 2002). Furthermore, it has been described in the study of
Miller and his collaborators that dicarba analog of -turn tetrapeptide Cys-Pro-Aib-Cys
exhibit structural similarity with the parent peptide, based on NMR- and IR-studies (Miller
et al. 1996). RCM can be performed using ruthenium-based catalysts which are air and
water tolerant and they can be used with a wide variety of functional groups and
protecting groups present in peptide synthesis (Li et al. 2002, Grubbs 2004). In general, in
the synthesis of the dicarba analogs for disulphide bridge, the L-cysteines are replaced by
(S)-allylglycines in the linear precursor of the peptide (Figure 19). After RCM-reaction, the
olefinic double bond instead of the disulphide is formed (Li et al. 2002). This double bond
can  be  further  reduced  to  olefin  (Figure 19). Recently, the dicarba analogs of both
somatostatin (D'Addona et al. 2008) and oxytocin and its antagonist atosiban (Table 1, see
page 3) (Stymiest et al. 2005) have been synthesized and their importance in structure-
affinity studies and in a pharmacophore model was highlighted.
Figure 19. Cyclization of a peptide by using RCM reaction between terminal allylglycines and the
reduction of a double bond to olefin
1.3 PROSTATE CANCER AND KALLIKREINS
1.3.1 Prostate Cancer
Prostate cancer (PCa) is the most common cancer in males and the third leading cause of
cancer deaths after lung and colorectal cancers in the developed countries (Jemal et al.
2011). For example, in the United States, one in six men have a lifetime risk of receiving a
PCa diagnosis and the chance of death due to PCa is 3,4% (Jemal et al. 2010). Most
commonly, PCa only causes clinical symptoms when the cancer has spread to the
surrounding tissues affecting directly on urinary function or after metastasis to the lymph
nodes or other organs, mostly bones. Unfortunately, PCa displays a wide range of clinical
behaviour, from clinically insignificant slow-growing tumors to aggressively metastatic and
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fatal disease posing remarkable challenges in the diagnosis and treatment of prostate
cancer.  The  risk  of  PCa  has  been  monitored  and  detected  via  screening  based  on  the
determination of KLK3 in serum (Stenman et al. 2005, Catalona et al. 1991, Stamey et al.
1987). Eventually PCa diagnosis is based on the combined use of KLK3 assay, a digital
rectal examination (DRE), transrectal ultrasonography (TRUS) and transrectal ultrasound-
guided biopsies (Cooner et al. 1990).
Human kallikrein 3 (KLK3), formerly known as prostate-specific antigen (PSA) has been
commonly used as a serum PCa marker for detecting early-stage PCa, for monitoring
disease progress and for evaluating the therapeutic response. However, the disadvantages
of  the  currently  used  KLK3  serum  test  are  that  it  detects  indiscriminately  many  types  of
prostate abnormalities. The level of KLK3 increases in the serum of a patient with
nonmalignant prostatic diseases, such as benign prostatic hyperplasia (BPH) and prostatitis
and thus the test is not cancer specific. These facts together with the reality that most PCa
tumors grow slowly has lead to a remarkable rate of overdiagnosis with many patients
having to undergo unpleasant examinations and unnecessary treatments such as radical
prostatectomy or radiotherapy with its attendant side effects for benign or latent tumors
(Lilja et al. 2008). The use of opportunistic screening with artificial limits of KLK3 in serum
has caused dramatic increase in the PCa incidence although many prostate cancers patients
would not have surfaced clinically without screening and the cancer would have posed no
threat to life or health (Stenman et al. 2005). Thus, KLK3 is currently used as a marker for
diagnosis but it has been stated that KLK3 values indicate only the relative degree of risk
and there is no KLK3 concentration which could rule out cancer (Thompson et al. 2005). It
is  important  to  devise  methods to  distinguish clinically  relevant  tumors  with  an ability  to
metastasize using more specific markers and methods for more accurate prognosis are
needed. KLK3 remains the most useful marker but a wide variety of candidates for new
biomarkers of PCa have been described including KLK2, early prostate cancer antigen
(EPCA), prostate cancer antigen 3 (PCA3) and hepsin and these have been widely discussed
in the literature (Sardana et al. 2008, Steuber et al. 2008). The serum levels of KLK2 and the
combination  of  KLK2  with  different  forms  of  KLK3  have  been  claimed  to  improve
diagnosis and the prognosis of PCa (Recker et al. 2000, Steuber et al. 2007, Lilja et al. 2008,
Becker et al. 2000). However, the search for markers or their combinations still continues
(Sardana et al. 2008, Pavlou & Diamandis 2009).
1.3.2 KLK3
KLK3 is a serine protease which belongs to the kallikrein related peptidase family
(Lundwall et al. 2006, Yousef & Diamandis 2001). It is a 28-kDa glycoprotein consisting of
237 amino acids and it is expressed as a proenzyme mainly in the epithelial cells of the
prostate but it has been shown that minuscule amounts can be detected in some other
organs such as mammary gland and ileum (Olsson et al. 2005, Shaw & Diamandis 2007).
KLK3 has a chymotrypsin-like activity and its physiological role is to degrade gel-forming
proteins semenogelin-I and –II, cleaving preferentially after tyrosine, leucine and glutamine
residues, causing liquefaction and thereby promoting sperm motility (Lilja 1985, Malm et
al. 2000, Robert et al. 1997). KLK3 is synthetized in healthy prostate but it is also expressed
in prostate abnormalities. In both malignant and some non-malignant conditions like BPH,
KLK3 is leaked to the circulation due to the altered tissue architecture (Stenman 1997).
When it leaks into the circulation, most of the catalytically active KLK3 is inactivated by
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protease inhibitors like 1-antichymotrypsin (ACT) and 2-macroglobulin (A2M) which
inhibit any catalytic activity of KLK3 by forming stable covalent complexes (Christensson et
al. 1990, Stenman et al. 1991). KLK3 also exists in blood in various noncomplexed forms
such as pro-KLK3, intact and nicked KLK3 (Lilja et al. 2008).
The role of KLK3 in cancer is still largely unknown but it has been shown that KLK3 has
an anti-angiogenic potential. KLK3 inhibits endothelial cell growth, invasion and migration
both in vivo and in vitro indicating  the  reduction  of  activities  needed  for  blood  vessel
formation (Fortier et al. 2003, Fortier et al. 1999). The mechanism for the anti-angiogenic
activity is unclear. It has been shown that only enzymatically active KLK3 can inhibit tube
formation  in  a  cell  culture  model  using  human  umbilical-vein  endothelial  cells  (HUVEC)
(Mattsson et al. 2008). This indicates that the enzymatic activity of KLK3 is needed for its
anti-angiogenic properties. Recently it has been shown that by using peptides which
stimulate the enzymatic activity of KLK3, the antiangiogenic activity of KLK3 can be
enhanced (Mattsson et al. 2012). Furthermore, it has been shown that KLK3 can cleave
plasminogen into angiostatin-like fragments achieving an anti-angiogenic effect
(Heidtmann et al. 1999). High KLK3 expression is associated with low microvessel density
and in poorly differentiated tumors, the expression decreases suggesting a tumor
suppressing role for KLK3 (Abrahamsson et al. 1988, Paju et al. 2007, Papadopoulos et al.
2001).
Conversely it has also been reported that KLK3 can promote tumor growth and the
formation of metastases by degrading extracellular matrix proteins and activating matrix –
metalloproteinase-2 (Webber et al. 1995, Ishii et al. 2004). KLK3 has been shown to cleave
insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) (Cohen et al. 1992). Increased
IGF-1 activity is associated with the stimulation of cell proliferation and thus it influences
the cancer growth in many cancers including prostate cancer (Samani et al. 2007). KLK3
also activates the latent form of transforming growth factor-2 (TGF-2) which can promote
the growth of the malignant cells (Killian et al. 1993, Dallas et al. 2005). Furthermore, KLK3
has been postulated to play a role in the development of bone metastases via the promotion
of osteoblast proliferation (Goya et al. 2006, Romanov et al. 2004). This includes the
hydrolyzation and inactivation of parathyroid hormone-related protein (PTHrP) which has
been shown to inhibit osteoblastic processes (Cramer et al. 1996, Iwamura et al. 1996). In a
recent study, lowering the KLK3 levels in LNCaP human prostate cancer cell line reduced
LNCaP growth rates suggesting that enzymatically active KLK3 is needed for PCa
progression (Williams et al. 2011).
In summary, the levels of KLK3 in tissue are easily measured and they have been used
for a long time to predict the incidence of PCa. Furthermore, KLK3’s activity as a serine
protease has been extensively studied. However, its role in both the normal prostate and
the PCa remains unclear. The fact that mice or rats do not possess the KLK3 gene or express
a functional KLK3 homolog in the prostate has hampered PCa research. KLK2 and KLK3
transgenic mice have been created but the levels of KLK3 produced in this model species
were estimated to be 1000-fold lower than in human prostate (Williams et al. 2010). In
addition, KLK3 expression level in human PCa cell lines varies and the tumor growth rate
in vivo is slow in immune-compromised animals (Williams et al. 2007a). Furthermore, there
have been difficulties in producing structural data such as obtaining a crystal structure for
KLK3.
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1.3.3 KLK2
The KLK2 is 78% homologous in its amino acid sequence to KLK3 and is its the closest
relative (Schedlich et al. 1987). Like KLK3, KLK2 expression is mainly restricted to the
prostate and it has been considered as a prostate cancer marker in addition to KLK3 (Shaw
& Diamandis 2007, Darson et al. 1997, Sardana et al. 2008). KLK2 has trypsin-like activity
differing from KLK3 (Frenette et al. 1997a) and it cleaves substrates mainly after lysine and
arginine. Like KLK3, KLK2 is secreted into the seminal fluid and its main physiological
function is believed to be the activation of KLK3 via cleaving proKLK3 (Lövgren et al. 1997,
Williams et al. 2010). It has been shown to cleave also semenogelins but from different sites
than KLK3 (Deperthes et al. 1996). It is rapidly covalently bound to protein C inhibitor
(PCI) when released into the seminal plasma (Deperthes et al. 1996) and in the circulation it
is  mainly  complexed  with  protease  inhibitors  such  as  A2M,  PCI,  2-antiplasmin and
plasminogen activator inhibitor 1 (PAI-1) (Mikolajczyk et al. 1998, Mikolajczyk et al. 1999,
Heeb & Espana 1998). KLK2 is also involved in proteolytic cascades which facilitate
prostate cancer growth and metastasis. KLK2 cleaves IGFBP-3 which may promote both
tumor growth and a more aggressive cancer phenotype (Rehault et al. 2001, Hekim et al.
2010). It also activates the zymogen form of urokinase-type plasminogen activator (pro-
uPA) (Frenette et al. 1997b) and inactivates PAI-1 (Mikolajczyk et al. 1999). Moreover,
several other cancer-related proteins are potential substrates for KLK2 based on its
substrate specificities (Cloutier et al. 2002). The expression of KLK2 is increased in prostate
tumors  but  it  differs  from  KLK3  and  increased  serum  levels  of  KLK2  are  associated  with
poor prognosis (Steuber et al. 2007, Darson et al. 1997).
Like KLK3, the role of KLK2 in prostate cancer is not clear and studies are complicated
also by the facts that KLK2 is not expressed in mouse and its concentrations in the seminal
plasma are much lower than those of KLK3 (Deperthes et al. 1996). Furthermore, even
though KLK2 is enzymatically active after ejaculation, it becomes quickly bound to PCI as
an inactive complex.
1.3.4 Peptides binding KLK3 and KLK2
The KLK2 and KLK3 are potential targets for the treatment of PCa because of their possible
influence on cancer development. In addition, they are normally highly prostate-specific
and thus represent an optimal target for specific imaging and therapy of PCa without side
effects. Usually small molecule protease inhibitors lack specificity and to overcome this
problem peptides or peptide derivatives that specifically bind to KLK2 and KLK3 have
been developed. Wu and his collaborators used phage-display technology to develop
peptides, which would specifically bind to KLK3 (Wu et al. 2000). As a result, three
differing 10-13 residue-long peptides 3 , which are cyclic via disulphide bridges, were
identified. These peptides bound to the same region as mAbs specific free KLK3, which
indicates that they were binding near to the active site of KLK3. Peptide C-4 with two
disulphide bridges  exhibited the  highest  binding affinity.  Zn2+ which is  known to  act  as  a
KLK3  inhibitor  increased  the  binding  affinity  toward  KLK3  for  all  three  peptides  studied
(Wu et al. 2000). In addition, the synthetic analogs of the peptides have been shown to
promote the proteolytic activity of KLK3 (Wu et al. 2004, Pakkala et al. 2004). KLK3
modulating peptides have also been used in peptide affinity chromatography to separate
3 Sequences are: cyclo[Cys-Val-Phe-Thr-Ser-Asn-Tyr-Ala-Phe-Cys] (which was nominated as A-1), cyclo[Cys-Val-Phe-Ala-
His-Asn-Tyr-Asp-Tyr-Leu-Val-Cys] (B-2) and bicyclo[Cys-Val-Ala-Tyr-(Cys-Ile-Glu-His-His-Cys)-Trp-Thr-Cys] (C-4)
50
the enzymatically active and inactive forms of KLK3 (Wu et al. 2004). Recently also small
molecule stimulators for KLK3 protease activity have been investigated (Härkönen et al.
2011). The phage display was also used to develop linear KLK2 binding peptides which
inhibit enzyme activity of KLK2 (Hekim et al. 2006)4. Peptides based activity inhibitors of
KLK3 have also been developed by other groups (Ferrieu-Weisbuch et al. 2006, Hassan et
al. 2007). Recently, LeBeau and co-workers reviewed peptide-derived inhibitors which may
have valuable therapeutic applications and advantages in imaging (LeBeau et al. 2010).
The role of KLK3 in PCa is still unknown as mentioned above, but for the modulation of
the anti-angiogenic activity of KLK3, the activity stimulation may be important. KLK3 has a
narrow chymotrypsin like substrate-specificity and for most substrates, its activity is low
when compared to chymotrypsin (Coombs et al. 1998). Recently it has been found that the
difference between substrate specificity of chymotrypsin and KLK3 is dependent on the
kallikrein loop of KLK3 which seems to regulate the entry of substrates into the active site
(Menez et al. 2008). The same study revealed that an antibody which stimulates the activity
of KLK3 could stabilize the kallikrein loop and it has been postulated that KLK3-binding
peptides possess a similar effect (Koistinen et al. 2008). KLK2 is highly active trypsin-like
protease and although it has also kallikrein loop, this might allow easier substrate entry
causing less sensitivity to modulation (Frenette et al. 1997a, Koistinen et al. 2008).
Compared to KLK3, the concentration of KLK2 in seminal plasma is very low but due to its
potential role in PCa cancer growth, it remains an interesting target for therapy. Thus,
peptides which inhibit KLK2 activity have been developed, and their influence on KLK2
activity studied (Hekim et al. 2006).
Peptides which bind specifically to prostate cancer serum markers KLK3 and KLK2 have
also  been studied for  therapeutic  and imaging purposes.  The specific  expression of  KLK3
and KLK2 in prostate and in PCa metastases has made it possible to develop peptide based
prodrugs activated by the KLK3 or KLK2 in PCa tumors. These prodrugs have been shown
to be able to kill prostate cancer cells in vitro and to reduce the size of the tumor in mouse
xenocraft models (DeFeo-Jones et al. 2000, Janssen et al. 2004, Janssen et al. 2006,
Christensen et al. 2009, Williams et al. 2007b, Denmeade et al. 2003). Peptide sequences for
prodrugs were modulated by the sequence modifications of the cleavage site of
semenogelin 1, the natural substrate of KLK3 (DeFeo-Jones et al. 2000, Denmeade et al.
2003) or via a combinatorial chemistry library (Janssen et al. 2004). LeBeau and his
collaborators have synthesized a selective KLK3-imaging agent using peptide-based KLK3-
inhibitor  but  the  results  from imaging studies  have still  not  been published (LeBeau et  al.
2010).
4 Sequences contain either motif Arg-Phe-Lys-Xxx-Trp-Trp or Ala-Arg-Arg-Pro-Xxx-Pro
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2 Aims of the study
Human kallikrein-related peptidases KLK2 and KLK3 (PSA) are produced nearly
exclusively by the healthy prostate but also by the prostate based tumors.  Because of the
high specificity of these proteases and their possible roles in prostate cancer progress and
proliferation, they are potential targets for prostate cancer therapy and have diagnostic
possibilities.  Previously  it  has  been  shown  that  peptides,  which  bind  specifically  to  these
proteases, are able either to inhibit or stimulate the proteolytic activity. These peptides are
therefore potential lead molecules not only for therapeutic but also for diagnostic purposes.
However, peptides tend to suffer from certain limitations such as low bioavailability due to
rapid metabolic degradation and rapid elimination. Their pharmacokinetic properties need
to be enhanced before they can be used in the clinical applications. One powerful method to
enhance the usefulness of peptides for therapeutic applications is to convert bioactive
peptide into peptide mimetics. Therefore it is important to identify the enzymatically labile
regions of bioactive peptides and evaluate their replacement with more stabile
compositions resulting in analogs which still maintain their biological activity.
The main objectives in this study were:
I. To identify the structural motifs essential for the biological activity of KLK3 binding
peptides.
II. To identify the parts of peptides which can be replaced without losing biological
activity.
III. To enhance stability against enzymatic degradation by developing alternative
cyclization strategy for an enzymatically labile disulphide bridge
IV. To enhance the stability of linear KLK2 binding peptides against enzymatic
degradation by synthesizing cyclic analogs
V. To identify the structural motifs essential for the biological activity of KLK2 binding
peptides by comparing the structural data obtained with linear and cyclized active
peptides
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3 General experimental procedures
3.1 PEPTIDE SYNTHESIS
The peptides were mainly synthesized using an Apex 396 DC multiple peptide synthesizer
(Advanced ChemTech, Louisville, KY, USA). In the earliest syntheses also a PerSeptive
9050 Plus automated peptide synthesizer was used. Difficult couplings such as non-
naturally encoded molecules and cyclizations were performed manually. All amino acids
and other reagents (GLS Biochem, Aldrich, Fluka, Bachem, Novabiochem) were purchased
in standard qualities and used without further purification.
3.1.1 Synthesis of linear peptides
The peptides were synthesized with the Fmoc strategy using HBTU/DIEA or TBTU/DIPEA
as the coupling reagents. NovaSyn TGA with 4-hydroxymethylphenoxyacetic acid linker,
Gly-preloaded Wang resin and Rink Amide AM resin were used as the solid phase
depending  on  peptide  needed  and  also  on  the  desired  peptide  end  modification  and
cyclization.  The  side-chain  protecting  groups  used  in  parallel  synthesis  were  Trt  for  Asn,
Gln and His, Boc for Trp and But for Glu, Asp Ser, Thr and Tyr. For Cys, both Acm and Trt
protection  groups  were  used.  The  additional  side  chain  protecting  groups  used  in  bridge
forming residues OAll for C-terminus and both But and ODmab for side chain protection of
aspartic acid and glutamic acid, Mtt for ornithine and lysine side chain protection.
For peptide C-terminal amides, Rink Amide Am resin was used for direct amide
formation during the cleavage step with 94-96% TFA. For N-terminal acetylation, the free
amino group was treated with 20% acetic anhydride in DMF twice for 10 min before
cleavage.
The final cleavage steps were performed using a high concentration of TFA 94-96% and
as scavengers; small aliquots of H2O, TIS and EDT were used. After cleavage, the peptides
were precipitated in diethyl ether and centrifuged. The precipitates were collected and
dissolved in 0-50% AcOH in H2O and lyophilized. The lyophilized peptide was purified by
HPLC as described later on chapter 3.2.
3.1.2 Peptide cyclization via disulphide bridge
For  Cys,  both  Acm  and  Trt  protection  groups  were  used.  During  cleavage  from  the  resin
with 94-96% TFA,  the  Acm protection group remained in  the  Cys side  chain and Trt  was
cleaved resulting in direct air oxidation and the formation of a disulphide bridge between
two cysteines.
Peptides with cysteines (Acm) were cyclized using the iodination method. Lyophilized
peptide was purified by HPLC and fractions the containing crude acyclic peptide were
pooled, lyophilized and then dissolved in 50% acetic acid (AcOH) in H2O at a concentration
of 2 mg/ml., 1 M HCl (0.1 ml/mg of peptide) was added followed immediately by 0.1 M
iodine solution in 50% AcOH (5 eq./Acm). The solution was stirred vigorously at RT for 40-
120 min. The reaction was terminated with 0.1 M sodium thiosulphate. After filtration (0.45
μm,) the peptides were purified with HPLC and the formation of the disulphide bonds was
verified in a mass spectrometer as described later on chapter 3.2.
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3.1.3 Peptide cyclization via amide bonds
The efficient head-to-tail cyclization method on-resin with side-chain anchoring of Asp or
Glu to the resin and with the use of All-protection for C-terminal carboxylic function was
first described by Kates and his collaborators (Kates et al. 1993). They achieved a good yield
for their selected cyclodecapeptide with all four differing anchoring and cyclization sites.
Over the next decade, an enormous number of studies were published concerning different
activators and reaction conditions for cyclization yield maximization and many useful
properties have been described in literature reviews (Li & Roller 2002, Davies 2003). During
the studies concerning this thesis, no reaction optimization was performed and therefore
basic  peptide  synthesis  procedures  were  mainly  used  and  if  cyclic  product  was  not
detected, the cyclization step was not repeated with an alternative procedure.
During this study, allyl-protected aspartic acid (Fmoc–Asp(OH)–OAll) was used for
head-to-tail cyclization. Carboxy terminal-protected aspartic acid was coupled to the Rink
Amide AM resin via the free side chain. C-terminal allyl deprotection was performed using
a  method  which  has  been  described  in  the  publication  of  Grieco  and  his  collaborators
(Grieco et al. 2001). A catalytic amount of Pd(PPh3)4 with PhSiH3 as a scavenger was added
to the  resin  in  anhydrous DCM. The mixture  was purged with an argon flow and stirred
under argon for 1.5 h. The resin was washed with DMF, 0.5% DIEA in DMF), 0.5% sodium
diethyldithiocarbamate trihydrate in DMF to remove the palladium catalyst, DMF and
finally with DCM. When a significant level of All-protection attached molecules were
detected after this procedure, also the method described in the publication of Alcaro and
her collaborators (Alcaro et al. 2004) was tested. C-terminal allyl deprotection was
performed using Pd(PPh3)4 in the mixture of CHCl3:AcOH:NMM (37:2:1). The mixture was
stirred under argon for 2 h at RT and washing steps were performed as described. No
traces of All-protection were detected. After the All-deprotection, the N-terminal Fmoc
protecting group was removed with 20 % piperidine in DMF.
Head-to-tail, sidechain to tail and side chain to side chain cyclizations were performed
on resin using HBTU or HATU/HOAt as the coupling agent and DIEA as the base. The
Kaiser test was used for monitoring of the cyclization success (Kaiser et al. 1970). When the
Kaiser test was negative, the peptides were cleaved from the resin, lyophilized, purified
and characterized as described in chapter 3.2.
3.2 PEPTIDE PURIFICATION AND CHARACTERIZATION
Typically, the peptides were cleaved from the resin using TFA:TIS:H2O:EDT (94:1:2.5:2.5)
and lyophilized. The disulphide bridge containing peptides was purified if needed or
cyclized as described in the previous chapter and purified immediately after oxidation. The
peptides were purified by HPLC (Shimadzu, Kioto, Japan) with a C18 reverse phase
column  and  acetonitrile  (ACN)  as  eluent  (0.1%  TFA  in  H2O/0–60% ACN gradient for 60
min) and verified by mass spectrometry with a MALDI-TOF mass spectrometer (Bruker
Analytic  GMBH,  Karlsruhe,  Germany)  or  an  ABI  QSTAR  XL  hybrid  mass  spectrometer
using  the  MALDI  interface  (Applied  Biosystems,  Foster  City,  CA).   The  purity  was
determined by analytical HPLC with 240 × 1.4 mm C18 column eluted with 0–60% ACN for
30 min or with 0–90% ACN for 42 min. The degradation rates were determined by
analytical HPLC on a 240 x 1.4 mm C18 column eluted with 0–90% ACN for 42 min.
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3.3 STRUCTURAL ANALYSIS BY NMR SPECTROSCOPY
3.3.1 Background
Different spectroscopic and spectrometric methods have been used to obtain information
about the 3D-structure of peptides and the flexibility of their structures, but also the
influences of pH and polarity of the solvent on the structure have been investigated
(Reissmann & Imhof 2004). Structural information can be obtained using UV-VIS-, Raman-
or IR-spectroscopy or circular dichroism but most commonly information about the 3D
structure in solution is obtained by NMR spectroscopy (Reissmann & Imhof 2004, Dyson &
Wright 1991). The most important data derived from NMR measurements were sequential
and long-range nuclear Overhauser effects (NOEs), CH conformational shifts, temperature
coefficients of amide protons and appropriate coupling constants, 3JNHCH, for
conformational determinations (Wüthrich 1986, Wishart et al. 1991). Long-range NOEs are
important for distance geometry determinations through space and can be used in
structural analysis performed with the appropriate software. Sequential NOEs, CH
conformational shifts and coupling constants can be used to determine residual
conformations. The conformations can be roughly divided into -conformations common in
tight turns like -turns and in helical conformations or the -conformations common in
extended and -sheet structures (Wüthrich 1986, Dyson & Wright 1991). The solvent
exposures of NH groups can be detected by determining the temperature coefficients of the
NH groups (Wüthrich 1986, Dyson & Wright 1991). Short peptides are known to have
flexible conformations, especially linear peptides and in NMR-based structural analysis
conducted  in  this  thesis,  the  main  focus  was  to  determine  if  there  was  some  local
conformational restriction such as hydrogen bonding and reversed turn structures. The
main procedure will be described in the next section. It has to be noted however, that
because the timescale of NMR-experiment is slow related to conformational fluctuation, all
of the information gained is a population-weighted average over all existing structures of
peptides in solution (Dyson & Wright 1991). Therefore, considerable caution is required
when the information of NMR-experiments is interpreted but after careful consideration
the information of the dominant conformations of the peptides in solution can be obtained.
3.3.2 Procedure
At first,  the temperature coefficients of the amide protons were determined. The chemical
shift of the amide proton 1H-resonance depends upon the temperature and it is upfield
shifted when the temperature of peptide sample is raised. The temperature coefficient,
	
	T (ppb/K) provides information about the interaction of the amide proton with
hydrogen-bond-accepting solvent molecules. A lowered temperature coefficient (< 3 ppb/K)
is  evidence  of  the  protection  of  the  amide  proton  from  solvent  and  is  most  commonly
associated with intramolecular hydrogen bonding (Wüthrich 1986, Dyson & Wright 1991).
Another chemical shift heavily affected by local backbone conformations is the 1H chemical
shift of CH. By analyzing, a large library of protein chemical shifts, it has been noted that
in the -conformation which is present in turns and helices, the 1H chemical shift of CH is
upfield shifted by around 0.39 ppm compared to a so called random coil value. Random
coil values are the approximated averages of chemical shifts from the differing 3D
conformations of peptides and proteins (Wüthrich 1986, Wishart et al. 1991). In contrast, in
-conformations which exist in extended structures, the 1H  chemical  shift  of  CH is
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downfield shifted around 0.37 ppm compared to random coil values (Wishart et al. 1991).
Other  possible  explanations  for  chemical  shift  differences  from  random  coil  values  are
dependent on pH, solvent used and ring-current effect existing nearby aromatic rings but
their influence is more or less local and does not cover all residues (Wishart et al. 1991). If a
low temperature coefficient was detected indicating solvent shielding for amide proton,
attempts to find the reason for low value were sought by further using NOESY-correlations
and  structural  analysis.  The  direct  NOE-signal  between  a  given  pair  of  protons  can  be
observed in  the  presence  of  at  least  some population of  conformers  in  which the  distance
between these  protons  is  relatively  short.  For  flexible  peptides  the  limit  for  observation is
defined as being less than 3.5 Å in solution (Dyson et al. 1988). Sequentially the most
important NOEs connectivities are between the CH of a given residue i and the NH of the
following residue (i+1)  which is  termed the  dN(i,  i+1)  NOE connectivity  and between the
amide protons of adjacent amino acid residues which is termed dNN(i, i+1) connectivity
(Figure 20). For example, the observation of a strong dN(i, i+1) NOE connectivity in the
absence of any observable dNN(i, i+1) NOEs indicates extended chain conformation as the
backbone dihedral angles (Figure 21) are predominantly in the  region of  space in the
Ramachandran plot (Ramakrishnan & Ramachandran 1965, Dyson & Wright 1991). The
observation of strong dNN(i, i+1) NOE connectivities is indicative of local structures with
dihedral angles in the  region  including  turned  and/or  helical  structures  (Figure 20). The
observation of both dN(i,  i+1)  and  dNN(i, i+1) types of sequential NOE connectivity at a
single site in a peptide can be an indication of a highly preferred local structure such as a
type  II  -turn  (Figure 21)  (Dyson  &  Wright  1991).  If  both  dN(i,  i+1)  and  dNN(i, i+1) are
detected in extended regions, this is a clear indication of a conformational fluctuation and
averaging (Dyson & Wright 1991). Thus, if indications of local structures were found, the
medium (i, i+2) and long range (i, i+n) NOE connectivities were used to confirm
observations since especially tight loop containing structures NOEs between opposite
chains could be present.
Figure 20. Main  observable  NOEs  indicated  as  sequential  (solid  arrows)  and  medium-range
(dashed and grey arrows) 1H-1H connectivities in the polypeptide chain (above). The main
differences in NOE-observations between extended and turned structures (below).
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Figure 21. Standard nomenclature for the atoms and dihedral angles in peptide chain (on the
left). The structure demonstrating a -turn structure stabilized via the hydrogen bond between
Oi and NHi+3 (on the right). The main rotable bonds differing between the different types of -
turns displayed with arrows.
The  main  problem,  when  measuring  the  NOESY-spectra  of  short  peptides,  is  the
misleading NOE-information due to aggregation (Dyson & Wright 1991). It is possible that
in the samples with a relatively high concentration of significantly large molecules like
peptides, the correlation time of the oligomer is greater than that of the monomer.
Therefore the intensities of the NOEs observed in the aggregate can be remarkably high
compared to the NOEs of the monomer (Dyson & Wright 1991). Additional information
about restricted conformations can be derived through the coupling constant between the
amide proton and H of  the  same residue;  this  is  termed as 3JHN coupling constant.  In  -
helical structure this value can be ~4 Hz, whereas in a regular -strand it is ~9 Hz.
However, for the detection of folded conformations in flexible peptides, the determination
of 3JHN is usually one of the least sensitive NMR parameters and values will be ~6-7 Hz
despite there may be rather large population of defined conformations (Dyson & Wright
1991).
The structural characterization based on distance geometry and restrained molecular
dynamics and the quantitative calculations of structure are meaningful only for peptides
that adopt some defined unique conformations in solution. For most linear peptides in
aqueous solution, the NOEs and 3JHN coupling constants will be a population weighted
average over all conformations but if conformational constraits such as cyclization exist,
then the population averaging is usually decreased. Thus, distance constraints and torsion
angle constraints collected by NMR experiments can be used to help in the estimation of 3D
peptide and protein structures using computer software which can evaluate molecular
dynamics in torsion angle space.
During the studies included in this thesis all spectra were recorded on a Bruker Avance
500 NMR spectrometer (Bruker Biospin, Karlsruhe, Germany) operating at 500.13 MHz for
1H. All one dimensional experiments were recorded at four or five different temperatures
and all two dimensional experiments were recorded at two different temperatures
depending  on  the  quality  and  clarity  of  the  spectra. All chemical shifts are reported with
respect to the 5 mM trimethylsilyl propanoic acid (TSP) peak at 0.00 ppm when 10% D2O in
H2O were used or to the DMSO peak at 2.50 ppm when used. For all 2D experiments,
standard pulse programs from the Bruker software library were used. For 2D-spectra
(COSY, TOCSY, NOESY, ROESY) various mixing times were tested with the optimal time
being determined based on the quality and clarity of the spectra. The temperature
coefficients (d/dT) of the amide protons were calculated by analysing the chemical shifts at
four temperatures.
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3.4 BIOSTABILITY STUDIES
The stability of peptides towards systemic metabolism is commonly evaluated by
incubating the peptide at +37°C and pH 7.4 in serum or plasma (Werle & Bernkop-Schnurch
2006). If more detailed knowledge about cleavage proteases is needed, the peptide can be
incubated  in  a  medium  containing  one  or  more  isolated  enzymes.  Trypsin  and
chymotrypsin are two of the most widely used proteases in metabolic stability studies
because they have major roles in protein and peptide digestion (Tal-Gan et al. 2011b).
Usually a purified cocktail of peptidases does not completely mimic the in vivo metabolic
behavior of peptides and it is reasonable to determine the metabolic stability also in vitro
with plasma and serum (Adessi & Soto 2002). Further, incubation with different tissue
homogenates or membrane preparations can also be attempted (Adessi & Soto 2002).
3.4.1 Stability of peptides against proteases
During this study, the stabilities against selected proteases were determined by incubating
selected peptides in a buffered solution at +37°C with proteases. Small samples were
collected at several time points. Proteases were removed from reaction mixture with
Microcon Centrifugal Filter Device (Microcon YM-10, cut off 10 kDa, Millipore, Bedford,
MA, USA) by centrifugation at 14000 – 15000 rpm in an Eppendorf 5415 D centrifuge
(Eppendorf, Hamburg, Germany) for 10 min. The filtrates were analyzed by HPLC and
peptide fragments were characterized by MSMS as described in chapter 3.2. Fragment ions
were calculated by using Prowl (http://prowl.rockefeller.edu/) if needed.
3.4.2 Stability of peptides in plasma
The stability of the peptides in human plasma was studied by mixing fresh human plasma
which was collected into EDTA-coated tubes with each peptide in phosphate buffered
saline (PBS) solution. The reaction mixtures were incubated for up to 24h at +37°C. The
peptides and peptide fragments were separated from plasma, analyzed and characterized
as described above.
3.5 EFFECT OF THE PEPTIDES ON THE ENZYME ACTIVITY OF KLK3 AND
KLK2
The effect of different peptides in the activity of KLK3 was measured using the
chromogenic chymotrypsin substrate S-2586 (MeO-Suc-Arg-Pro-Tyr-pNA) purchased from
Chromogenix Instrumentation Laboratory (Milano, Italy). During activity measurements of
KLK2, chromogenic substrate S-2302 (H-D-Pro-Phe-Arg-pNA, Chromogenix, Milano, Italy)
were used. KLK3 or KLK2 was incubated for 30 min at RT with synthetic peptides in Tris-
buffer solution. After the addition of the substrate, the absorbance at 405 nm was measured
at 5 min intervals for 30 min with a Victor 1420 Multilabel fluorometer (Perkin-Elmer-
Wallac, Turku, Finland) if not otherwise stated.
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4 Optimization of Amino Acid Composition and
Conformational Analysis of the Cyclic Peptides which
Stimulate KLK3 Protease Activity5
4.1 INTRODUCTION
By using phage display libraries, specific KLK3 binding peptides A-1 (cyclo-
[CVFTSNYAFC]), B-2 (cyclo-[CVFAHNYDYLVC]) and C-4 (bicyclo-[CVAYCIEHHCWTC])
have been identified. They bind only to the enzymatically active form of KLK3 (Wu et al.
2004). The structures of three KLK3 activating synthetic peptides having one or two
disulfide bridges were studied by NMR spectroscopy to determine possible conformational
information of these bioactive peptides. Furthermore, the amino acid sequences of the three
peptides were studied using alanine replacement-based structure-activity studies in order
to determine the amino acid residues important for the activity of the peptides. Based on
NMR studies and peptide modifications, a common structure and the amino acid residues
that are important for the KLK3 promoting activity of the peptides, were proposed.
In  an  additional  study*,  the  structure-activity  relationships  of  C-4  peptide,  which
displays the highest activity stimulation toward KLK3, were examined using selective
amino acid and multi-alanine replacements (unpublished data). The aim of the additional
study  was  to  determine  residues  or  sections  which  can  be  simplified  without  decreasing
biological activity and possibly replaced by mimicking structures.
4.2 RESULTS AND DISCUSSION
4.2.1 Conformation of peptides
Every peptide investigated (A-1, B-2, C-4) has NH group or groups showing very low
	
	T values (<3 ppb/K) characteristic of strong solvent shielding. Low temperature
coefficients of amide protons were found for Tyr7 and especially for Ala8 in peptide A-1,
for Tyr7 in peptide B-2 and for His9 in peptide C-4 (Table 5). The upfield chemical shifts of
CHs suggest that there exist -conformations between residues Ser5-Tyr7 in peptide A-1,
between His5-Asp8 in peptide B-2 and between Glu7-His8 in peptide C-4 (Figure 22)
(Wishart et al. 1991, Maynard et al. 1998). Very strong sequential NH(i)-NH(i+1) NOEs
were found for Asn6-Tyr7 in peptide A-1, for His5-Asn6, Tyr7-Asp8 and Asp8-Tyr9 in
peptide B-2 and for Val2-Ala3 and His8-His9 in peptide C-4 indicating -conformations and
possible  turn  structure.  Strong  sequential  CH(i)-NH(i  +  1) NOEs were found between
residues Val2-Asn5 in peptide A-1, between Val2-Ala4 and Tyr9-Cys12 in peptide B-2 and
between Cys1-Glu7 and His9-Cys13 in peptide C-4 indicating the existence of -
5 Adapted with permission of John Wiley and Sons from: Pakkala M, Jylhäsalmi A, Wu P, Leinonen J, Stenman U-H, Santa
H, Vepsäläinen J, Peräkylä M, Närvänen A. Conformational and biochemical analysis of the cyclic peptides which
modulate serine protease activity, Journal of Peptide Science, 10(7): 439-447, 2004
* Additional unpublished data on selective amino acid and multiple alanine replacements is included (the additional
study is indicated in the text)
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conformations. Long-range inter-residual NOEs were found for peptides B-2 and C-4. No
significant inter-residual NOEs were observed for peptide A-1 (Figure 23).
Table 5. 1H chemical shifts measured in DMSO-d6 and amide proton temperature coefficients of
KLK3-binding peptides. The temperatures of the NMR-samples, when the 1H chemical shifts
presented in this table were detected, were 305K for peptides A-1 and C-4 and 310K for peptide
B-2.
Peptide
Residue NH CH CH CH CH Other
-/T
(ppb/K)
A-1
Cys1 4.20 2.98
Val2 8.52 4.23 1.88 0.81 6.1
Phe3 8.36 4.83 3.08,  2.88 7.18 7.13-7.23 (CH, CH) 6.0
Thr4 8.02 4.38 4.18 1.04 7.4
Ser5 8.06 4.14 3.72, 3.65 4.7
Asn6 7.99 4.46 2.46, 2.39 6.93, 7.38 (NH) 7.2
Tyr7 7.81 4.36 2.86, 2.67 6.94 6.62 (CH) 3.7
Ala8 7.89 4.37 1.09 1.8
Phe9 8.00 4.60 3.06, 2.82 7.13-7.23 (CH, CH) 7.0
Cys10 8.48 4.58 3.17, 2.96 7.5
B-2
Cys1 - 4.39 3.03, 2.82
Val2 8.62 4.42 2.07 0.87, 0.81 4.7
Phe3 8.40 4.77 3.07, 2.73 7.25 7.21-7.24 (CH, CH) 9.3
Ala4 8.02 4.25 1.16 7.6
His5 8.42 4.27 3.13, 3.02 7.27 (4H) 8.81 (CH, 2H) 8.7
Asn6 7.99 4.26 2.59, 2.59 6.87, 7.44 (NH) 5.0
Tyr7 7.85 4.13 2.86, 2.75 6.84 6.58 (CH) 0.7
Asp8 8.16 4.53 2.68, 2.50 7.3
Tyr9 7.53 4.58 2.94, 2.72 6.94 6.57 (CH) 4.0
Leu10 8.30 4.50 1.35, 1.35 1.33 0.55, 0.53 13.1
Val11 8.21 4.29 1.92 0.88, 0.87 10.8
Cys12 8.75 4.67 3.21, 2.89 10.3
C-4
Cys1 - 4.22 3.23
Val2 8.61 4.28 1.98 0.89, 0.88 6.7
Ala3 8.15 4.65 1.20 6.4
Tyr4 7.96 4.71 2.87, 2.66 6.89 6.53 (CH) 4.5
Cys5 8.67 5.38 2.83, 2.72 9.9
Ile6 8.55 4.20 1.81 1.14, 1.55
0.92 (CH3)
0.86 6.5
Glu7 8.98 3.57 2.17, 1.95 2.28 8.5
His8 8.41 3.93 3.27 7.24 (4H) 8.74 (CH, 2H) 5.9
His9 7.86 4.72 3.04, 2.87 7.18 (4H) 8.63 (CH, 2H) 1.0
Cys10 8.60 5.27 2.74, 2.65 9.1
Trp11 8.58 4.76 3.09, 2.89 7.14 (2H) 7.65 (4H), 6.95 (5H),
6.98 (6H), 7.26 (7H),
10.62 (NH)
4.3
Thr12 8.20 4.40 3.94 1.10 10.3
Cys13 7.97 4.50 3.17 4.0
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Figure 22. Differences between the CH chemical shift values in the random coil and values
determined experimentally in DMSO-d6 for A-1 (above), B-2 (middle) and C-4 (bottom).
A part of the NH peaks was broadened indicating solvent-exposed NH groups or
conformational fluctuation and dynamic behavior (Wüthrich 1986, Raghothama et al. 1996).
Because of broadening all 3JNHCH could not be detected and the detected coupling constants
were usually between 6.0 and 8.0 Hz.
The common turn structures in the peptides investigated were identified as a type I -
turn between residues Ser5-Ala8 for peptide A-1, a type I -turn between residues Ala4-
Tyr7 for peptide B-2 and a type II -turn between residues Ile6-His9 for peptide C-46.
However, peptide C-4 has a disulphide bond between residues 5 and 10, which causes a
tight turn in the sequence between those residues. Whenever a loop structure was formed
in the peptides studied the aromatic side chains of phenylalanine, tyrosine or tryptophan
were found to locate on the same side of the peptide loop and near each other.
6-turn is formed by four consecutive residues which are not part of -helix and the distance between C(i) and C(i+3) is
less than 7Å. The nomenclature is depending on backbone torsion angles of two center residues, i+1 and i+2. The most
commonly  existing  -turn  types  are  classified  as  type  I,  I’,  II,  II’  VIII,  Via,  VIb  and  IV  (Wilmot  and  Thornton  1998,
Hutchinson and Thornton 1994).
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In  peptide  A-1,  a  relatively  strong  NH(i)-NH(i+1) correlation between Asn6 and Tyr7
was detected (Figure 23) supporting the existence of an -conformation for the backbone of
Asn6 and thereby proposing the existence of a type I -turn between residues Ser5-Ala8
(Wüthrich 1986). A moderately low temperature coefficient for the amide proton of Tyr7
(3.7 ppb) was detected (Table 5), which is likely due to an interaction between the NH-
proton of Tyr7 and the side chain oxygen of Ser5. This is in line with serine’s potential to be
at position i of the type I turn (Hutchinson & Thornton 1994, Wilmot & Thornton 1988).
However, strong CH(i)-NH(i + 1) correlation for Asn6 and Tyr7 provides evidence for the
existence of a significant population of type II turns in the same area (Figure 23). Thus, these
mutually exclusive NOE-correlations indicate high flexibility or conformational
interconversion in the turn (Gunasekaran et al. 1998).
Figure 23. Summary of significant NOE-correlations for peptides A-1 (a), B-2 (b) and C-4 (c) in
DMSO-d6. Relative cross-peak intensities were estimated from volume integration and depicted
as  strong,  medium  and  weak.  Mark  *  means  disturbed  NOE-correlation  by  some  other  NOE.
NOEs indicated as “other” interaction include long range main chain-main chain, side chain-
main chain or side chain-side chain interactions.
In peptide B-2, a strong NH(i)-NH(i+1) correlation between residues His5 and Asn6, and
a weak correlation between Asn6 and Tyr7 were found (Figure 23), indicating that there is a
type I -turn at residues 4–7 (Wüthrich 1986). Furthermore, weak NOE-correlations
between  Ala4  CH3-protons and both Tyr7 and Tyr9 amide protons indicate that a tight
turn exists.
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In peptide C-4, both strong NH(i)-NH(i+1) correlation between His8 and His9 (Figure 23)
and strong intraresidual CH(i)-NH(i)  correlation  for  His8  indicate  a  type  II  turn.  A  very
strong downfield shift  for  Glu7 NH evidences  its  solvent-exposed conformation,  which is
most probably intrinsic for a type II turn. A NOE was observed between Ile6 NH and Tyr9
NH indicating the existence of a tight turn.
The cyclization of the peptides is suggested to force the peptides in turned
conformations essential for the KLK3-promoting activity. Long-range NOE analyses
indicate loop structures and common - turn structures for each peptide. In A-1 Tyr7 is
located at position i+2 (turn 5–8) and in B-2 at position i+3 (turn 4–7) of a -turn. Due to the
fluctuation of the A-1 backbone, Tyr7 may also locate at position i+3. It is suggested that
this  fluctuation  is  more  favoured  in  water  solutions,  because  DMSO-d6 may  act  only  as  a
hydrogen bond donor, whereas water has hydrogen bond donor and acceptor properties.
Therefore, distances between the aromatic residues and the conformations of A-1 and B-2
are likely to be similar. In peptide C-4, a disulphide bond close to Tyr and Trp is the main
factor determining the overall structure of the peptide. In addition, hydrophobic
interactions may exist between Tyr, Ile and Trp forming a hydrophobic cluster on one side
of the peptide. NOE-correlation peaks were found between the side chains of Tyr4 and Ile6.
The distance between a pair of protons has to be less than 3.5 Å in flexible structures for
a NOE to be observed (Dyson & Wright 1991). The sequential NH(i)-NH(i+1) NOE cross
peaks are evidences of folded or turned conformations (Dyson & Wright 1991). In the case
of short peptides, the NH(i)-NH(i+1) NOE is seen if the population of a turn conformation
is at least 10% (Wüthrich 1986, Dyson et al. 1988). Both - and -conformations were found
for Phe3, Asn6, Ala8 and Phe9 in peptide A-1, for Phe3, Ans6, Tyr7, Asp8, Tyr9 and Val11
in peptide B-2 and for Val2, Tyr4, Glu7, His8 and Trp11 in peptide C-4. Thus, in spite of the
fact that these peptides are relatively short cyclic structures, several conformations were
observed.
4.2.2 The KLK3-promoting activity of A-1, B-2, C-4 and their modifications
The activities of the three KLK3-promoting peptides and corresponding alanine
replacement sets were compared with the activity of KLK3 alone (Figure 24). Most of the
changes inactivated or reduced the activity of peptides A-1 and B-2. The exception was the
replacement of His5 by Ala in B-2, which improved the activity. In addition, two
replacements (Phe3Ala and Asn6Ala) in the A-1 sequence slightly decreased the KLK3
reactivity. In the B-2 sequence the carboxy terminal Leu and Val, which are not present in
the A-1 sequence, could not be replaced by alanine without losing the activity. The C-4
peptide contains 13 amino acids and two disulphide bridges. None of the alanine
replacements totally inhibit the activity. Reduced activities were observed in TyrAla,
IleAla and TrpAla modifications. In contrast to this, slightly increased activities were
seen when Val2, Glu7, His8, His9 and Thr13 were mutated to Ala.
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Figure 24. Alanine replacement sets of A-1, B-2 and C-4 peptides. Every column represents
amino acid, which is changed with alanine and the height is calculated from the equation:
absorbance of peptide KLK3/KLK3 alone. Value 1 illustrates KLK3 activity alone. In peptide A-1
some of the modifications have values below 1 suggesting KLK3 inhibitory activity.  The parent
sequences are shown by the arrow.
On the basis of the results from alanine replacements, three sequences of 10 amino acid
residues were synthesized and their activities were compared with the A-1 sequence.
Reduced activities resulted in the peptides having alanines at positions 2, 4 and 5 (54%) or
2, 4, 5 and 6 and Asp at position 8 (37%). When Tyr7 was replaced by alanine the activity
was completely lost (Table 6).
Table 6. Sequences  with  more  than  one  residue  replaced  with  alanine.  The  activities  of  the
modified peptides reported are relative to the activity of the parent sequence. S/C means
singnal to control ratio, where control is the activity of KLK3 alone (value = 1.00).
peptide S/C %
CVFTSDYAFC 2.52 100
CAFAADYAFC 1.83 54
CAFASAADYC 1.08 5
CAFAAAYDYC 1.57 37
Alanine replacement studies showed that the biological activities of all three peptides
arise  mainly  from  the  aromatic  and  hydrophobic  interactions  of  Tyr  and  Phe  with  the
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KLK3. However, also small hydrophobic residues, Ile, Leu and Val, have a role in the
activities  of  the  peptides.  This  was  further  studied with consensus  peptides,  in  which the
replacement of Tyr totally inactivated the peptide, whereas alanines in other positions
reduced the activity. It can be assumed that the aromatic rings or hydrophobic side chains
are the contact residues, and their spatial arrangement is important for activity while the
rest of the peptide acts as a backbone for the active side chains, influencing the
conformation of the peptides. In B-2 peptide, the replacement of Leu10 or Val11 with
alanine inactivates the peptide. On the other hand, A1-peptide, which contains sequential
similarity to B-2 but lacks carboxyterminal Leu and Val, is active.
Aspartic acid stabilizes the turn structures by hydrogen bonding via its side chain. The
replacement  of  Asp  with  Ala  both  in  A-1  and  B-2  sequences  inactivated  the  peptides.
Histidine is not as favoured in position i+1 in type I -turns (Hutchinson & Thornton 1994).
It can be assumed that removing this relatively large and basic side chain near the contact
residues increases the biological activity. The same effect can be seen in peptide C-4, where
replacement of His8 or His9 increases the activity. It is suggested that the biological activity
of the three peptides is based on the interaction of the aromatic and hydrophobic side
chains with KLK3. The turn structures of the peptides place the important contact residues
in an arrangement crucial for the KLK3 recognition. Since it has been shown that B-2 and C-
4 peptides bind only to the intact and active form of KLK3, the interaction of the peptides is
dependent on the native structure of KLK3 (Wu et al. 2004).
4.2.3 Cross-inhibition of the peptides
The binding of GST-peptide C-4 to KLK3 was blocked in a dose dependent fashion by each
of the synthetic peptides A-1, B-2 and C-4. The inhibition was up to 60%–70% when using
100-fold molar excess of the peptides showing that these three peptides bind to the same
site or to sites which are very close to each other on KLK3 (Figure 25).
Although the  three  peptides  contain  tyrosine,  which has  the  aromatic  side  chain of  the
substrates recognized by KLK3, the peptides are not supposed to bind to the active site of
the protease (Wu et al. 2000). The cross-inhibition studies indicate that, despite significant
differences in the sequences of A-1 and B-2 compared with C-4, all three peptides bind to
the same area of the KLK3. Furthermore, in the presence of Zn2+, the affinities of the three
peptides increase three- to sevenfold, suggesting the involvement of Zn2+ in the binding of
the peptides to KLK3 (Wu et al. 2000). It is reasonable to suggest that the KLK3-promoting
peptides do not directly interact with Zn2+ but upon binding of Zn2+ the KLK3 structure is
altered so that the affinities of peptides are increased.
The KLK3-promoting activities of the three cyclic peptides are comparable in spite of the
differences in the amino acid sequences and the number of disulphide bonds. Originally
these sequences were determined by using phage display technology (Wu et al. 2000). This
technology allows the synthesis of millions of different combinations of short peptides,
which  can  be  screened  with  a  binding  assay  to  the  target  molecule.  During  the  selection,
several sequences with similar binding properties can be characterized (Scott & Smith 1990,
Devlin et al. 1990, Cwirla et al. 1990). These sequences serve as valuable lead structures in
order to study the mechanism of the biological interactions.
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Figure 25. Effect  of  synthetic  peptides  on  the  binding  of  GST-peptide  fusion  protein  C-4  to
immobilized KLK3. 1.7,  17 and 34 μM concentrations of  synthetic  peptides together with 0.17
μM  GST-peptide  C-4  were  added  to  wells  containing  KLK3  bound  by  MAb  5E4  resulting
concentration dependent inhibition of GST-peptide binding.
The crystal structure of human KLK3 is not known. However, the 3D-structure of the
corresponding horse prostate kallikrein (HPK) has been determined. The common prostate
origin and significant sequence homology between the human and horse PSA suggest that
HPK may serve as  a  model  for  the  structure  of  human KLK3.  The catalytic  site  of  HPK is
similar to the other chymotrypsin-like proteases containing a catalytic triad of His57,
Asp102 and Ser195. A common feature for all kallikreins is the kallikrein loop near the
active site of the protease but there are major differences in the kallikrein loop sequences
between  HPK  and  other  kallikreins.  In  HPK,  the  kallikrein  loop  and  the  loop  comprising
Trp215-Cys220 form lid-like structures covering the catalytic site. This lid-like structure is
suggested to act as a regulator of the protease activity and specificity (Carvalho et al. 2002).
In human KLK3, the regulatory mechanism may be similar. Zn2+ is a non-competitive
inhibitor of KLK3 and it is coordinated by Asp91, His101 and His234 close to the residues
of the catalytic triad. The exact binding site and mechanism of the peptides are not known
but  it  is  proposed  that  the  peptides  bind,  like  Zn2+, near the active site of KLK3 and they
interfere with the possible regulatory function of the kallikrein loop. The recognition of
KLK3 takes probably place via hydrophobic interactions and aromatic rings of
phenylalanine or tyrosine. The specific binding of the peptides may provide a diagnostic
tool for selective recognition of an active form of KLK3.
4.2.4 Additional SAR-study using single and multiple replacements
Because the single alanine replacement sets were tested earlier for C-4 (chapter 4.2.2), this
additional  study  focused  on  point  mutations  with  other  amino  acids  and  further  alanine
replacements in two or three positions at the same time (unpublished data). The main focus
was the CIEHHC-loop because of its structural role nearby essential amino acids Tyr4 and
Trp11 determined in single alanine replacement studies. The loop could be an object for a
peptide mimetic structure with more stable molecule in sights. Ile6 is supposed to have a
possible conformational stabilizing effect with Tyr4 and Trp11 because their close location
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in space (Figure 23). Therefore it was one focus of the mutations. The inner disulphide
bridge  between  cysteines  5  and  10  with  alanines  was  replaced  in  order  to  monitor
essentiality of bridge. Further, the analog, in which both Val2 and Thr12 were replaced with
alanines, or the analogs, in which either Val2 or Thr 12 were replaced with asparagines,
were synthetized for further modifications, in order to define if there was a possibility to
link peptide to the resin in another way than via C-terminal cysteine. Stimulation of KLK3
activity for all synthesized peptides was measured. Both high and totally reduced
stimulation of KLK3 activity were detected, which gives valuable information about the
structure activity relationships between KLK3 and activity stimulating peptides. The results
are also helpful for peptide mimetic design.
Sythesized sequences shown in Table  7 and  the  stimulation  of  the  KLK3  activity  of
successfully cyclized peptides are represented in Figure 26. The activity studies of some of
the intended sequences were declined due to the low cyclization rates of peptides. The low
cyclization rates caused significantly low yields of peptides with satisfactory purity.
However, in the method used in the activity stimulation studies includes high excess of
peptide  versus  KLK3.  Thus,  despite  of  the  low  purity  of  some  peptides,  the  activity
stimulation results are still indicative. All peptides 2-21 were synthesized with C-terminal
amide because in our previous studies, we had noticed that in the case of C-4, the charge in
N-terminus was not essential for the activity.
Table 7. Sequences of peptide C-4 analogs in replacement study.
peptide mutation sequence peptide mutation sequence
1 parent 11 Ala7,8
2 Gly8 12 Ala7,9
3 Phe6 13 Ala8,9
4 Gly6 14 Ala6,9
5 Leu6 15 Ala6,8
6 Val6 16 Ala7,8,9
7 Ala6 17 Ala6,7,9
8 Asn12 18 Ala6,7,8
9 Asn2 19 Ala4,6
10 Cys6-Cys9 20 Ala6,10
21 Ala2,12
Single replacements. The replacement of His8 with glysine (2) maintained the equal
activity indicating possibilities to modify some residues heavily (Figure 26). Glysine is also
highly favored in the place i+2 in type II -turn (Hutchinson & Thornton 1994). The activity
stimulation results show the essentiality of hydrophobic side chain in position 6. Replacing
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Ile6  with  especially  bulky phenylalanine (3) increased the activity but the replacement by
glysine  (4)  reduced  the  activity  stimulation  almost  totally.  Replacement  by  leusine  (5)
reduced the activity stimulation slightly. Via decreasing the size of the hydrophobic side
chain (6, 7) the activity stimulation was reduced. Involvement of asparagines (8, 9) to either
side of the disulphide bridge resulted remarkable loss of activity stimulation excluding the
possibility for alternative resin attachment site for possible disulphide bridge replacement
synthesis.
Figure 26. Results of KLK3 activity stimulation by C4 analogs. Purity of sequences marked with
asterisk (*) was moderate 50-80%.
Multiple replacements. The replacement of the inner disulphide bridge between
cysteines  5  and  10  with  alanines  (data  not  shown)  or  changing  the  site  of  bridge  (10)
eliminated the biological activity, indicating that correct conformation of inner bridge is
essential for biological activity. The residues in the loop-area between Cys5 and Cys 10
could be replaced with two or three alanines without losing the activity totally. Peptide 11
with residues Glu7 and His8 replaced with alanines at the same time maintained
stimulation of activity almost equally compared to peptide 1. It seems however that
replacement of any other two residues in the loop between cysteines 5 and 10 resulted
reduced  activity  (12, 13, 14, 15) and especially, if Ile6 is among the replaced residues, the
activity stimulation was reduced heavily (14, 15). Replacing three residues at the same time
reduced the activity stimulation no matter which residues were replaced (16, 17, 18). Both
combinations in which one of the essential residues, Tyr4 or Trp11, in combination with Ile6
(19, 20) were replaced were totally inactive. The replacement of valines nearby the terminal
disulphide bridge resulted almost total elimination of activity ensuring the essentiality of
residues, which are directly connected to the cysteine residues in the terminal bridge (21).
4.3 CONCLUSIONS
The structures of three KLK3 activating synthetic peptides having one or two disulfide
bridges  were  studied by NMR spectroscopy,  and a  population of  reversed turn structures
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was found for each peptide. Turn types were identified as a type I -turn between residues
Ser5-Ala8 for peptide A-1, a type I -turn between residues Ala4-Tyr7 for peptide B-2 and a
type II -turn between residues Ile6-His9 for peptide C-4. Furthermore, the amino acid
sequences of the three peptides were studied using alanine replacement-based structure-
activity studies. The alanine replacement studies showed that the biological activities of all
three peptides arise mainly from the aromatic and hydrophobic interactions of Tyr and Phe
with the KLK3. The cross-inhibiton test showed that despite different structures, the
peptides  bind to  the  same area  on the  KLK3.  Further,  it  was  shown that  commonly know
KLK3 inhibitor Zn2+ increases the binding affinity of KLK3 stimulating peptides suggesting
that peptides bind near to catalytic triad of KLK3.
In the additional study of KLK3 activity stimulating peptides, the presence of essential
residues  Tyr4  and Trp11 in  combination with hydrophobic  residues,  especially  Ile,  Leu or
Phe in position 6,  was found to be highly favored (Figure 26). The loop between Cys5 and
Cys10 enables minor modifications, especially at positions 7 and 8. This site is important for
peptide mimetic design toward more biologically stable conformation as it eases the design
and synthesis of mimetics.
4.4 EXPERIMENTAL
4.4.1 Synthesis of linear peptides
The single peptides for NMR were synthesized using a PerSeptive 9050 Plus automated
peptide synthesizer, with Fmoc strategy, TBTU/DIPEA as the coupling reagent and
NovaSyn TGA with 4-hydroxymethylphenoxyacetic acid linker as the solid phase. Alanine-
replacement sets and other modified peptides were synthesized with an Apex 396 DC
multiple peptide synthesizer. In original alanine replacement sets, all amino acids except
cysteines were replaced one by one. In the additional study, peptide 1 was obtained from
AnaSpec (San Jose, CA). Peptides 2-21 were synthesized using Rink Amide AM resin
yielding peptides with C-terminal amide.
4.4.2 Cyclization of the peptides
For peptides A-1, B-2 and their modifications Cys(Acm) was used in the Cys position 1:
C(Acm)VFTSNYAFC(Trt) and C(Acm)VFAHNYDYLVC(Trt), for peptide C-4 and its
modifications Cys(Acm) in positions 6 and 9: C(Trt)VAYC(Acm)IEHHC(Acm)WTC(Trt)
was used. The solution was stirred vigorously at RT for 40 min. In the additional study, the
only side-chain protecting group used for cysteine was Acm.
4.4.3 KLK3 activity measurements
77 pmoles (2 μg) of KLK3 substrate and 20 nmoles of B-2 and C-4 series and 9 nmoles with
A-1 were incubated in Tris-buffer (10 mM Tris and 150 mM NaCl at pH 8.0) with 1.6 mM
concentration  of  the  substrate  at  RT.  KLK3  reaction  without  any  peptide  was  used  as  the
basic level control. The reaction was measured at 405 mm at 10 min intervals for 60 min
using a Multiscan RC photometer (ThermoLabsystems, Helsinki, Finland). The effects of
the peptides were calculated as a ratio of the optical density (OD) value of the KLK3-
peptide complex to the KLK3 alone after 60 min incubation.
In the additional study, different concentrations were used as KLK3 (0.3 μM, 30 pmol)
was incubated for 30 min at RT with a multifold molar excess of synthetic peptide (13 μM,
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1,3 nmol) in 0.05 M Tris buffer, pH 7.7, containing 0.154 M NaCl, 8 mM NaN3 and 0.1%
bovine serum albumin. After the addition of the substrate to a final concentration of 0.2
mM, the absorbance at 405 nm was measured as described in the chapter 3.4.
4.4.4 Cross-inhibition test
The relative binding sites of the peptides on KLK3 were mapped by competition
experiments with chemically synthesized peptide and GST-peptide fusion protein (Wu et
al. 2000). Briefly, KLK3 specific monoclonal antibody (mAb5E4) was coated in
microtitration plate wells (ThermoLabsystems, Helsinki, Finland) and KLK3 was bound to
the antibody. The GST fusion peptide C-4 (0.17 μM) and each of the synthetic peptides (A-1,
B-2 or C-4) at 10–100 fold molar excess were incubated with KLK3. After 1 h, the wells were
washed and Eu3+-labelled anti-GST antibody was added. After a further incubation for 1 h
and washing, the bound fluorescence was measured with a 1234 Delfia Research
fluorometer (Perkin Elmer Wallac, Turku, Finland).
4.4.5 NMR spectroscopy
Because of the low solubility in water (especially C-4) all spectra were recorded in DMSO-
d6. NMR samples were prepared by dissolving purified and lyophilized peptides in 600 μl
DMSO-d6 to 5–10 mM. The pHs of the samples were not tested. All one-dimensional
experiments were recorded at five different temperatures over the range 300 K to 320 K. All
two-dimensional experiments were recorded at either 305 K or 310 K depending on the
quality  and  clarity  of  the  spectra.  All  the  chemical  shifts  are  reported  with  respect  to  the
DMSO peak at 2.50 ppm (Table 5).
For all 2D experiments, standard pulse programs from the Bruker software library were
used.  TOCSY  spectra  were  recorded  with  mixing  times  of  80  ms  by  means  of  a  MLEVTP
mixing sequence with TPPI phase cycling (Bax & Davis 1985). NOESY spectra were mainly
recorded with mixing times of 400 ms for A-1, 420 ms for B-2 and 300 ms for C-4 using TPPI
phase cycling (Jeener et al. 1979). Various mixing times were tested and the best were
determined based on the quality and clarity of the spectra. NOE-build up curves were not
determined. Some COSY spectra were recorded with mixing times of 30 ms. Data sets were
processed with phase-shifted sine bell functions. Typically the data were recorded with a
resolution of 1024 points for both t1 and t2.
4.4.5 Structural analysis
Starting structures for structural analysis were constructed by DYANA software (Guntert et
al. 1997). NOE-intensities were calibrated approximately relative to the -protons of Tyr7
and Cys10 and the aromatic ring protons of Tyr7 in A-1, the aromatic ring protons of Tyr7
in B-2 and the aromatic ring protons of Trp11 in C-4. NOE correlations were classified
either as strong (1.8–2.5Å), medium (1.8–3.5Å) or weak (1.8–5.0Å). Pseudo-atom corrections
of 1.5Å for methyl, 1.0Å for methylene protons and 2.0Å for tyrosine ring protons were
added when needed. Dihedral angles were not restricted mainly because of fluctuation of 3-
D structures (Wüthrich 1986). The final DYANA structures were modelled and visualized
with the software package QUANTA with help of the CHARMM program on a Silicon
Graphics workstation (Brooks et al. 1983).
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5 Mimetics of the disulfide bridge between the N- and C-
terminal cysteines of the KLK3-stimulating peptide B-27
5.1 INTRODUCTION
This chapter is based on the findings of two separate studies7 in which the strategies to
improve the in vivo stability and bioavailability of KLK3 binding peptides were
investigated.  In  the  study  presented  in  the  chapter  4,  it  has  been  shown  that  most  of  the
amino acid side chains are essential for the promoting activity of the KLK3 binding peptide
B-2, making the side chain modifications difficult. The KLK3-stimulating peptides, A-1, B-2
and C-4 are cyclic, containing disulfide bridge between the N- and C-terminal cysteines.
Peptide C-4 contains also a second internal disulfide bridge. The first step in stabilizing the
peptides was to use alternative cyclization methods. It has been shown that the plasma
stability of linear KLK2 inhibiting peptide is increased by head-to-tail cyclization. This
study is presented later in the chapter 6.
The earlier attempts to perform head-to-tail cyclization of the two most potent peptides
B-2 and C-4 have failed without detectable yields of cyclic peptides (data not shown).
Typically, the cyclization of peptides is highly dependent on the sequence, amino acid
composition and the length of the peptide. Several research groups have published
successful cyclization of penta- and hexapeptides but the head-to-tail cyclization of longer
sequences is more challenging, as recently discussed by Davies (Davies 2003). Of the two
most active peptides, B-2 (1)  (Figure 27) was chosen as the lead peptide, since its
conformation is less restricted than that of C-4 (chapter 4).
In  the  first  study  presented  in  this  chapter,  the  strategy  was  to  use  various  types  of
linking units, which are connected by amide bonds and also suitable for automated SPPS,
for the replacement of conventional cysteines in N- and C-terminus. In some cases, also one
of the valines on either side of the cysteines was replaced. A set of differently cyclized
peptides with lysine, ornithine, -alanine or -amino butyric acid (GABA) at the N-terminal
site and aspartic acid at the C-terminal site was generated. The C-terminal aspartic acid was
linked to the resin via either the backbone or side chain carboxylic group depending on the
synthesized bridge structure. In addition, longer linking units, such as 6-aminohexanoic
acid (Ahx) and 8-aminooctanoic acid (Aox), were also investigated. Successfully cyclized
structures are shown in Figure 28.
7 Adapted  with  permission  of  Springer  from:  Pakkala  M,  Weisell  J,  Hekim  C,  Vepsäläinen  J,  Wallen  E,  Stenman  U-H,
Koistinen H, Närvänen A, Mimetics of the disulfide bridge in the KLK3 stimulating peptide B-2, Amino Acids, 39(1): 233-
242, 2010. (referred in this chapter as “the first study”)
Adapted with permission of: Meinander K,# Pakkala M,# Weisell  J,  Vepsäläinen J,  Hekim C, Stenman U-H, Koistinen H,
Närvänen A, Wallen E, Synthesis and Evaluation of Analogs of the KLK3-activating Peptide B-2, manuscript. (referred in
this chapter as “the second study”)
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Figure 27. Structure of peptide B-2. Area for replacement studies is shadowed with gray.
The stimulation of the KLK3 activity was evaluated for the successfully cyclized
peptides. The stability in plasma was evaluated for the peptides which significantly
stimulated KLK3 activity. As KLK3 cleaves substrates mainly at the C-terminal  side  of
tyrosine and glutamine (Coombs et al. 1998, Malm et al. 2000) it is feasible that the B-2
peptide also acts as a substrate for KLK3. Therefore, the stability against enzymatic
degradation by KLK3 was also studied.
Figure 28. The structures of the successfully synthesized disulfide bridge replacements.
In the second study presented in this chapter, the disulfide bridge was replaced by other
types of linkers. Based on the first study, the use of the E-alkene and the alkane linkers for
mimetics of the disulfide bridge in peptide 1 were also studied. The strategy of replacing
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disulphide bridges with carbon isosteres has already been proven to yield peptides that are
both structurally (Ghalit et al. 2007a) and biologically (Ghalit et al. 2007b) equivalent to the
original  compound.  Tadd and his  collaborators  have recently  presented the  synthesis  of  a
series of disulfide bridge mimetics with different hydrocarbon cross links (Tadd et al. 2011).
The same type of  hydrocarbon cross  linkers  have recently  been successfully  used to  cross
link -helices (stapled peptides) while retaining biological activity (Kim & Verdine 2009).
5.2 RESULTS AND DISCUSSION
5.2.1 Synthesis of B-2 variants
Initially, the original B-2 peptide (1)  was  synthesized  with C-terminal amide using Rink
Amide AM resin, yielding peptide 2. The synthesis strategies for alternatively cyclized
peptides are represented in Figure 29. In the first set of alternatively cyclized peptides, the
disulfide  bridge  was  replaced  with  a  side  chain  to  side  chain  bridge,  using  side  chain
ODmab-protected aspartic acid at the C-terminus and side chain Mtt-protected lysine or
ornithine at the N-terminus. The aspartic acid residue was coupled to Rink Amide AM
resin via the carboxyl terminus, leaving the side chain free for cyclization after Dmab-
deprotection (10, 11, 12). The length of the modified bridge area (marked with gray
background in Figure 27) was also changed by removing either Val11 or Val2 (11, 12). The
carboxylic acid group attached to the resin was converted to the corresponding amide
using Rink Amide AM resin.
Figure 29. Representative solid-phase synthesis of peptides 3–9.
The cyclization of the peptides having an N-terminal ornithine was successful, yielding
peptides 3–5 but only when the amino group of the N-terminus of the peptides was
acetylated. The cyclization of Fmoc-protected peptides was not successful. The cyclization
of  the  peptides  having  an N-terminal lysine failed, although the -amino group was
acetylated. Earlier studies with peptide 1 have shown that modification of the N-terminus
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does not reduce the activity of the peptides (Wu et al. 2004). The peptide with an N-
terminal ornithine and C-terminal aspartic acid was also coupled  to  the  resin  via  the  side
chain of  aspartic  acid (13), leaving the C-terminal carboxyl group free for cyclization. The
cyclization of this peptide, yielding peptide 6, was successful although the amino group of
the N-terminus was not acetylated. In peptide 6, the length of the bridge replacement was
reduced by one –CH2– group as compared to peptide 3.
Peptides 7 and 8 have a bridge where the amino group of the GABA at the N-terminus is
coupled to the main chain carboxylic acid group of aspartic acid at the C-terminus. Peptide
1 contains asparagine at position 6, which provides an additional resin binding site. Peptide
7 was synthesized using C-terminal All-protected aspartic acid, conjugated to Rink Amide
resin via the side chain producing Asp6 in free peptide (14). After completing the synthesis,
the peptide was cyclized via the free amino terminus of tyrosine (original position 7) to the
deprotected resin-bound aspartic acid. In peptide 8, aspartic acid at position 12 was
conjugated to Rink Amide resin via the side chain and the bridge was formed via GABA
(16). Peptide 9 was synthesized with the same method as peptide 7 by attaching Asp6 to the
resin (15). The bridge in peptide 9 was constructed by using Ahx as a linker.
Also other bridge structures were tried to be synthesized, but the cyclization of them
failed  or  gave  only  extremely  low  yields  and  purities  (Figure 30). These included a
cyclization of an N-terminal -alanine with the side chain of a C-terminal aspartic acid (17),
where the peptide was attached to the resin from the C-terminal carboxylic acid of the
aspartic acid. Another unsuccessful trial (18) was the analog of peptide 9 with an Aox linker
instead of Ahx. Furthermore, a peptide with a tri-alanine bridge between valines (19), using
resin-bound Asp6 as a cyclization site, was also unsuccessful.
Figure 30. The structures of the unsuccessfully synthesized disulfide bridge replacements.
5.2.2 Synthesis of hydrocarbon disulphide bridge mimetics and peptides containing
these mimetics
The replacement of disulphide bridge with E-alkene  and  the  alkane  linkers  resulted
pseudopeptides 20a and 20b (Figure 31). The orthogonally protected bridge mimetics were
synthesized using the Grubbs metathesis reaction (Figure 32) and the conformation of the
double bond determined as previously published (Tadd et al. 2011). The methyl ester group
of the building blocks was hydrolyzed and the building blocks were incorporated in the
peptide synthesis as described in the experimental section.
Figure 31. The structures of E-alkene 20a and alkane 20b linkers.
74
Figure 32. Synthesis of building blocks 22 and 23.
The syntheses of the peptides were performed on-resin attaching an aspartic acid to the
Rink  Amide  AM  resin  (Figure 33). That made it possible to maintain the sequence of the
original B-2-peptide unmodified with just the disulphide bridge replaced. Longer reaction
times were used to improve the coupling efficiency of the bridge mimetic building blocks.
Syntheses of the linear sequences were straightforward but the cyclization step on-resin
was obviously the yield limiting step. The length of the peptide and the bulky tyrosine in
the N-terminal site of the cyclization point were affecting the cyclization rates and the low
yields  were  expected.  The  head-to-tail  cyclization  with  different  building  blocks  has
resulted  in  low  yields  also  in  the  first  study.  Peptide 20a with  a  double  bond  gave  the
highest yields with the yields decreasing when the double bond was removed. It seems that
the more flexible the bridge mimetic is, the lower the yield of the cyclization. It was
common for all of the sequences synthesized that there were a lot of impurities, and the
purifications with HPLC were repeated two or three times yielding decreasing amounts of
the products. One common impurity according to MS studies was incomplete deprotection
of OAll-group of the aspartic acid preventing the head-to-tail cyclization.
Figure 33. Representative solid-phase synthesis of peptides 20a and 20b.
5.2.3 Determination of activity
The ability of the synthesized peptides 1–9 to  stimulate  KLK3-activity  in  the  first  study is
shown in Figure 34. Peptides 3–5 did not show any activity against KLK3. These peptides
had side chain to side chain cyclizations between an ornithine at the N-terminus and
aspartic acid at the C-terminus, and peptides 4 and 5 were shortened with one valine from
either side of the bridge. These results suggest that the structure of the bridge is important
for activity, especially the length of the bridge. The B-2 peptide (1) has 14 atoms counting
the atoms in the bridge fragment. In peptide 3 the number of atoms is 16. Peptides 4 and 5,
on the other hand, have only 13 atoms in the bridge and they lack one of the adjacent valine
residues. Peptide 6 stimulated KLK3 activity but less than peptide 1. Peptide 6 has 15 atoms
in the bridge, suggesting again that the length of the bridge is important and it is getting
closer to the optimal length. In addition, in peptide 6 the configuration of the stereocenter
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derived from L-aspartic acid is reversed with respect to the main chain in the ring, and the
carboxylic acid group side chain is one –CH2–  group  further  apart  as  compared  to  the
peptide 1. Peptide 7 was almost as potent as the peptide 1 and peptide 2. Peptide 7 has the
same number of atoms in bridge (14) as the peptide 1, again emphasizing the importance of
the length of the bridge. Furthermore, peptide 7 clearly shows that the amino group at the
N-terminus is not needed for the KLK3-stimulating activity. Peptide 8 differs from peptide
7 only in that the carboxylic acid in the side chain in peptide 7 is an amide in peptide 8. This
reduces the activity, which is in agreement with the earlier observation that the free
carboxylic acid is preferred over an amide, i.e., peptide 2 is slightly less active than peptide
1 (Figure 34). Interestingly, the relative configuration of the stereocenter next to the
carboxylic acid group is not important. Peptide 9 showed no activity, indicating again the
importance of a C-terminal carboxyl group. However, peptide 9 is one atom shorter than
peptides 7 and 8,  having only  13  atoms in  the  bridge,  which might  also  have an effect  on
the activity.
Figure 34. Effect of the synthetic peptides on KLK3 activity. Stimulation of activity of synthetic
peptides  as  compared  to  KLK3  without  peptides  (KLK3  alone  is  indicated  as  100%).  Peptide
concentration used was 13 M.
The ability of the synthesized peptides 20a and 20b to stimulate the activity of KLK3 in
the second study is shown in Figure 35. Both peptides stimulated the activity of KLK3 but
the stimulations were lower compared to the original peptide 1 and slightly lower
compared to the earlier analogs with a linker consisting of aspartic acid and -amino
butyric acid as the bridge mimetic. The pseudopeptides containing the E-alkene (20a) and
the alkane (20b) replacements for the disulphide bridge increased the enzymatic activity of
KLK3 as compared to the original peptide 1 by 76 % and 22 %, respectively.
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Figure 35. Effect of the synthetic peptides on KLK3 activity. Stimulation of activity of synthetic
peptides as compared to KLK3 without peptides (KLK3 alone is indicated as 100%).
5.2.4 Concentration dependency of KLK3-stimulation by the peptides
The concentration dependency was studied using the most active peptides, i.e., 1, 2 and 7 in
the first study. While these peptides showed a dose-dependent stimulation of KLK3-
activity at low concentrations, the original B-2 (1) started to show reduced stimulation at
higher concentrations (Figure 36). The results suggest that peptide 1 could  also  act  as  a
substrate for KLK3 (see below), especially at high concentrations at which the activation by
peptide 2 reaches its maximum. Preliminary molecular modeling has suggested that while
the major binding site of peptide 1, where it is likely to exert its stimulatory effect, is
outside of the active center of KLK3, there might be a second binding site at the active site
where it could compete with substrate (Henna Härkönen, personal communication). Unlike
the peptides 1 and 2, peptide 7 stimulated KLK3 activity dose dependently at all
concentrations studied, exceeding the effect of other peptides. This finding together with a
lower degradation rate of peptide 7 by KLK3 or plasma proteases (see below) suggests that
the binding of peptide 7 to KLK3 is different from that of peptide 1.
Figure 36.  Concentration  dependency  of  the  KLK3  stimulation  by  peptides 1, 2 and 7. Data
represent average +SD of three independent experiments, except for *n = 2 and **n = 1. Solid
line shows the concentration (13 M) used for the data shown in Figure 34.
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5.2.5 Stability studies
The original peptide 1 and peptide 7 were  cleaved by KLK3 at  high concentrations  in  the
first study. The cleavage rate of peptide 7 was slower than that of peptide 1.  Using  a
ninefold molar excess of peptides and after 2 h incubation, 59% of peptide 1 and 72% of
peptide 7 were intact. After 24 h 5.7% (1) and 34% (7) were found intact, respectively (Figure
37A). Mass spectrometry analysis indicates that the ring opens between Tyr7 and Asp8
(data not shown). Although the amino acid sequence of peptide 7 is identical to the original
peptide, excluding the bridge, it is more stable against KLK3, suggesting different binding
behavior.
The original peptide 1 and peptide 7 were tested for plasma stability. During the first 2 h,
26% of peptide 1 and 13% of peptide 7 disappeared, either by degradation or binding to
plasma proteins. After 2 h, the disappearance rate became slower, and finally after 24 h,
58% of peptide 1 and 73% of peptide 7 were found intact (Figure 37B). These results suggest
that the replacement enhances the stability of the KLK3-stimulating peptides against
plasma proteases or decreases binding to plasma proteins.
Figure 37. Stability of peptides 7 (black columns) and 1 (gray columns) over the time (A) with
purified KLK3 and (B) in plasma.
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5.3 CONCLUSIONS
Since the earlier studies have shown that Ty7 and Asp8 are essential for the promoting
activity of B- 2 peptide (chapter 4), the alternative cyclization methods were used in order
to improve the stability of B-2 peptide instead of side chain modifications. Based on the
new analogs of peptide B-2 (1), it can be concluded that the bridge between the N- and C-
termini is highly important for the KLK3-stimulating activity. The number of the atoms in
the alternative bridge structure was found to be important. A free carboxylic acid group at
the C-terminus was also important for the KLK3-stimulating activity but there was no
difference  whether  the  free  carboxylic  acid  was  in  side  chain  or  in  the  main  chain  of L-
aspartic acid. The free carboxylic acid could be replaced by an amide group but this
replacement reduced the KLK3-stimulating activity. On the other hand, the amino group at
the N-terminus could be removed without affecting the KLK3-simulating activity. Peptide 7
with  a  cysteine  based  disulfide  bridge  mimetic  consisting  of  GABA  and  aspartic  acid,
where the amino group from the former was linked to the main chain carboxyl group of the
latter, is more stable than peptide 1 and, at high concentrations, the activity exceeds that of
peptide 1.
Further in the second study, it was shown that no heteroatoms are necessary for
biological activity, a linker consisting of a simple hydrocarbon chain is sufficient. Peptide
20a displayed the lowest activity, possibly due to incorrectly restricted conformation of the
peptide compared to the conformation of the parent peptide. Peptide 20b displayed
moderate activity stimulation. This is likely due to the more flexible linker which eases the
peptide to adopt the biologically active conformation.
5.4 EXPERIMENTAL
5.4.1 Peptide synthesis
Rink Amide AM resin (50 mg, loading 0.575 mmol/g) was used as solid-phase with Fmoc
strategy and HBTU/DIEA as coupling reagent. The side chain protecting groups used in
bridge  forming  residues  were  Acm  for  cysteine,  OAll  for C-terminus  and  both  ButO and
ODmab for side chain protection of aspartic acid and glutamic acid, Mtt for ornithine and
lysine side chain protection. Additional amino acids used for bridge formation were Fmoc-
protected -alanine, GABA, Ahx and Aox. Fmoc group was not removed from peptidyl
resins 13–16 after final amino acid coupling. Peptide 1 was obtained from AnaSpec (San
Jose, CA, USA) and was >95% pure as detected by HPLC.
5.4.2 Purification and mass spectrometry of peptides
The purity and degradation were verified by mass spectrometry on an ABI QSTAR XL
hybrid mass spectrometer using MALDI or ESI interface (Applied Biosystems Inc., Foster
City, CA, USA) for the disulfide bridge containing sequences. Negative mode was used for
the detection of head-to-tail, side chain to tail and side chain to side chain cyclic peptides.
5.4.3 Cyclization of the disulfide bridged peptide
Peptide 2, containing cysteines protected with Acm, was cyclized by the standard
iodination method in solution. Peptide was purified by HPLC and lyophilized yielding
peptide 2. ESI–MS: (m/z) 1.443.6 [M + H]+. HPLC: tR = 15.6 (purity >95%).
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5.4.4 Cyclization method for alternatively cyclized peptides
Head-to-tail, side chain to tail and side chain to side chain cyclizations were performed on
resin  using  HATU  and  HOAt  as  the  coupling  agent  and  DIEA  as  the  base  (Figure 29, see
page 72). The yields were not expected to be higher than a few percent due to the long
sequences. Furthermore, bulky Tyr7 adjacent to the cyclization sites in case of the B-2
analogs connected to resin via Asp6 (peptides 7 and 9)  expected  to  cause  problems  in
cyclization. Therefore, the coupling step was performed repeatedly and with different
solvent concentrations between DMF and DCM because those solvents swell the resin and
peptides differently due to their different polarities. Yields of crude peptides after
lyophilization varied between 25 and 35 mg and after purification by HPLC between 1 and
3 mg (2–8%) depending on peptide synthesized. Unsuccessfully cyclized peptides yielded
no analytical HPLC detectable amounts of pure peptide.
The Kaiser test was performed for all alternatively cyclized peptides before the
cyclization step and all tests were found positive indicating a free amino group (Kaiser et
al. 1970). Usually the peptidyl resin was swelled for 30 min with the solvent used in the
coupling step, the solvent was removed and the coupling agents, HATU (3 equiv), HOAt (3
equiv) and DIEA (4.5 equiv), were added with a small amount of anhydrous solvent
achieving a final volume of 3 ml. The mixture was stirred for 2.5 h at RT under argon, the
solvent was then removed, and the resin was washed with DMF (3 ml, 3 x 5 min) and with
anhydrous DCM (3 ml, 3 x 5 min). The Kaiser test was performed to monitor the success in
cyclization. If the Kaiser test results turned out to be positive, the cyclization was repeated.
Usually the first cycle was performed in DMF, the second in 25% DCM in DMF and the
third in 50% DCM in DMF. Higher concentrations of DCM were discarded due to the low
solubility of HATU in DCM. When the Kaiser test was negative, the peptides were cleaved
from resin and then lyophilized.
5.4.5 Deprotection and characterization of alternatively cyclized peptides
Peptidyl resins 10, 11 and 12 with Orn–Asp bridge as well as corresponding lysine based
peptidyl resins (schemes not shown) from automated SPPS were placed in reaction
columns, and the free N-terminal amino groups were acetylated manually adding 20%
Ac2O in DMF (3 ml) and stirring resulting solution 10 min at RT. Treatments were repeated
and resins washed with DMF (3 x 3 ml). Side chain Dmab-protection was removed using
2% hydrazine in DMF (3 ml) agitating 10 min at RT. The treatment was repeated twice,
followed by washing with 20% DIEA in DMF:H2O; 9:1 (3 ml) to make sure that all traces of
Dmab  were  removed.  Resins  were  washed  with  DMF  (3  x  3  ml)  and  DCM  (3  x  3  ml). N-
terminal Mtt was deprotected using 1% TFA in DCM (3 ml) agitating 10 min at RT.
Treatment was repeated three times and the deprotection was monitored by disappearance
of the orange color characteristic for traces of Mtt. Resins were washed with DMF (3 x 3 ml)
and DCM (3 x 3 ml) and dried. Peptides were cyclized on resin using HATU/HOAt/DIEA-
method as described above. After cleavage peptides were lyophilized yielding peptides 3, 4
and 5. Peptide 3, ESI–MS: (m/z) 1,493.0 [M - H]-,  HPLC: tR = 16.0 (purity >90%). Peptide 4,
ESI–MS: (m/z) 1,393.95 [M - H]-,  HPLC:  tR = 16.8 (purity >95%). Peptide 5, ESI–MS: (m/z)
1,393.90 [M - H]-, HPLC: tR = 16.0 (purity >85%).
Peptidyl resin 13 from automated SPPS was placed in reaction column and washed with
DCM (3  x  3  ml). C-terminal allyl deprotection was performed using a catalytic amount of
Pd(PPh3)4 (0.1 equiv) with PhSiH3 (10 equiv) as a scavenger in anhydrous DCM (3 ml). The
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mixture  was purged with an argon flow and stirred under  argon for  1.5  h.  The resin  was
washed  with  DMF  (3  x  3  ml),  0.5%  DIEA  in  DMF  (3  x  3  ml),  0.5%  sodium
diethyldithiocarbamate trihydrate in DMF (3 x 3 ml), DMF (3 x 5 ml) and finally with DCM
(3 x 5 ml). The treatment was repeated to drive the deprotection to completion.
Deprotection of side chain Mtt was performed as described in previous chapter. Peptidyl
resin 13 was additionally deprotected using 2% TFA in DCM (3 ml) to increase the
deprotection rates, although this might also lead to cleavage of the peptides from the Rink-
resin (Bourel et al. 2000). Peptide was cyclized on resin using HATU/HOAt/DIEA-method
as described above. N-terminal Fmoc deprotection was performed after cyclization using
20% piperidine in DMF (3 ml, 2 x 15 min), followed by washing with DMF (3 ml, 3 x 5 min)
and DCM (3 ml, 3 x 5 min). After cleavage peptide was lyophilized yielding peptide 6. ESI–
MS: (m/z) 1,451.0 [M - H]-, HPLC: tR = 15.5 (purity >95%).
Peptidyl resins 14, 15 and 16 from automated SPPS were placed in reaction columns and
washed  with  DCM  (3  x  3  ml). C-terminal allyl deprotection and N-terminal Fmoc
deprotection were performed as described in previous chapter. After deprotection peptides
were cyclized on resin using HATU/HOAt/DIEA-method as described above. After
cleavage peptides were lyophilized yielding peptides 7, 8 and 9. Peptide 7, ESI–MS: (m/z)
1,422.5 [M - H]-,  HPLC:  tR = 16.8 (purity >95%). Peptide 8, ESI–MS: (m/z) 1,421.5 [M - H]-,
HPLC: tR = 16.4 (purity >85%). Peptide 9, ESI–MS: (m/z) 1,335.8 [M - H]-, HPLC: tR = 18.3
(purity >90%).
5.4.6 Synthesis of building blocks
Compound 21 was  synthesized  according  to  a  previously  published  procedure  in  similar
yields (Tadd et al. 2011).
(7S,E)-7-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-8-(tert-butoxy)-2-((tert-
butoxycarbonyl)amino)-8-oxooct-4-enoic acid (22). Trimethyltinhydroxide (76.3 mg, 0.42
mmol) was added to a stirred solution of compound 21 (Figure 32, see page 74, 50 mg, 0.08
mmol) in 1,2-dichloroethane (2.0 mL) under argon. The reaction mixture was then heated at
70 °C for 4 hours. After this time, the reaction mixture was concentrated in vacuo, and the
residue dissolved in ethyl acetate (ca. 15 mL). The organic phase was washed with 0.5 M
HCl(aq) (3 × 15 mL) and brine (ca. 15 mL), dried over anhydrous sodium sulphate, filtered
and concentrated in vacuo before purification by flash column chromatography.
(7S)-7-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-8-(tert-butoxy)-2-((tert-
butoxycarbonyl)amino)-8-oxooctanoic acid (23). Compound 22 was dissolved in EtOAc,
Pd/C added and the mixture stirred 24h at RT under an atmosphere of H2. The Pd/C was
filtered off using a small pad of silica at the mixture concentrated in vacuo. This gave 23
which was used without further purification.
5.4.7 Synthesis of peptides with all-hydrocarbon disulphide bridge mimetics
The peptides were synthesized using an Apex 396 DC multiple peptide synthesizer
(Advanced ChemTech, Louisville, KY, USA). Manual couplings were performed using a
PD-10 column with a magnetic stirring. A Rink Amide AM resin (50 mg, loading 0.575
mmol/g) was used as a solid-phase.
General method for the manual SPPS: The resin was swelled for 30 min in DMF and
DMF was removed. All natural residues (D, H, A, F, V, L, Y, N, 4.9 eq.) were coupled using
HBTU (5 eq.) as the activating agent and DIEA (10 eq.) as the base. Fmoc-protected amino
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acids were dissolved in DMF. HBTU and DIEA were added to the mixture and the mixture
was added to the resin. The coupling times used were 40 min. The resin was then washed
with DMF (3 x 3 ml). A N-terminal Fmoc deprotection was performed using 20% piperidine
in DMF (2 ml, 3 x 5 min).  The resins were carefully washed with DMF (3 x 5 ml) after the
Fmoc-deprotection. Coupling and deprotection steps were monitored usually after couple
of cycles with Kaiser-tests.
The couplings and deprotection of orthogonally protected disulphide bridge mimetics
(Figure 33, see page 74) was performed as above using 4 h as a coupling time to ensure
higher coupling efficiency. The Fmoc-deprotections were performed as mentioned above.
5.4.8 Deprotection of terminal protecting groups of peptides with an all-hydrocarbon
bridge
C-terminal allyl deprotection was performed using Pd(PPh3)4 (1  eq.)  in  2  ml  mixture  of
CHCl3:AcOH:NMM (37:2:1) and stirred under argon for 2 h at RT. Washing, catalyst
removal and N-terminal Fmoc-deprotection was performed as described in chapter 5.4.4.
5.4.9 Cyclization of peptides with an all-hydrocarbon bridge
Head-to-tail cyclizations were performed on resin using HATU and HOAt as the coupling
agent and DIEA as the base (Figure 33). Reactions were performed using HATU (4.8 equiv),
HOAt (4.8 equiv) and DIEA (7.2 equiv) as described in chapter 5.4.4. After cleavage
peptides were lyophilized and purified as described previously. After the first purification
cycle, the purity varied between 30 -70% and second purification was needed. After the
second purification, peptides were lyophilized yielding ca. 1.0 mg of peptide 20a (~ 5%),
and around 0.1 mg 20b (<1%). Peptide 20a, ESI–MS: (m/z) 1406.01 [M - H]-, HPLC: tR = 15.3
(purity > 90%). Peptide 20b, ESI–MS: (m/z) 1408.03 [M - H]-, HPLC: tR = 15.0 (purity 90%).
5.4.10 Effect of the peptides on KLK3 activity
KLK3 (0.3 μM) was incubated for 30 min at RT with synthetic peptides (13-14 μM) in 0.05 M
Tris buffer, pH 7.7, containing 0.154 M NaCl, 8 mM NaN3 and 0.1% bovine serum albumin.
After the addition of the substrate to a final concentration of 0.2 mM, the absorbance at 405
nm  was  measured  at  5  min  intervals  for  30  min.  The  concentration  dependency  of  the
activity was determined by measuring the activity of KLK3 in the presence of the synthetic
peptides in a series of concentration from 0.16 to 351 μM.
5.4.11 Stability tests
Proteolytic cleavage of selected peptides with KLK3 was followed for 24 h. Peptide (0.18
mM) was incubated with KLK3 (0.02 mM in PBS final concentration) in 150 μl volume at
+37°C or with PBS as the control. Peptide samples of 35 μl were collected at 2, 4, 8 and 24 h
time points.
Plasma stability tests for the selected peptides were performed by incubating the
peptides with 250 μl fresh human EDTA plasma, 125 μl PBS and 125 μl peptide solution
(0.5 mg/ml in H2O) for 24 h at +37°C. For controls, the peptides were added to PBS. Peptide
samples of 100 μl were collected at 2, 4, 8 and 24 h time points.
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6 Activity and stability of human kallikrein-2-specific
linear and cyclic peptide inhibitors8
6.1 INTRODUCTION
Previously, Hekim and his collaborators have identified KLK2-specific peptides by using
the phage display methodology. These peptides are enzyme-specific and do not inhibit
other proteases (Hekim et al. 2006). The motifs required for biological activity of KLK2-
specific peptide inhibitors were characterized by alanine substitution analysis, and also
sequences with improved inhibitory capacity were found (Hekim et al. 2006).
The proteolytic stability is an important factor for the use of peptides in vivo. Most
peptides have to be modified to prevent enzymatic degradation. Several approaches
including the use of D-amino acids, unusual amino acids, peptidomimetics or cyclization
have been used to improve the peptide stability (Adessi & Soto 2002, Okarvi 2004). In this
study,  cyclic  variants  of  KLK2  inhibitory  peptides  were  prepared  and  their  inhibitory
activities were compared to the original peptides. Furthermore, the effect of cyclization on
the peptide stability against digestion by trypsin and human plasma were studied. The
conformational constraints of the peptides were studied by proton NMR spectroscopy.
6.2 RESULTS AND DISCUSSION
Phage display is a powerful method to produce peptides with novel biological activities,
which  may  be  useful  for  forming  lead  structures  for  the  design  of  new  diagnostic  and
therapeutic molecules. Hekim and his collaborators have identified novel peptide inhibitors
that are specific to the serine protease KLK2 by phage display (Hekim et al. 2006). Two
linear synthetic analogs, KLK2a (ARRPAPAPG) and KLK2b (GAARFKVWWAAG), display
specific  and  efficient  inhibition  of  KLK2.  Although  the  amino  acid  sequences  of  the  two
peptides are dissimilar, their inhibition of KLK2 is competitive, suggesting that they bind to
the same site. Both peptides contain arginine, which cannot be replaced with alanine,
suggesting its important role for binding (Hekim et al. 2006). Substrate-specificity studies
indicate that KLK2 has strict preference for arginine at position P1 in cleavage site followed
by a serine at position P’1 (Cloutier et al. 2002). In spite of this, peptides KLK2a and KLK2b
are not cleaved by KLK2 but its protease activity in vitro is inhibited. The replacement of
arginine  with lysine  in  the  peptide  KLK2b did not  abolish its  inhibitory effect,  suggesting
that inhibition is based on the positive charge that guides binding of the peptides to KLK2.
8 Adapted with permission of John Wiley and Sons from: Pakkala M,# Hekim C,# Soininen P, Leinonen J, Koistinen H,
Weisell J, Stenman U-H, Vepsäläinen J, Närvänen A. Activity And Stability of Human Kallikrein-2 Specific Linear And
Cyclic Peptide Inhibitors, Journal of Peptide Science, 13(5): 348-353, 2007.
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6.2.1 Inhibitory activity of the peptides
In order to study the correlation between structure and function, a set of cyclic variants of
both peptides KLK2a and KLK2b were synthesized by adding cysteines to the amino and
carboxyl ends. The inhibitory effect of the linear and cyclic forms of the KLK2a and KLK2b
peptides was measured by using 0.17 μM concentration of the KLK2 enzyme and a 100-fold
molar excess of each peptide. There was a clear difference in the effect of cyclization
between the two KLK2-specific peptides. Most of the cyclic forms of KLK2a were totally
inactive and only one KLK2a(c2) displayed slight (23%) inhibition, while all cyclic KLK2b
peptides were active and some of them were even more active than the original linear
peptide. The most active peptide (KLK2b(c1)) inhibited 97% of the activity, while the linear
peptide displayed 74% inhibition. A variant with the point mutation R4K in the linear form
of KLK2b displayed equal activity compared to the original peptide (Table 8). Inhibition
assays showed that essentially all the cyclic KLK2a peptides were inactive, while only one
showed a slight inhibitory activity. The corresponding cyclic forms of the KLK2b peptides
were active. Since the disulfide-bridged cyclic forms of KLK2b were biologically active, a
set of cyclic peptides were further synthesized using the head-to-tail cyclization strategy.
After cyclization, the inhibitory activity of the KLK2b peptides with various sequence
lengths was similar and slightly higher than that of the corresponding linear peptide.
Table 8.  Activities of  linear KLK2 peptides and the corresponding cyclic  forms (c = cyclic  form
with cysteine bridge, ht = head-to-tail cyclic peptide). Activities indicate the degree of inhibition
of KLK2 activity.
Peptide Sequence MW
(g/mol)
KLK2
inhibition (%)
±SD
(%)
KLK2a linear A R R P A P A P G 891.30 72 1.6
KLK2a(c1) C A R R P A P A P C G 1095.35 4 0.0
KLK2a(c2) C A A R R P A P A P C G 1166.56 23 1.2
KLK2a(c3) C A A A R R P A P A P C G 1237.36 3 0.1
KLK2a(c4) C R R P A P A C G 927.49 9 0.1
KLK2a(c5) C A R R P A P A C G 1098.34 1 0.2
KLK2a(c6) C A R R P A P A A C G 1069.13 4 0.0
KLK2a(c7) C A A R R P A P A A C G 1140.28 7 0.2
KLK2a(c8) C A A A R R P A P A A C G 1211.42 0 0.0
KLK2b linear G A A R F K V W W A A G 1318.53 74 0.3
KLK2b(c1) G C A A R F K V W W A A C G 1522.60 97 0.0
KLK2b(c2) C A A R F K V W W A A C 1408.60 95 0.2
KLK2b(c3) G C A R F K V W W A C G 1380.59 94 1.7
KLK2b(c4) G C A A R F K V W W A A C G 1522.80 90 1.8
KLK2b(c5) C R F K V W W C 1124.40 72 1.4
KLK2b(c6) G C R F K V W W C G 1238.50 70 1.2
KLK2b linear G A A R F K V W W A A G 1318.53 72 1.2
KLK2b linear R4K mutation G A K F K V W W A A G 1219.60 82 1.0
KLK2b ht1 A R F K V W W N 1087.69 93 0.8
KLK2b ht2 A R F K V W W A N 1158.62 94 0.6
KLK2b ht3 A A R F K V W W A N 1229.66 94 0.8
KLK2b ht4 A A R F K V W W A A N 1300.69 96 0.3
KLK2b ht5 A A A R F K V W W A A N 1371.73 95 2.1
KLK2b ht6 A R F K V W N 901.48 68 0.7
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6.2.2 Biological stability
The stability of linear acetylated and two cyclic forms of KLK2b were determined by using
modified  trypsin,  which  cuts  peptide  bonds  after  lysine  and  arginine.  Complete
degradation of the linear forms occurred in 30 min, producing fragments cleaved after the
positively charged amino acids (Table 9). Proteolytic cleavage of the peptide with cysteine
bridges, produced a peptide with an additional 18 Da because of the degradation of one
amide bond while the cysteine bridge remained intact. The same addition was seen with
the head-to-tail form of the KLK2 peptide (KLK2b ht1). The cleavage rate of this peptide
was much slower than that of the three other forms. HPLC analysis showed that only 57%
of the KLK2b ht1 peptide was cleaved by trypsin in 4 h (Figure 38A). According to MSMS
analyses, the major cleavage site was after arginine.
Table 9. Four  different  forms  of  KLK2b  peptides  digested  with  trypsin  for  30–240  min  and
analyzed by mass spectrometry. Sequences of the fragments were deduced from the masses of
the  fragments  (MW)  by  mass  spectrometry.  A  dash  ()  in  the  sequence  indicates  a  possible
cleavage site but the resultant peptides are still attached by cysteine bridges.
Sequence Mw
linear
uncleaved ARFKVWWG 1048,55
fragment 1 ARFK 520,30
fragment 2 VWWG 546,25
fragment 3 AR 245,14
fragment 4 FKVWWG 821,41
acetylated linear
uncleaved AcARFKVWWGG 1147,57
fragment 1 AcARFK 562,30
fragment 2 VWWGG 603,27
fragment 3 AcAR 287,14
fragment 4 FKVWWG 821,41
cyclic with Cys-bridge
uncleaved GCAARFKVWWACG 1451,470
estimated fragments +18 D GCAARFK - VWWACG 1469,480
estimated fragments +18 D GCAAR - FKVWWACG 1469,480
head-to-tail cyclic
uncleaved KLK2b ht1 ARFKVWWN 1088,53
linear fragment 1 VWWNARFK 1105,57
linear fragment 2 FKVWWNAR 1105,57
To simulate the proteolytic environment in vivo, all four peptides were incubated in
human plasma. The two linear forms as well as the cyclic form with a cysteine bridge were
degraded within 30 min, whereas the head-to-tail peptide remained intact for 24 h (Figure
38B).
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Figure 38. (A) HPLC analyses of the degradation of the head-to-tail form KLK2 ht1 with trypsin.
About  57%  of  the  peptide  was  cleaved  after  4  h.  (B)  HPLC  analyses  of  KLK2  ht1  peptide
incubated with plasma. No significant degradation occurred during 24 h. Peptides and peptide
fragments corresponding to the masses are shown in Table 9.
Although the linear forms of the peptides were not degraded by KLK2, they were
sensitive to trypsin digestion and they were also degraded in plasma. The fragments
detected after trypsin digestion indicate that the linear forms were cleaved after arginine
and lysine. An adduct of 18 Da was detected after protease treatment of the cyclic form
with a cysteine bridge, indicating that the peptide was cleaved after arginine or lysine,
leaving the cysteine bridge intact. The most stable form was the cyclic peptide without
terminal amino acids, i.e. head-to-tail cyclic form. After 4 h incubation with trypsin, 57% of
the KLK2b ht1 peptide was still intact, and even after 24 h no fragmentation was observed
in plasma. It is noteworthy that the used trypsin concentration was very high, i.e. fivefold
higher than generally used for protein digestion for mass spectrometry. Head-to-tail
cyclization has also been found to improve the stability of peptides against proteases of -
conotoxin,  while  maintaining  the  biological  activity  (Clark  et  al.  2005).  The  cyclic  form  of
the conotoxin was sensitive to the size of the linker between the amino and carboxy termini.
As opposed to peptides in the present study, the 3D structure of the cyclic conotoxin could
be determined, which indicated a rigid conformation and influence of the sequence length
on the correct conformation of the peptide. Absence of a rigid conformation in both the
linear  and  cyclic  forms  of  the  KLK2b  peptide  could  explain  why  both  cyclic  and  linear
forms with variable sequence lengths displayed similar activity towards KLK2. Usually
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cyclization of peptides has been used to restrict conformational mobility and to enhance the
affinity to the target molecule (Osapay et al. 1997, Weiner & Thakur 2005). In the case of
KLK2 inhibitory peptides, a rigid structure does not seem to be needed for biological
activity or stability. The results indicate that backbone cyclization is an efficient and simple
approach to improve the resistance to proteolytic digestion also of flexible structures, and
this  approach,  without  any  sequence  modifications,  could  be  useful  for  modification  of
other peptides that are used for in vivo studies. Although there were no defined rigid
structural elements in cyclic forms, the slightly higher activity compared to the linear ones
may be due to the restricted conformational space during binding. Lower internal
rotational entropy may translate into higher binding affinity for the cyclic analogs.
6.2.3 NMR analyses
Solvent exposures of the NH groups were detected by determining their temperature
coefficients. None of the investigated peptides had an amide proton showing very low
	
	T values (<3 ppb/K) characteristic of strong solvent shielding (Raghothama et al. 1996).
No reasonable differences were found between the chemical shifts of CH’s and random
coil values (Wishart et al. 1991). Medium or strong sequential CH(i)–NH(i+1) NOEs were
found between almost all residues in both peptides, indicating predominant -
conformations. Furthermore, no long-range interresidual NOEs were detected. Some
broadening of the NH peaks was detected, indicating solvent-exposed NH groups or
conformational fluctuation and dynamic behavior (Raghothama et al. 1996, Wüthrich 1986).
Structural studies of linear and cyclic peptides by NMR spectroscopy indicated the
absence of major rigid conformations. Neither sequential NH(i)–NH(i+1) NOEs nor low-
temperature coefficients were found for acyclic forms of KLK2a. Cyclic forms of KLK2a
were not investigated with NMR because of their lack of biological activity. In the case of
cyclic forms of KLK2b, only weak sequential NH(i)–NH(i+1) NOEs were found between
some of the residues, and no low temperature coefficients for amide protons were found in
the cyclic and linear forms of KLK2b. A majority of the recognized NOE correlation peaks
were intraresidual or sequential (i  i+1). This suggests that there is no major
conformational constrains in the KLK2b sequences. Furthermore, the chemical shifts
between cyclized and acyclic forms of KLK2b were almost equal in all residues enabling
structural similarity and therefore similar biological activity.
6.3 CONCLUSIONS
In conclusion, the head-to-tail cyclization of peptide inhibitors of KLK2 dramatically
improves their resistance to proteolytic digestion and enhances their inhibitory capacity.
Due to the long term stability in plasma, these peptides are potential candidates for the in
vivo studies of prostate cancer in animal models.
6.4 EXPERIMENTAL
6.4.1 Peptide synthesis
The peptides (Table 1) were synthesized with Fmoc strategy and TBTU/DIPEA as the
coupling reagent.  Fmoc-Gly-Wang and Rink resins were used as the solid phase. For Cys,
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both Acm and Trt protection groups were used. Allyl-protected aspartic acid (Fmoc–
Asp(OH)–OAll) was used for head-to-tail cyclization. For stability tests, one of the peptides,
KLK2b, was acetylated on the resin. The free amino group was treated with 20% acetic
anhydride in DMF twice for 10 min before cleavage.
6.4.2 Cyclization of the peptides
Peptides  containing cysteines  with  Acm were  cyclicized by the  iodination method.  Head-
to-tail cyclization was performed on the resin. Deprotection of the allyl ester was performed
manually  with  Pd(0)  under  argon.  The  catalyst  dissolved  in  a  small  amount  of  dry  DCM
was transferred to a sealed vial containing the Fmoc–peptidyl(resin)–OAll and PhSiH3. The
reaction mixture was stirred for 2.5 h at RT under argon. The catalyst was removed and the
resin was washed and dried. The N-terminal Fmoc group was removed and head-to-tail
cyclization of the peptides was performed twice by the addition of HBTU/DIEA (8 equiv., 1
: 1, mol/mol) in DMF for 2 × 3 h at RT. Peptides were cleaved from the Rink resin with 95%
TFA, which introduced an asparagine into the final cyclic peptide. The yields of the both
cyclic forms varied between 10 and 15%.
6.4.3 Effect of the peptides on the enzyme activity of KLK2
KLK2 (0.17 μM) was incubated with a 100-fold molar excess of synthetic peptides in 20 mM
Tris-buffer, pH 8.0, containing 0.1% BSA for 30 min at RT. After the addition of the
substrate to a final concentration of 0.2 mM, the absorbance was monitored at 405 nm at 5–
10 min intervals for 1 h.
6.4.4 Stability studies
Initially, stability was studied by using modified trypsin (sequencing-grade modified
trypsin V5113, Promega, Madison, USA). Four hundred microliters of each peptide (1
mg/ml)  dissolved  in  200  mM  NH4HCO3 buffer (pH 8.0) was mixed with 1 μl of trypsin
solution (1 mg/ml in NH4HCO3, pH 8.0). The peptides were incubated at +37 °C and 30 μl
samples were taken every 30 min. Thirty microliters of 2% TFA and 5% ACN in water were
added, and the samples were analyzed by HPLC and by mass spectrometry. The open rings
of the KLK2 ht1 peptide were analyzed by MSMS.
The stability of the peptides in human plasma was studied by mixing 400 μl of human
male plasma and 400 μl of each peptide in PBS (1 mg/ml). The peptides were incubated at
+37 °C and 100 μl aliquots were taken after 30 min and then every hour up to 4 h. In the
case of the head-to-tail form, the peptide was incubated for 24 h. The remaining plasma
proteins on the filter were washed after centrifugation with 50 μl of 0.1% TFA and 0.1%
Tween 20 in water and centrifuged again for 10 min.
6.4.5 NMR spectroscopy
Samples were prepared for NMR by dissolving the purified and lyophilized peptides in 500
μl 10% D2O in H2O to a peptide concentration of 20–25 mM. The pH of the samples varied
between 2 and 3. One-dimensional experiments were recorded at different temperatures
over the range 285–340 K. Two-dimensional (2D) experiments were recorded at 300 or 330
K depending on the quality and clarity of the spectra. All chemical shifts are reported with
respect to the 5 mM TSP peak at 0.00 ppm. Two-dimensional experiments included COSY,
TOCSY and ROESY with mixing times of 80 ms for KLK2a and 225 ms for KLK2b.
88
7 General discussion and Conclusions
7.1 GENERAL DISCUSSION
Prostate cancer is one of the most common cancers in the developed countries and also the
one of the leading causes of cancer deaths. PCa is most commonly a clinically insignificant
slow-growing tumor but it can also be expressed as an aggressively metastatic and lethal
disease. Clinically PCa is very challenging because of its non-accurate, complicated
diagnosis and unpleasant therapy. The decision to initiate therapy is difficult because in the
most cases slow-growing tumors do not affect to the quality of the life of patients. The
increased  serum  concentrations  of  KLK3  have  been  used  as  a  marker  for  the  detection  of
early-stage PCa but the drawback of serum tests is the high rate of false-positives, mostly
due to benign prostate hyperplasia. KLK3 and its relative KLK2 are mainly expressed in
prostate, in both healthy and abnormal conditions and are both very prostate specific. Both
enzymes have been also shown to participate the prostate cancer development, KLK3 may
have anti-angiogenic properties due its ability to inhibit endothelial cell growth whereas
KLK2 is associated with tumor growth via proteolytic cascades. Therefore, agents with
specific binding and interference with KLK2 and KLK3 activities may hold diagnostic and
therapeutic potential.
Previously several peptides with specific binding and activity modulation toward KLK2
(Hekim et al. 2006) and KLK3 (Wu et al. 2000) have been identified. The therapeutic
potential of peptides is limited due to their low in vivo stability. In this study, these peptides
were further characterized by conducting structure-activity relationship studies and NMR-
based structural characterization. The aim was to develop anologues with increased
potential for in vivo applications.
Due to the limited information of the structures of the target proteins, the binding
structures  of  these  peptide  ligands  were  unknown.  Short  peptides  rarely  maintain  rigid
conformations in solution and their binding is dependent on the target conformation and
the surrounding chemical and physical environment. KLK3 binding peptides were
developed  using  the  phage  display  method  with  one  or  two  pre-determined  disulphide
bridges as a conformational restriction. The sequential differences between KLK3 binding
peptides in combination with the similarities of their biological response were striking. The
cross-inhibition test revealed that these peptides bind to the same region of KLK3.
Therefore,  at  the  beginning  of  this  study,  the  existence  of  common  structural  motifs  in
KLK3 binding peptides were studied to determine if it would be possible to modulate the
structure by incorporating non-natural synthetic building blocks. For all three KLK3
binding peptides, A-1, B-2 and C-4 (Figure 39), the populations of reversed turn structures
were found. All peptides contained one amide proton protected from solvent indicating
that  there  were  hydrogen  bonds  between  the  backbone  carbonyl  group  and  the  amide
proton. Intra- and inter-residual NOE-connectivities were used in the detection of turn
types and the presence of NOE-connectivities suitable for the certain types of -turns were
observed. However, strong indications about conformational fluctuation were also detected
reflecting the  reality  that  the  bioactive  conformation cannot  be  derived solely  from NMR-
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based structure determinations. In peptide C-4, close connectivity between isoleucine and
aromatic residues was detected.
Figure 39. The original sequences of KLK3 binding peptides.
The  essential  residues  for  biological  activity  and  residues  whose  side  chains  can  be
removed without losing biological activity in terms of peptide mimetic design were
mapped via alanine replacement studies. The replacement of a certain residue by alanine
removes all atoms beyond C but it still maintains the conformational limitations of the
backbone indicating the essentiality of the side chain for the biological response. In shorter
peptides and those with only one disulphide bridge containing peptides A-1 and B-2, most
of the replacements reduced the activity emphasizing the importance of correct sequence in
the structure-activity relationship. The most dramatic effects were noted when aromatic
and hydrophobic residues were replaced highlighting their importance. In the case of C-4,
some activity stimulation remained in the most of cases, evidence that several residues are
responsible for the maintenance of biological activity. The most important residues were
once again aromatic and hydrophobic side chains. The importance of several residues for
biological activity was studied by using peptide A-1 and by replacing two or three out of its
ten residues at the same time. Moderate activity stimulations were detected except for one
analog when tyrosine was replaced in position 7. In an additional study, peptide C-4, which
had the highest stimulatory activity, was studied using multiple alanine replacements.
Further, a targeted positional scan examined the possibility to replace valines nearby to the
terminal disulphide bridge with residues suitable for use in a head-to-tail cyclization
strategy. The multi-alanine replacement studies showed the importance of aromatic
residues  with  hydrophobic  isoleucine  in  position  6.  The  replacement  of  those  residues
eliminated the activity stimulation, although the replacement of one of them alone only
reduced the stimulation of activity. It was possible to replace Ile6 with a hydrophobic
residue. The importance of the correct location for disulphide bridge between Cys5 and
Cys10 was demonstrated and no modifications near to the terminal disulphide bridge
between Cys1 and Cys13 were permitted. Both Glu7 and His8 could be replacede by
alanines at the same time. This is important for peptide mimetic design since it eases both
the design and the synthesis.
Peptides  are  rapidly  degraded  in  living  organism  by  peptidases,  both  endo-  and
exopeptidases. Endopeptidases are usually selective for certain residues whereas
exopeptidases degrade peptides from their terminal ends. Head-to-tail cyclization is a
widely used method to increase the in vivo stability of peptides. KLK3 binding peptides
already contained disulphide bridges and those bridges were subjected to alternative
cyclization strategies. A series of the cyclic analogs of peptide B-2 with head-to-tail, side
chain  to  tail  and  side  chain  to  side  chain  cyclic  structures  were  synthesized  and  their
activity stimulation examined. Based on the results obtained with the peptide B-2 analogs,
it was clear that the bridge between the N- and C-termini was very important for the KLK3-
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stimulating activity. The number of the atoms in the alternative bridge structure was found
to be important although the conformational fluctuation of these analogs was restricted as
compared to the original disulphide bridge. The presence of a free carboxylic acid moiety
around the C-terminus was also important for the KLK3-stimulating activity. The
carboxylic acid could be replaced by an amide group, but this replacement reduced the
KLK3-stimulating activity. One analog included a disulfide bridge mimetic consisted of
GABA and aspartic acid, where the amino group from the former was linked to the main
chain  carboxyl  group  of  the  latter.  This  derivative  was  found  to  be  more  stable  than  the
original peptide B-2 against enzymatic degradation in plasma and with the presence of
KLK3.
The possibility to replace disulphide bridge by all-hydrocarbon linker was studied. The
results revealed that no heteroatoms were necessary to maintain biological activity, a linker
consisting of a simple hydrocarbon chain was sufficient. A peptide with a flexible linker
containing all-sp3-hybridized carbon atoms displayed moderate activity stimulation
whereas structurally more restricted E-double bond containing peptide exhibited low
activity stimulation.
The original KLK2 binding peptides characterized by phage display were linear. In order
to increase their stability, several cyclic analogs using additional disulphide bridge and
head-to-tail cyclization were synthesized (Figure 40). After cyclization, the structural motifs
common to both biologically active linear and cyclic peptides were studied by NMR.
However, the NMR studies emphasized the conformational flexibility of the peptides
studied and no remarkable conformational motif could be found, not even hydrogen
bonding.  The  cyclization  of  peptides  increased  the  inhibitory  activity  of  KLK2  binding
peptides and their stability against enzymatic degradation by trypsin or plasma proteases.
Both the linear and cyclic forms with a disulphide bridge were degraded in plasma within
30 minutes but the head-to-tail cyclized peptide was stable against degradation for at least
24 h. The head-to-tail cyclic form was relatively stable against degradation by purified
trypsin, which is known to cleave the peptide bond after Lys or Arg. In all, 57% of head-to-
tail cyclic peptide remained uncleaved after 4 h whereas the linear forms were completely
broken down within 30 minutes suggesting that cyclic peptides could be suitable for in vivo
applications.
Figure 40. The sequences of linear, disulphide bridged and head-to-tail cyclized versions of
KLK2 binding peptides.
91
7.2 CONCLUSIONS
The present study describes the structural characterization, sequential optimization and the
enhancement of the plasma stability of specific KLK2 and KLK3 binding peptides. The
modified peptides could modulate the enzymatic activities of KLK2 and KLK3. The results
lead to the following conclusions.
I. Populations of reversed turn structures were found for KLK3 binding peptides but
also  there  were  clear  indications  of  conformational  fluctuation.  Further  studies  will
be needed to clarify the interactions between KLK3 and ligand.
II. The important residues of KLK3 binding peptides for biological activity response
were defined. The residues which were replaceable in the peptide mimetic design
were also determined.
III. The stability of KLK3 binding peptide B-2 against enzymatic degradation was
improved via an alternative cyclization strategy. Both amide bond and all-
hydrocarbon containing disulphide bridge mimetics were synthesized without
losing biological activity.
IV. The stability of KLK2 binding peptides against enzymatic degradation in plasma
was improved by head-to-tail cyclization. In addition, head-to-tail cyclization
improved the stability of the molecules against degradation by KLK2. Thus
increased stability of the cyclic peptide means that this agent has therapeutic
potential for use in prostate cancer.
V. Several  KLK2  binding  peptide  analogs  had  preserved  inhibitory  activity  but  no
common structural motifs were found highlighting the essentiality of a flexible
structure for binding and biological activity of KLK2 binding peptides.
VI. Valuable information about the structure-activity relationships of KLK2 and KLK3
binding peptides was gained.
7.3 FUTURE PERSPECTIVES
Although no rigid conformational motifs were detected for KLK2 and KLK3 modulating
peptides and the structures responsible for their biological activity have not been defined,
the mapping of residues important for biological activity would help in identifying new
modified peptides with in vivo applications. C-4 peptide, which has been shown to decrease
angiogenesis in cell cultures and has the highest activation capacity for KLK3, contains two
disulphide bridges. The new cyclization methods and the knowledge of replaceable
residues in C-4 peptide sequence may lead to the discovery of a more active and stable
KLK3 modulating analog. Analog with increased in vivo stability would be essential if one
wishes  to  undertake  future  studies  of  the  KLK3  and  KLK2  producing  tumors  in  animal
models.
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Prostate cancer (PCa) is common 
cancer in males with challenging 
diagnosis. Prostate specific proteases 
KLK3 (PSA) and KLK2 are used 
in monitoring of PCa but they are 
also involved in prostate cancer 
progression. Synthetic peptides, 
which modulate the protease 
activity of KLK2 and KLK3, have 
low bioavailability limiting the 
use of the peptides in therapeutic 
applications. This study focuses on 
the improvements in the activity and 
stability of peptide-based activity 
modulators of KLK2 and KLK3.
